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Stefan Pasichnyk Tarnawsky 
 
THE ORIGIN OF JUVENILE MYELOMONOCYTIC LEUKEMIA: 
INSIGHTS FROM DEVELOPMENTAL HEMATOPOIESIS 
 
Hematopoiesis proceeds through three developmental phases, each with a unique 
and indispensable function. The individual roles of these phases in the pathogenesis of 
blood disorders is unknown. We have adapted murine lineage trace models to identify the 
relative contributions of embryonic, fetal, and adult hematopoietic phases to the origin of 
Juvenile Myelomonocytic Leukemia. We hypothesized that the fetal phase would have the 
most pronounced contribution to the development of JMML, a pediatric myeloproliferative 
disorder whose disease-initiating somatic mutations occur in utero. Progenitors 
expressing PTPN11E76K from all three waves were growth hypersensitive to GM-CSF due 
to hyperactive RAS-ERK signaling. However, fulminant myeloproliferation was only seen 
in fetal and adult cohorts. We observed equal disease severity in FLT3Cre; PTPN11E76K; 
ROSA26mTmG and CSF1R-MCM; PTPN11E76K; ROSA26YFP cohorts, which had high and 
low mutant allele frequencies, respectively. This led to the revelation that all progenitors 
in the BM niche of mutant animals have equal growth hypersensitivity and RAS-ERK 
hyperactivation due to non-cell autonomous effects of PTPN11E76K.  We further identified 
that FLT3Cre has hematopoietic-restricted expression, and thereby circumvented 
morbidity from PTPN11E76K expression in endothelial and stromal cells. This led us to 
hypothesize that FLT3Cre; KrasG12D; ROSA26mTmG would be the first faithful model of 
JMML to express this disease-initiating mutation. Indeed, FLT3Cre; KrasG12D mice were 
born at expected Mendelian ratio and showed normal weight gain to 2 weeks of age. 
Thereafter, they acquired defining features of JMML including monocytosis, anaemia, 
thrombocytopenia, and hepatosplenomegaly. All FLT3Cre; KrasG12D mice succumb to a 
vii 
JMML-like disease, which was propagated following transplantation. This is in contrast 
with CSF1R-MCM; KrasG12D; ROSA26YFP mice, in which low mutant allele frequencies in 
either fetal or adult HSCs uniformly resulted in T-ALL. Our models reveal previously 
underappreciated features of JMML including an expansion of dendritic cells and a 
pronounced defect in T-lymphocyte development. We are the first to demonstrate non-cell 
autonomous effects of hematopoietic-restricted PTPN11E76K expression. Most importantly, 
we have shown that both the spatial and the temporal origin of JMML-initiating mutations 
will affect disease manifestations. Each of our findings suggest novel strategies to treat 
this intractable disease. 
 
 
 
 
Mervin C. Yoder, M.D., Chair 
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CHAPTER I 
INTRODUCTION 
Outline 
Hematopoiesis is a hierarchical process. Stem cells divide and progressively 
commit themselves to the production of a single mature blood cell lineage. This 
commitment occurs through a series intermediary progenitors that lose differentiation 
potential in a stepwise fashion. The textbook dogma suggests that all blood progeny trace 
their origin to a single progenitor type: the hematopoietic stem cell (HSC, see Figure I-1). 
Whereas this schematic is a useful heuristic tool it overlooks the nuanced origin of 
hematopoiesis. In reality, blood cells emerge in distinct hematopoietic phases, each with 
its own spatial and temporal origin. These phases require different signals for their 
emergence and they contain distinct progenitors whose differentiation potentials are 
unique. Progenitors in each phase may share cell surface markers, but nonetheless have 
different function and longevity. As such, it is imperative to appreciate the distinctions of 
hematopoietic phases in order to understand the scope of blood cell development.  
This work will consider three sequential phases of hematopoiesis: embryonic, fetal, 
and adult (Figure I-2). The embryonic phase emerges independently and prior to the first 
HSC, whereas the fetal and adult phases are HSC-dependent. We will describe the spatial 
and temporal origin of each phase as well as their unique functions. Finally, we will 
consider the significance of these phases in the context of a pediatric blood disorder with 
a known in utero origin: Juvenile Myelomonocytic Leukemia. We will do so by describing
the contribution of these phases to murine models of JMML. 
Three Phases of Hematopoiesis 
The first hematopoietic cells produced in a developing mammal arise directly from 
mesoderm in the extraembryonic yolk sac (YS) (Maximow 1909; Lux et al. 2008; 
1
Figure I-1. The Traditional Hierarchy of Hematopoiesis. The classic hierarchy suggests 
that all hematopoietic cells are progeny of the hematopoietic stem cell, which gives rise to 
mature cells through a series of progenitors with progressively more committed lineage 
differentiation potential. 
2
Figure I-2. The Three Phases of Hematopoiesis. The first hematopoietic cells emerge 
in the extraembryonic yolk sac around embryonic day (E)7.0. Erythromyeloid progenitors 
emerge around E8.25 followed by lymphoid progenitors around E9.0. The first definite 
hematopoietic stem cells (HSCs) emerge in the aorta-gonad mesonephros (AGM) region 
around E10.5. They migrate to the fetal liver and proliferate before seeding the bone 
marrow around birth. They continue to proliferate and differentiate until 4 weeks of age 
when they enter quiescence. This marks the fetal to adult phase transition. This graphic 
highlights the relevant developmental events for studies performed in this work. See (Lin 
Y, MC Yoder, Yoshimoto M, 2014) for in-depth review of embryonic hematopoiesis. 
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Ferkowicz 2003; Palis et al. 2001; Migliaccio et al. 1986). These are bipotent 
megakaryocytic-erythroid progenitors (MEP) that produce large, nucleated erythrocytes 
(Tober et al. 2007). Because these features resemble similar previously-characterized 
avian and reptilian cells, this lineage was termed primitive (Frame, McGrath, and Palis 
2013). This designation distinguished these cells from definitive erythrocytes that shrink 
in size following enucleation. It was later shown that a myeloid-restricted progenitor (Mac-
CFC) emerged concurrently with the primitive MEP (Bertrand et al., 2005; Moore and 
Metcalf, 1969). The progeny of Mac-CFC had morphological and functional properties of 
phagocytes and these were named primitive macrophages (Bertrand et al. 2005; Moore 
and Metcalf 1969).  
Shortly following the emergence of this first hematopoietic wave were bipotent 
erythromyeloid progenitors (EMPs). These arise from an endothelial-to-hematopoietic 
transition in the YS around E8.25 (Frame et al. 2016). They seed the fetal liver around 
E10.5, where they contribute to monocytes, granulocyte, and erythroid progeny that 
sustain the conceptus as the HSC-dependent phase emerges and proliferates (Palis et al. 
1999; Chen et al. 2011; McGrath et al. 2015). Whereas initial studies suggested EMPs 
had a transient role in development, recent evidence conclude that the progeny of EMPs 
persist into adulthood as tissue resident macrophages (Schulz et al. 2012; Gomez 
Perdiguero et al. 2015; Epelman et al. 2014; Kierdorf et al. 2013; Ginhoux et al. 2010; 
Samokhvalov, Samokhvalova, and Nishikawa 2007). This contribution is most significant 
in the brain; all microglia are thought to arise from HSC-independent yolk sac progenitors 
in unperturbed hematopoiesis. Microglia are only replenished by BM progenitors or CNS 
stromal precursors in the context of inflammation (Ajami et al. 2007; Mildner et al. 2007; 
Ginhoux et al. 2010; Elmore et al. 2014).  
The embryonic phase of hematopoiesis also contributes to lymphoid progeny. 
Whereas neither MEPs, Mac-CFCs nor EMPs have lymphoid potential, B and T-
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lymphocytes emerge in the yolk sac prior to and independently from HSCs (Yoshimoto et 
al. 2010; Yoshimoto et al. 2012). Beginning around E9.0, B-lymphoid progenitors emerge 
in the YS via an endothelial to hematopoietic transition. These progenitors preferentially 
contribute to peritoneal B1 cells and marginal zone cells in the spleen. This suggests that 
YS B-cell progenitors preferentially give rise to innate-type cells rather that adaptive B2 
cells that preferentially arise from HSCs. Additional work has identified that multipotent 
progenitors with of tri-lineage lymphocyte potential arise in the YS independently of HSCs 
(Yoder and Hiatt 1997; Inlay et al. 2014). As such, the yolk sac produces blood cells from 
all lineages and does so prior to the emergence of the first HSC. Together, these 
progenitors constitute the HSC-independent hematopoietic phase. 
The HSC is functionally defined as a cell that can i) give rise to all blood cell 
lineages and ii) that can self-renew indefinitely upon serial transplantations into adult 
recipients. This definition distinguishes it from neonatal HSCs, which first arise in the yolk 
sac, give rise to all lineages, but can only engraft neonatal recipients (Yoder et al. 1997; 
Yoder and Hiatt 1997; Johnson and Yoder 2005). Other progenitors from the embryonic 
phase are equally incapable of durable contributions in adult recipients (McGrath et al. 
2015). The HSC definition further draws the distinction with non-self-renewing progenitors 
in adults that are capable of clonal contributions to all lineages but cannot self-renew upon 
serial transplantation (Yamamoto et al. 2013).  
The current standard to evaluate of an HSC is the single-cell transplant (Wilson et 
al. 2015). Therein a single cell is injected into a conditioned adult recipient and the 
engraftment is monitored for at least 16 weeks. To be considered an HSC, the cell must 
contribute to a minimum of 1% of peripheral blood cells from all lineages and must be able 
to sustain this contribution for a minimum of two additional sequential transplantations. 
This definition, however, is problematic. Historically HSCs have been variously defined as 
cells able to give rise to multilineage colonies in methylcellulose, cells able to give rise to 
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grossly-visible colonies in recipients’ spleens, cells able to rescue a lethally-ablated 
recipient, among others (Eaves 2015). Additionally, the current definition requires a 
functional test that irrevocably alters the assayed cell. As such, you cannot have your HSC 
and test it too. Furthermore, since the HSC assay requires transplantation, there is no 
accepted definition for an HSC in its native host (Busch and Rodewald 2016). Indeed, 
recent studies demonstrate major differences between post-transplant and unperturbed 
hematopoiesis (Henninger et al. 2017; Sun et al. 2014; Busch et al. 2015); these will be 
discussed in detail below. In short, these difficulties make it challenging to compare HSCs 
from different studies. Herein HSCs will be defined as single cells capable of multilineage 
serial reconstitution in adult recipients. 
The first HSCs arise in the mouse around E10.5-E11.0 on the ventral wall of the 
dorsal aorta (Muller et al. 1994; Medvinsky and Dzierzak 1996; Boisset et al. 2010). This 
occurs through an endothelial to hematopoietic transition that is dependent on Runx1 and 
Sox17 signaling (Chen et al. 2009; Zovein et al. 2008; Kim, Saunders, and Morrison 2007). 
Shortly thereafter, HSCs also emerge in other tissues including the placenta and the yolk 
sac (Samokhvalov, Samokhvalova, and Nishikawa 2007; Gekas et al. 2005). They migrate 
to the fetal liver where they rapidly proliferate (Taoudi and Medvinsky 2007; Ema and 
Nakauchi 2000). Chemotactic signals later induce migration to the spleen and/or the 
thymus before HSCs seed the bone marrow (BM) around birth (Kiel et al. 2005; 
Christensen et al. 2004). There, HSCs undergo gradual functional changes that define the 
fetal to adult phase transition. 
The distinction between fetal and adult HSC-dependent phases is not arbitrary. 
Fetal progenitors are highly proliferative and have greater repopulating ability than adult 
progenitors, which are predominantly quiescent (Bowie et al. 2006; Bowie et al. 2007; 
Dykstra et al. 2007). Genetic or microenvironmental alterations that force adult HSCs to 
enter the cell cycle result in bone marrow failure (Ye et al. 2013; Kunisaki et al. 2013). The 
6
differentiation potential of the two phases is also different. Fetal HSCs are biased to 
produce lymphoid progeny whereas adult HSCs are biased to produce myeloid progeny 
(Benz et al. 2012). Nonetheless, due to their enhanced proliferative potential, fetal 
progenitors produce greater numbers of myeloid colonies in methylcellulose assays that 
can be serially replated (Ema and Nakauchi 2000; Lansdorp, Dragowska, and Mayani 
1993). With respect to lymphoid progeny, fetal progenitors are capable of robust 
contributions to innate immune cells, whereas adult progenitors predominantly contribute 
to adaptive immune cells (Benz et al. 2012; Yuan et al. 2012; Beaudin et al. 2016). Fetal 
HSCs have a unique immunophenotype that includes expression of CD11b and CD144 
(Kim, Yilmaz, and Morrison 2005) and have differential response to exogenous cytokines 
and signaling mediators than their adult counterparts (Chanda et al. 2013; Kim, Saunders, 
and Morrison 2007; Park et al. 2003; Ye et al. 2013; Copley and Eaves 2013). Importantly, 
parallel studies in humans have also identified developmental changes in hematopoietic 
progenitors: fetal progenitors are more proliferative and transition into the adult phase at 
approximately two years of age (Lansdorp, Dragowska, and Mayani 1993; Sidorov et al. 
2009). Fetal and adult HSC-dependent phases are also differentially susceptible to 
transformation. For instance, fetal progenitors are relatively resistant to transformation by 
FLT3ITD mutations and are more likely to produce myeloid rather than lymphoid 
malignancies (Porter et al. 2016; Man et al. 2016). 
We have described the origin and function of three hematopoietic phases: HSC-
independent, fetal, and adult. These phases, however, do not exist in isolation. Their 
interdependence is highlighted by seminal experiments that showed the emergence of 
HSCs from hemogenic endothelium is dependent on sterile inflammatory signals (Espin-
Palazon et al. 2014). These signals come from myeloid cells that are descended from YS 
EMPs (Li et al. 2014). Loss of EMPs is not compatible with life, as they are required to 
sustain the embryo during the late fetal period when HSC-dependent progenitors are 
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proliferating (Mucenski et al. 1991). Furthermore, the high proliferation rate of fetal 
progenitors may be a requirement for the prompt population of rapidly growing tissues 
during development. Additionally, the propensity of fetal HSCs to preferentially contribute 
to lymphoid tissues may be an adaptation to protect neonates from the abrupt exposure 
to exogenous pathogens at birth. Finally, the high proliferative rate of fetal HSCs is not 
suitable for life-long maintenance of hematopoiesis. As such, the transition from fetal to 
adult phases is likely an adaptation to prevent exhaustion of progenitors and lessen the 
acquisition of deleterious mutations that occurs at each cell division.  
Given that each phase has a defined role in mammalian development, it is 
surprising that their respective contributions to hematologic disease have not been 
evaluated. Pediatric hematologic disorders are markedly different from adult ones 
(Greaves 2015). Nonetheless, the majority of animal models do not consider distinctions 
between embryonic, fetal, and adult hematopoiesis. In this study, we sought to evaluate 
the contribution of these three phases to the pediatric myeloproliferative neoplasm 
Juvenile Myelomonocytic Leukemia. 
 
Case Report 
 The patient is a 16 month-old Caucasian male that presented to his pediatrician 
with lethargy, abdominal distention, and skin lesions. Parents relate that the patient was 
healthy until 2 months ago when they noticed weakness and a progressive weight loss. 
Physical exam revealed a palpable liver and spleen 7cm and 4cm below the costal margin, 
respectively, with skin pallor, widespread bruising, and dyspnea. Peripheral blood exam 
showed thrombocytopenia (16500/uL), and anaemia (7 g/dL), and marked leukocytosis 
(104 600/uL; 9% band forms; 71% neutrophils; 7% monocytes; 12% leukocytes, 0.8% 
eosinophils) with elevated fetal hemoglobin (15.3%). BM aspirate showed hypercellularity 
with dysplastic neutrophils and 11% blast cells. Patient karyotype shows monosomy 7 
8
without translocations. A diagnosis of JMML was suspected and sequencing analysis of 
peripheral blood cells confirmed a somatic PTPN11 226G>A mutation. Two months after 
presentation two 5/6HLA-matched cord blood units were transplanted following a Bu-Cy-
Mel conditioning regimen. The patient developed mild GVHD 46 days after transplant and 
was treated with steroids. 167 days after transplant monosomy 7 was identified in 37% of 
peripheral leukocytes indicating disease relapse. 13 months after initial presentation, the 
patient underwent a second transplant with matched sibling donor. 90 days after HSCT 
complete donor chimerism was confirmed and the patient remains disease-free 3 years 
later. [Based on published studies (Osumi et al. 2017; Locatelli and Niemeyer 2015; 
Inagaki et al. 2013)]. 
Juvenile Myelomonocytic Leukemia 
JMML is a pediatric myeloproliferative neoplasm (MPN). The World Health 
Organization also classifies JMML as a myelodysplastic syndrome (MDS) due to an 
abundance of abnormal myeloid cells in patients’ BM and blood (Arber et al. 2016). The 
diagnosis of JMML is clinically challenging (Locatelli and Niemeyer 2015). Patients 
present very young with a mean age of <2 years. They show hepatosplenomegaly, failure 
to thrive, non-specific dermatologic features, and they are prone to infections. Blood 
analysis will reveal an absolute monocytosis along with anaemia and thrombocytopenia. 
BM biopsy will reveal a moderate elevation of blasts (<20%) that lack AML and CMML-
associated translocations. These features are non-specific and the differential diagnosis 
is broad. Definitive diagnosis of JMML requires its distinction from viral infections, non-
malignant hematologic disorders, and pediatric AML. 
A breakthrough for JMML diagnosis came when researchers discovered that 
hematopoietic progenitors from JMML patients had unique growth hypersensitivity to the 
cytokine GM-CSF (Emanuel et al. 1991). The search for the causative mechanism 
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subsequently revealed that >90% of patients have somatic mutations in signaling 
mediators downstream of the GM-CSF receptor (Figure I-3). These gain of function 
mutations in PTPN11, Kras, Nras, or loss of function mutations in NF1 or c-CBL caused 
hyperactivation of RAS-ERK and led to disease. More recent exome-wide sequencing 
studies have identified that a minority of JMML patients have secondary mutations in 
overlapping or parallel signaling pathways, such as SETBP1, JAK3, RAC2, and ASXL1 
(Sakaguchi et al. 2013; Caye et al. 2015; Stieglitz, Taylor-Weiner, et al. 2015). In so doing, 
however, these studies confirmed that single nucleotide polymorphisms and single gene 
deletions are sufficient for JMML emergence and are the sole drivers of disease in the 
majority of patients.  
JMML has a low incidence of only 1 in 1.2x106 births. This is fortunate given its 
poor prognosis. Chemotherapy is ineffective; the only curative treatment is allogeneic HSC 
transplantation (HSCT). Nonetheless, the 5 year overall survival of JMML patients 
following HSCT is only 52%, considerably lower than that of pediatric AML patients treated 
with HSCT (Locatelli et al. 2013). The reason for this poor efficacy is unclear. Atypical 
histiocytes infiltrate the tissues of JMML patients (Ng et al. 1988; Ozono et al. 2011). Such 
populations are relatively resistant to myeloablation and thus may contribute to disease 
recurrence (Haniffa et al. 2009; Hashimoto et al. 2013). Additionally, these histiocytes and 
other granulocytes may irrevocably damage patients’ hematopoietic niche, possibly 
through oxidative damage or alterations in stromal cell populations (Zheng et al. 2013; 
Dong et al. 2016). This could lead to engraftment failure and subsequent relapse (Chan 
and Yoder 2013). Finally, whereas JMML unquestionably has a clonal origin, it has been 
proposed that the disease-initiating cell may not be the bona fide HSC. This hypothesis 
stems from findings that lymphocytes in patients frequently do not express the disease-
initiating mutation (Sakaguchi et al. 2013; Stieglitz, Taylor-Weiner, et al. 2015; Flotho et 
al. 1999). If true, this could explain why HSCT may not cure an HSC-independent disease. 
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Figure I-3. Aberrant Signaling in Juvenile Myelomonocytic Leukemia. Mutations 
frequently found in JMML patients are highlighted in red. The growth factor receptor is 
shown in blue. The GM-CSF receptor is frequently implicated in human disease; in murine 
models other cytokine receptors, including the SCF receptor and the IL-3 receptor, are 
involved. 
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Groups have hypothesized that progenitors from JMML patients may have 
differentiation blocks and/or biased differentiation that impedes the production of mature 
progeny in certain lineages. Murine studies suggest hyperactive Ras induces a block in 
erythroid maturation in the BM (Braun et al. 2006), which may thereby prompt common 
myeloid progenitors to commit to the granulocyte-monocyte lineage rather than to the 
megakaryocyte-erythroid lineage. Additionally, groups have identified that JMML patients 
have relatively fewer T-lymphocytes in the blood, BM, and spleen compared to age-
matched controls (Oliveira et al. 2016; Krombholz et al. 2016). This hints at a mechanism 
for the lack of mutation expression in lymphocytes; progenitors from JMML patients may 
undergo a lineage-specific differentiation block that prevents the production of mature 
progeny. This notion of aberrant differentiation is further supported by studies that showed 
progenitors from JMML patients spontaneously differentiate into dendritic-like cells 
(Longoni et al. 2002; Estrov et al. 1986). These in vitro findings parallel the histiocytic 
infiltrates that have been documented in the skin and spleen of JMML patients. 
Evidence from recent studies has converged to implicate a fetal origin for JMML. 
This disease is unique in causing a persistently elevated fetal hemoglobin (Weinberg et 
al. 1990). Additionally, retrospective analysis determined that disease-initiating mutations 
were present in the majority of JMML patient samples collected at birth (Kratz et al. 2005; 
Matsuda et al. 2010). This confirms an in utero origin for this disease. Finally, gene 
expression analysis of unfractionated BM cells from JMML patients revealed a signature 
that was pathognomonic of fetal progenitors (Helsmoortel, Bresolin, et al. 2016). It was 
characterized by elevated expression of Lin28B, a master-regulator of stem cell-like 
features (Shyh-Chang and Daley 2013). This signature was present in the majority of 
JMML patients and was associated with an inferior overall survival. In contrast, only 10% 
of pediatric AML patients, 2% of pediatric ALL patients and no pediatric MDS patients had 
a similar gene expression signature (Helsmoortel, De Moerloose, et al. 2016). 
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In summary, JMML is a clonal pediatric MPN caused by somatic mutations in 
PTPN11, K/N-Ras, NF1, and c-CBL. These mutations evoke two defining disease 
features: growth hypersensitivity in response to GM-CSF and hyperactive RAS-ERK 
signaling. HSCT is the only curative therapy, which nonetheless has a very high failure 
rate. Hypotheses for this failure include an HSC-independent origin, myeloablation-
resistant tumour cells, and irrevocable alterations to hematopoietic niches. Whereas the 
cellular origin of JMML is debated, there is strong evidence for a fetal origin: mutations 
occur in utero, patients have elevated fetal hemoglobin, and gene expression from tumour 
cells bears hallmarks of fetal progenitors. 
Current Mouse Models of JMML 
JMML is an ideal disease model because it can be evoked by a single 
nucleotide polymorphism. As such, minimal genetic manipulations are required to 
create a model. Since Ras mutations are sufficient to cause JMML, and since Ras 
mutations are the most common genetic abnormality seen in human cancers, findings 
from JMML models have broad applicability to other malignancies (McCormick 
2015). Initial studies utilized retroviral vectors to introduce gain of function PTPN11 or 
Ras mutations in cultured cells (Chan et al. 2005; Serrano et al. 1997; Mohi et al. 
2005). Such in vitro studies of JMML-disease initiating mutations helped resolve the 
aberrant signaling mechanisms that underlie this disease. It became clear that a 
linear pathway could not account for all observed disease manifestations. Rather, 
crosstalk between multiple signaling mediators converged to enhance proliferation and 
mediate cell-intrinsic and cell-extrinsic defects (Goodwin et al. 2012).  As such, it was 
crucial to develop animal models to study the mutations’ effects in vivo. 
The Cre-loxP system is the most widespread tool for genetic manipulation in mice 
(Kuhn and Torres 2002). This technique replaces a portion of an existing allele with an in 
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vitro designed vector using homologous recombination. The modified allele has two 
components: i) the mutation of interest and ii) a loxP-flanked stop cassette 5’ of the 
mutation. The stop cassette encodes tandem polyadenylation signals that cause 
premature transcriptional termination. As such, the knocked-in locus is silenced and the 
animal is haploinsufficient for the gene of interest. However, the loxP sites that flank the 
stop cassette are recognized by the Cre recombinase. This enzyme will cut out the 
intervening DNA sequence. Thus, in the presence of an active Cre enzyme, the stop 
cassette will be removed and the conditional mutant allele will be transcribed. 
Therefore, in the Cre-loxP system two mouse strains must be bred together: i) a 
strain that encodes the Cre recombinase and ii) a strain that encodes a conditional 
mutation flanked by loxP sites. Since a single genetic alteration is sufficient to give rise to 
JMML, only one mutation must be introduced into a mouse to recapitulate the underlying 
cause of the patient disease. The KrasG12D mouse was the first conditional animal model 
of JMML (Braun et al. 2004) and was shortly followed by numerous others including 
multiple PTPN11 mutations, NF1, and c-CBL (Chan, Kalaitzidis, et al. 2009; Xu et al. 
2011; Le et al. 2004; Naramura et al. 2010 and see Table I-1). 
Expressing the mutation, however, is not sufficient to produce a faithful disease 
model. The expression must be restricted to the cellular compartment that matches the 
pathophysiology of the studied disease. As such, the specificity of Cre expression is the 
major determinant of Cre-loxP model success. A variety of murine Cre strains have been 
created in which tissue-specific and/or developmentally-regulated cis regulatory elements 
drive Cre expression. In designing a conditional mouse model, one must identify a Cre 
stain whose spatial and temporal activity recapitulates that observed in patients. 
JMML is caused by somatic in utero mutations within hematopoietic progenitors. 
Successful modelling of this disease, therefore, requires the Cre enzyme to have 
developmentally controlled and hematopoietic restricted expression. Unfortunately, it has 
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proven very challenging to find Cre strains with these criteria (Table I-1). The most 
commonly used hematopoietic Cre stain is Mx1Cre (Kuhn et al. 1995). Therein, interferon-
responsive cells begin to express Cre following stress. Typically, this is experientially 
introduced through the administration of polyI:polyC (pI:pC) to mice. However, Mx1Cre is 
active in up to 10% of hematopoietic progenitors in the absence of exogenous pI:pC 
(Sabnis et al. 2009). Furthermore, Mx1Cre activity is not restricted to hematopoietic 
cells; it is also expressed in stromal, endothelial, and intestinal cells (Staffas et al. 
2015; Dong et al. 2016). Finally, pI:pC administration is toxic to the growing fetus (Liu 
and Hansen 1993). As such, this system’s use is typically restricted to adult mice.  
The VavCre and LysMCre strains are also widely disseminated and largely 
regarded as hematopoietic-restricted. Their expression is developmentally controlled and 
does begin in utero (Clausen et al. 1999; Ghiaur et al. 2008). However, these models have 
their drawbacks. Like Mx1Cre, VavCre and LysMCre will introduce mutations in all cells in 
which their promoter is active. As such, they cannot recapitulate the clonal origin of JMML. 
Additionally, their constitutive activity cannot be turned off. Each time a progenitor acquires 
Vav or LysM promoter activity it will activate de novo mutations. This never-ending 
cascade of mutations makes drug studies a challenge; even if a treatment eradicates all 
mutation-expressing cells, new clones with freshly-acquired mutations will inevitably 
emerge to take their place. Finally, VavCre and LysMCre activity is also not restricted to 
hematopoietic cells (Siegemund et al. 2015; Stadtfeld, Ye, and Graf 2007). As such it is 
unclear which symptoms in these models are the result of hematopoietic expression and 
which stem from stromal or alveolar cell expression (Xu et al. 2011). 
To circumvent the non-specific expression patterns of Cre strains, researchers 
have turned to transplantation studies (Till and McCulloch 1961). In these experiments, a 
recipient animal’s hematopoietic system is ablated and replaced with donor HSCs. If donor 
cells express a mutation the reconstituted mouse may be a model for the corresponding 
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Cre Expression 
Pattern 
Oncogene 
Disease 
Phenotype 
Median Survival 
(weeks) 
Mx1Cre >90% HSCs 
Endothelial cells 
Osteoblasts 
MSPCs 
PTPN11E76K MPN (?) 11 
KrasG12D T-ALL 28 
VavCre >90% HSCs 
Endothelial cells 
PTPN11E76K MPN (?) Not reported. 
KrasG12D In utero lethal N/A 
LysMCre ~80% monocytes 
~5% HSCs 
Alveolar cells 
Heart septum 
PTPN11E76K MPN (?) 36 
KrasG12D 
Lung 
adenocarcinoma 
3 
Table I-1. Existing Murine Models of Conditional PTPN11E76K and KrasG12D. MSPCs 
mesenchymal stem and progenitor cells; MPN myeloproliferative neoplasm; T-ALL T-
lymphocyte acute lymphoblastic leukemia/lymphoma. (?) Indicates that a MPN phenotype 
was reported but that effects of non-hematopoietic expression were not explicitly 
characterized. In this work we will restrict our analysis to PTPN11 and Ras models of 
JMML. Other models that evaluate loss of function mutations in NF1 and c-CBL have 
equally been studied using Cre strains with non-hematopoietic expression (Le et al. 2004; 
Naramura et al. 2010; An et al. 2015). 
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disease. Control transplants with healthy donor cells must be performed to account for 
irradiation-induced injuries. Since donor cells are hematopoietic any disease 
manifestations can be attributed to hematopoietic causes. Such studies have identified 
disease features that were mistakenly attributed to hematopoietic effects in Cre-loxP 
systems. For instance, Mx1Cre;KrasG12D mice develop progressive anaemia but transplant 
recipients of KrasG12D expressing cells do not (Braun et al. 2004). It was determined that 
Mx1Cre;KrasG12D animals become anaemic from intestinal bleeding caused from 
endothelial and intestinal expression of the oncogene (Staffas et al. 2015). 
Transplantation studies are also the cornerstone of cancer stem cell studies 
(Bonnet and Dick 1997). This hypothesis proposes that malignancies emulate the 
progenitor hierarchy observed in normal hematopoiesis. At the top of the malignant 
hierarchy is the leukemia stem cell, which is defined by its ability to propagate the 
malignancy upon transplantation (Kreso and Dick 2014). As such, transplantations permit 
researchers to seek the cellular origins of a disease. Specific populations are separately 
transplanted into recipient cohorts and disease burden in these cohorts are compared. 
This technique can identify the progenitor capable of initiating a disease. It determined 
that myeloid-restricted progenitors in Mx1Cre;KrasG12D mice cannot initiate disease in 
recipients, in contrast to HSCs which do initiate T-ALL following transplantation (Zhang et 
al. 2009; Sabnis et al. 2009). 
Transplantation experiments, however, have notable shortcomings. Donor cells 
are removed from their native environment, required to engraft a foreign host, and are 
forced to proliferate. As such, developmental context is lost in transplantation studies. This 
can be mitigated by selecting recipients that permit engraftment of the desired 
hematopoietic phase (Arora et al. 2014). For instance, sublethally-irradiated 
immunodeficient neonates readily permit engraftment of yolk sac progenitors, whereas 
lethally-irradiated adult congenic mice are the best recipients of BM donors (Yoder and 
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Hiatt 1997; Johnson and Yoder 2005). However, these developmentally-synchronous 
transplants are technically challenging and the overwhelming majority of studies restrict 
themselves to BM donor cells and adult recipient mice.  
More troubling still are the striking differences between post-transplant and 
unperturbed hematopoiesis (Busch and Rodewald 2016). Only a small fraction of donor 
cells contribute to hematopoiesis 16 weeks after transplantation (Yamamoto et al. 2013). 
In contrast, progenitors in their native hosts have much longer lifespans and are capable 
of significant clonal contributions to mature cell populations (Sun et al. 2014). Additionally, 
studies of unperturbed hematopoiesis suggest a periodicity of HSC activity, in which only 
1% of HSCs contribute to peripheral populations at any given time. Furthermore, these 
authors estimated that only ~30% of transplantable HSCs will have any significant 
contribution to mature progeny in the course of a lifetime (Busch et al. 2015). Finally, the 
differentiation patterns following transplantation do not mirror those of unperturbed 
hematopoiesis. For instance, ~90% of myeloid cells will be labelled by FLT3Cre under 
native conditions, but only ~50% of cells will be labelled following transplantation with 100 
HSCs (Boyer et al. 2011). Additionally, the diversity of hematopoiesis in recipient animals 
is greatly reduced from that of the donor HSC pool due to the engraftment and cycling 
stresses imposed by transplantation (Henninger et al. 2017). As such, both existing Cre-
loxP and animal transplantation models of JMML have notable shortcomings that have 
inadequately recapitulated the defining features of the human disease.  
In an effort to circumvent these challenges, researchers have taken advantage of 
recent technologies to develop humanized models of JMML. Two groups have established 
induced pluripotent stem cell (iPSC) lines from JMML patients (Gandre-Babbe et al. 2013; 
Mulero-Navarro et al. 2015). These lines demonstrate disease-defining features: growth 
hypersensitivity to GM-CSF due to hyperactive RAS-ERK signaling. Additionally, these 
studies identified novel microRNAs that may contribute to myeloid dysregulation and may 
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thus be targets for future therapies. However, iPSCs can only recapitulate the HSC-
independent hematopoietic phase (Vanhee et al. 2014; Buchrieser, James, and Moore 
2017). Despite increasingly innovative and complex strategies, human iPSC-derived 
HSCs have remained elusive (Doulatov et al. 2013; Sturgeon et al. 2014). As such, JMML-
specific iPSCs are a useful tool to study signaling mechanisms in human samples. 
However, they cannot be used to probe the developmental origins of the disease. 
Several groups have also modeled JMML in xenograph experiments. They 
transplanted progenitors from patients into immunodeficient mice and monitored disease 
progression using species-specific reagents (Lapidot et al. 1996; Nakamura et al. 2005). 
Initial attempts showed varying engraftment efficiency, were dependent on 
supplementation with human cytokines, and were difficult to reproduce. A more recent 
study (Krombholz et al. 2016) was able to engraft 4/5 tested patient samples in the majority 
of recipient animals without the use of exogenous cytokines. Engrafted recipients showed 
clinical features of JMML such as enhanced myeloid populations, decreased lymphocyte 
populations, histiocytic tissue infiltrates and early death. However, this study was not able 
to identify the JMML-initiating cell and relied on large bulk donor cell populations. It 
remains to be seen whether this model will be suitable for drug studies and if it will help 
identify new disease mechanisms and therapeutic targets. 
In summary, JMML is ideally suited for animal studies. The disease-initiating 
mutations can be readily introduced and their signaling mechanisms have been thoroughly 
validated. However, previous studies have failed to address the in utero and 
hematopoietic-restricted origin of this disease. The relative contributions of the three 
hematopoietic phases to JMML are not known. The clonal nature of the disease has not 
been recapitulated and it is not known which disease manifestations are the result of cell-
autonomous vs. non-cell autonomous effects of the mutation. Finally, it has proven 
challenging to interpret existing studies due to non-hematopoietic expression of mutations 
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or due to uncertainties as to the physiologic-appropriateness of post-transplant 
hematopoiesis. In the studies presented herein we sought to circumvent these previous 
shortcomings to create the most representative animal model of JMML.  
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CHAPTER II 
HEMATOPOIETIC PHASE-SPECIFIC MODELS OF MUTANT PTPN11 
Abstract 
Somatic mutations in PTPN11 are the most common cause of JMML and are a 
prognostic indicator of poor overall survival. Existing murine models of JMML using 
PTPN11 mutations have demonstrated molecular characteristics of the disease. However, 
these studies have not recapitulated two defining pathophysiologic features of JMML: 
hematopoietic restricted expression, and a clonal origin. Furthermore, they have not 
considered the independent consequences of PTPN11 mutations in the embryonic, fetal, 
and adult phases of hematopoiesis. In this study, we show that progenitors expressing 
mutant PTPN11 from all three phases will show growth hypersensitivity following GM-CSF 
stimulation due to hyperactive RAS-ERK. We use conditional models and transplant 
studies to show that embryonic progenitors that express either PTPN11D61Y or PTPN11E76K 
cannot cause myeloproliferation in adult mice. We validate the CSF1R-MCM as a 
hematopoietic-restricted Cre that targets HSCs with a physiologically-appropriate low 
efficiency. We generate CSF1R-MCM; PTPN11E76K; ROSAYFP cohorts that express the 
mutation in either the fetal or adult phases. We show that both fetal and adult cohorts 
develop a JMML-like disease despite a very low mutant allele frequency. They develop 
monocytosis, anaemia, thrombocytopenia and have a paucity of peripheral T-
lymphocytes. Tissue examination reveals pronounced extramedullary hematopoiesis. 
Both YFP+ and YFP- progenitors from mutant mice have equal growth hypersensitivity 
and RAS-ERK activation following stimulation with GM-CSF, indicating non-cell 
autonomous effects of hematopoietic-restricted PTPN11E76K. In summary, we 
demonstrate that both fetal and adult phases have a pronounced contribution to 
PTPN11E76K-evoked MPN. Additionally, we demonstrate that low mutant allele frequencies 
are sufficient to cause disease due to non-cell autonomous effects of this mutation.  
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Materials and Methods 
Mice 
C57BL/6J, B6.SJL-Ptprca Pepcb/ (BoyJ), and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice 
were bred in-house and/or obtained from the IUSM In Vivo Therapeutics Core. LSL-
PTPN11D61Y/+ mice were obtained from Dr. Gordon Chan and Dr. Benjamin Neel. LSL-
PTPN11E76K/+ mice were obtained from Dr. Cheng-Kui Qu.  FLT3Cre+; ROSAmTmG/mTmG 
mice were obtained from Dr. Slava Epelman. ROSAYFP/YFP mice were obtained from Dr. 
Anthony Firulli. CSF1R-Mer-Cre-Mer mice (#019098) and LSL-KrasG12D/+ mice (#008179) 
were purchased from Jackson Labs. Mice were identified by ear notches or toe clips. 
Genomic DNA was obtained from tails snips by boiling for 1hr in 50mM NaOH, 2mM EDTA 
and genotyping was performed with conventional PCR using primers listed in the 
Appendix. Experimental and control animals were housed together in the same cages. All 
animal studies were performed with prior approval from the IUSM Institutional Animal Care 
and Use Committee. 
Mouse hematologic analysis 
Blood collections were done via tail vein into EDTA-coated tubes (Fisher #NC9628695). 
Counts were obtained using a HemaVet 950 (Drew Scientific) or Element HT5 (Heska). 
Blood smears and cytospins were stained using Modified Wright-Giemsa dyes on a 
Hematek 3000 system (Siemens). For subsequent flow cytometric analysis, up to 60ul of 
blood was aliquoted into 1ml of Blood Collection Medium (IMDM +10%FBS +1% 
Pen/Strep + 20U/ml Heparin (Sigma #H3149)). 
Timed Matings 
Male studs (10-26 weeks of age) were housed in separately and mated after at least 2-3 
days of acclimatization to their cage. In the evening one or two female mice (8-26 weeks 
of age) were moved to the stud cage. The following morning, successful matings were 
confirmed by visual inspection of a vaginal plug and assigned a gestational age of E0.5. 
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Embryo Harvests 
Pregnant females were euthanized by cervical dislocation followed by bilateral 
pneumothorax. The abdominal cavity was opened using sterile scissors and forceps. The 
uterine horns were removed and placed in a petri dish with sterile PBS. The uterine fascia, 
musculature, and placental tissues were sequentially removed using forceps to expose 
the YS-enclosed embryo. Embryo age was confirmed by counting somite pairs. Desired 
tissues were dissected out and placed into collection tubes containing PBS. Tissue digests 
were performed for 5-30min at 37oC in 0.2% collagenase D (Sigma #11088866001).  
Ex Vivo Culture 
All cells were cultured in a humidified incubator at 37oC, 5% CO2 in IMDM (Fisher 
#12440079), 10% FBS (Fisher #SH30070.03), and 100 U/ml P/S (Fisher #15140122). As 
needed, the culture was further supplemented with 440nM β-Mercaptoethanol (Sigma 
#M6250), 2mM L-Glutamine (Fisher # 25030-081) and specified concentrations of the 
following murine cytokines: GM-CSF (Peprotech #315-03), M-CSF (Peprotech #315-02, 
SCF (Peprotech #), IL-3 (Peprotech #213-13), IL-6 (Peprotech #216-16), TPO (Peprotech 
#315-14), and Epoetin Alfa (Epogen). BMDM were generated by plating BM cells for 7d in 
IMDM medium containing 10ng/ml M-CSF. Cells were serum-starved for 16h in plain 
IMDM prior to stimulation with specified concentrations of cytokine in serum-free medium. 
Hematopoietic Cell Isolations 
All tissues were kept on ice in PBS +2mM EDTA. Bone marrow cells were flushed from 
forelimb and hindlimb bones using a 23G of 27G needle. Spleens and thymuses were 
triturated with glass cover slides. Livers, hearts, and brains were minced with razors and 
digested at 37oC in 0.2% collagenase D (Sigma #11088866001), 0.5% Dispase (Fisher # 
17105-041) and 50U/ml DNase I (Sigma # 10104159001) for 60min. BM stromal cells 
were isolated from flushed long bones by crushing with mortar and pestle, and digested 
as above for 3hrs. All cells were strained through a 70um mesh. Enucleated RBCs were 
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depleted as necessary using density gradient centrifugation (Sigma #10771) or RBC lysis 
buffer (Quiagen #158904). As needed, liver and brain suspensions were depleted of 
parenchymal cells and lipids via centrifugation through a gradient of 37% and 50% Percoll 
(Sigma #P1644) gradient, respectively. 
Flow Cytometry 
Cells were stained at a concentration of 1-5 x 107/ml in PBS +2% FBS + 2mM EDTA. 
Antibodies were purchased from Biolegend, eBioscience, or BD Biosciences and required 
concentrations were determined experimentally. If required, cells were fixed in 1% PFA 
(Fisher #50-980-487). For cell cycle analysis, stained cells were permeabilized with 
eBioscience Intracellular Fixation & Permeabilization Buffer Set (#88-8824-00). For 
Intracellular phosphor-flow, cells were fixed with 1% PFA and permeabilized using BD 
Perm Buffer III (#558050). Stained cells were analyzed using the BD LSR Fortessa, BD 
FACS CANTO II, or BD Accuri C6. Post run analysis was performed using FlowJo 
(Treestar). 
Tissue Histopathology 
Tissue samples were fixed in 4% PFA, dehydrated with ethanol, cleared with xylenes and 
embedded in paraffin. 5um sections were cut on a rotary microtome and stained with 
hematoxylin and eosin. 
DNA isolation 
Murine tails were digested for 1hr at 95oC in 50mM NaOH + 0.2mM EDTA, vortexed, 
pelleted, and then diluted to 100mM Tris buffer. Alternatively, DNA was isolated from 
tissues using the DNeasy Blood & Tissue Kit (Quiagen # 69504). 
PCR 
The GoTaq Green Master Mix (Promega #M712) was used with primers listed in the 
Appendix. Reaction products were run out on a 2% agarose gel and strained with ethidium 
bromide (Sigma # E1510). 
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Hematopoietic Progenitor Colony Forming Assay 
5x104 BM mononuclear cells were plated in 1ml of 30% methylcellulose in IMDM (Stemcell 
Technologies #M3120) supplemented with 30% FBS, 2.2% Pen/Strep, 2.45mM L-
Glutamine, and 440nM β-Mercaptoethanol (Sigma #M6250) and defined concentration of 
murine GM-CSF. For inhibitor studies, 100 nM PD0325901 (Selleck Chemicals) 
solubilized in DMSO was added to methylcellulose media. 
Quantitative PCR 
mRNA was isolated from 0.5-10x106 freshly-harvested or previously flash-frozen cells 
using RNeasy kits (Qiagen #74034 or 74134). cDNA was obtained using the QuantiTect 
Reverse Transcription Kit (Qiagen #205310). qPCR was run on a 7500 Real-Time PCR 
System (Applied Biosystems) using a SYBR Green kit (Roche # 4913850001) using 
250nM of each primer pair listed in the Appendix. 
Transplantations 
Adult recipients (8-24wks) were lethally irradiated with 950cGy or 700cGy+400cGy. Within 
16hrs, donor cells were adoptively transferred via tail vein in 250ul PBS using a 28G insulin 
syringe (Fisher #BD 329461). A heat lamp and alcohol swab was used to engorge the 
vein.  Neonatal recipients (2-3d) were sublethally irradiated with 350cGy. Immediately 
after irradiation, donor cells were adoptively transferred via facial vein or intraperitoneally 
in 30ul PBS using 30G needle and 0.1ml syringe (Hamilton #1710). Donor cell numbers 
are listed in Table II-1. 
Tamoxifen Treatment 
To induce recombinase activity in adult mice 75ug/g tamoxifen (Sigma #T5648), dissolved 
in sunflower oil, was injected i.p. To induce recombinase activity in utero, pregnant dams 
were injected i.p. with 75ug/g 4-hydroxy tamoxifen (Sigma #H6278) along with 37.5ug/g 
progesterone (Sigma # P0130). Litters of tamoxifen-treated dams were routinely delivered 
by C-section and raised by foster females. 
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Western blots 
Protein extracts were obtained by lysing cultured or primary cells for 30min on ice in 50mM 
HEPES, 150mM NaCl, 10% Glycerol, 1% Triton X100, 1.5mM MgCl2, 1mM EGTA, 100mM 
NaF, 10mM NaPP, along with a protease inhibitor cocktail containing sodium vanadate, 
ZnCl2, PMSF, and enzymatic inhibitors (Sigma # 10837091001). Protein lysates were run 
using SDS-PAGE, transferred to nitrocellulose membranes. Blots were exposed using 
SuperSignal West Pico Chemiluminescent Substrate (Fisher #34080). 
Statistical analyses 
P-values were calculated using Graph Pad Prism 7.0. Two-tailed t-tests were used to
compare two-variable experiments. Chi-squared analyses were used to compare birth 
ratios. Survival analyses were performed by Mantel-Cox log-rank tests. Two-way ANOVA 
analyses were used to compare changes in variables over time. All error bars represent 
S.E.M. Notation of statistical significance: * p-value<0.05; ** p-value<0.01; *** p-
value<0.001; n.s. not significant. 
26
Results 
A. HSC-Independent Disease Manifestations of PTPN11D61Y 
We hypothesized that in utero expression in early development of the PTPN11D61Y 
JMML-initiating mutation would result in the rapid onset of MPN in mice. To test this 
hypothesis we evaluated the mutation’s effect on isolated in utero hematopoietic 
progenitors. The expression of VavCre in fetal liver HSCs is well documented (Chen et al. 
2009). VavCre; PTPN11D61Y mice were viable and born at expected Mendelian ratio 
(Figure II-1A). They developed leukocytosis and monocytosis before 8 weeks of age, 
indicative of early-onset MPN (Figure II-1B). This early onset suggested that hyperactive 
RAS-ERK signaling may be contributing to disease emergence in these animals. To test 
this notion, we plated FL cells in methylcellulose colony forming assays at increasing 
doses of GM-CSF. VavCre;PTPN11D61Y mutant cells showed marked increase in colony 
formation at low cytokine doses compared with cells from littermates (Figure II-1C). 
Additionally, FL cells differentiated into myeloid cells demonstrated elevated 
phosphorylation of ERK both at baseline and following 30min stimulation with 5ng/ml GM-
CSF (Figure II-1D). These findings confirm that FL progenitors in VavCre;PTPN11D61Y 
animals demonstrate GM-CSF hypersensitivity and RAS-ERK hyperactivation; two 
defining features of JMML. 
E14.5 fetal livers contain progenitors from both embryonic and fetal phases. As 
such, our results could not determine whether HSC-independent progenitors from the 
embryonic phase demonstrated JMML-like features. Therefore, we isolated cells from 
E9.5 yolk sacs, a full day prior to the emergence of the first HSC. We confirmed that 
VavCre labels the majority of hematopoietic cells, including Ter119- CD45+ CD41+ cKit+ 
EMPs, in the E9.5 YS (Figure II-2A). Progenitors from mutant YS at this time also 
demonstrated GM-CSF growth hypersensitivity in colony forming assays and had greater 
RAS-ERK signaling following cytokine stimulation compared to littermate controls (Figure 
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 Figure II-1. VavCre+;PTPN11D61Y/+ Mice Have Defined Features of JMML. A) Genotype 
ratios at weaning of VavCre+ x PTPN11D61Y/+ matings; Chi-Squared p-value=0.04. B) 
Leukocyte counts at 8 weeks of age. C) Methylcellulose colony forming assays from E14.5 
fetal liver cells. D) M-CSF cultured fetal liver cells were stimulated for 30min with 10ng/ml 
GM-CSF and lysates were probed with indicated antibodies. 
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 Figure II-2. Yolk Sac EMPs from VavCre+;PTPN11D61Y/+ Mice Have Defined Features 
of JMML. A) VavCre is active in E9.5 YS EMPs (representative gating of 2 litters). B) 
Methylcellulose assay with E9.5 yolk sac unfractionated cells or sorted Ter119- cKit+ 
CD41dim EMPs (N=8 unfractionated litters and 2 sorted litters). C) pERK and pSTAT5 
signaling in M-CSF cultures of E9.5 YS progenitors following 30min of 5ng/ml GM-CSF 
stimulation (N=5 biological replicates/group from 2 independent experiments). 
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II-2B-C). These results confirmed that JMML disease-defining mutations cause features
of MPN in HSC-independent progenitors. The presumptive YS progenitor targeted by the 
mutation was the erythromyeloid progenitor (EMP), which is the dominant myeloid 
progenitor in the YS at this developmental stage (McGrath et al. 2015). To confirm, we 
sorted Ter119- cKit+ CD41dim EMP progenitors from mutants and littermates and plated 
them in colony forming assays. Mutant EMPs produced greater numbers of colonies at 
the tested concentrations of GM-CSF (Figure II-2B). This proved that the EMP is the YS 
progenitor responsible for the observed JMML features in the YS of VavCre;PTPN11D61Y 
animals. 
Nearly all JMML patients undergo HSC transplantation as first-line therapy. Half of 
these treated patients will relapse and will require a second transplant (Locatelli and 
Niemeyer 2015). Since the therapeutic efficacy of HSCT in JMML patients is significantly 
inferior to that of pediatric leukemias, we reasoned that long-lived HSC-independent 
hematopoietic cells may contribute to disease relapse. The progeny of YS EMPs persist 
in murine tissues as tissue resident macrophages in the brain, heart, liver, and spleen 
(Epelman et al. 2014; Gomez Perdiguero et al. 2015; Schulz et al. 2012; Hoeffel et al. 
2015). Under non-inflammatory conditions, these macrophages self-renew independently 
of HSC contributions. Furthermore, they are relatively resistant to myeloablation in the 
setting of transplantation (Hashimoto et al. 2013). Complementary studies in humans have 
demonstrated that macrophages and dendritic cells also resist replacement by donor cells 
following transplantation (Haniffa et al. 2009). These findings suggest the tantalizing 
possibility that JMML mutations in YS progenitors may persist in tissue resident myeloid 
cells and contribute to disease relapse in children following HSCT. 
We therefore hypothesized that VavCre;PTPN11D61Y mice would relapse following 
transplantation with healthy donor BM cells. We reasoned this relapse would occur due to 
poor donor engraftment resulting from a hyperinflammatory niche caused by ablation-
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resistant and mutation-expressing YS-derived macrophages. We transplanted 12-24week 
old lethally irradiated mutant and littermate animals (CD45.2+) with 5x105 heathy congenic 
CD45.1+ BM cells (Figure II-3A). We were surprised to observe that healthy donor cells 
engrafted more readily in mutant recipients that in control recipients (Figure II-3B). 
Furthermore, the engrafted cells preferentially gave rise to CD11b+ myeloid cells and to 
fewer CD3+ T-lymphocytes (Figure II-3C). Despite this robust engraftment, mutant 
recipient mice rapidly succumbed after transplantation, with a mean survival of 16 weeks 
(Figure II-3D). 
We hypothesized that the increased engraftment in our mutant animals stemmed 
from enhanced proliferation of healthy lineage-committed progenitors. This enhanced 
cycling may have been due to abnormal signaling cues in the mutants’ microenvironment. 
We reasoned that, as reported in pediatric transplant studies, a saturating dose of donor 
cells would improve the survival of our mutant recipients by diminishing the proliferative 
requirements of the donor cells (Kalwak et al. 2010). We therefore repeated the 
transplantation with 1x107 donor cells (Figure II-4A). In this setting no difference in donor 
chimerism was observed between mutant and littermate recipients (Figure II-4B). 
Furthermore, donor cells gave rise to myeloid, B, and T cells with equivalent frequencies 
in both groups (Figure II-4C). Nonetheless, mutant recipients had a mean survival of only 
18 weeks following transplantation (Figure II-4E).  
At analysis, moribund mutant recipients had a hypercellular BM with an effacement 
of the normal splenic follicular architecture (Figure II-5A). Blast-like cells were observed in 
the peripheral blood and mutant recipients had larger spleens than littermates. We were 
surprised, however, to find markedly enlarged thymuses in moribund mice. Subsequent 
immunophenotye analysis confirmed that both the BM and spleen were filled with recipient 
CD45.2+ CD4+ CD8+ abnormal T-lymphocytes (Figure II-5B). Transplantations of BM or 
spleen cells from HSCT-treated mutants into BoyJ recipients confirmed that the CD45.2+ 
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 Figure II-3. HSCT of VavCre+;PTPN11D61Y/+ Mice with 5x105 Healthy Donor Cells. A) 
Schematic of transplant. B) Donor engraftment in blood at indicates times after transplant. 
C) Analysis of lineages produced by engrafted cells at indicated times after transplant. D) 
Overall survival of mutant and control recipients following healthy donor HSCT (N=5 
mutant and 13 control recipients).  
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 Figure II-4. HSCT of VavCre+;PTPN11D61Y/+ Mice with 1x107 Healthy Donor Cells. A) 
Schematic of transplant. B) Donor engraftment in blood. C) Donor contribution to CD11b+ 
cells D) Spleen weights at analysis of mutant and control recipients (pooled from 5x105 
and 1x107 donor cohorts). E) Overall survival of animals transplanted with 1x107 healthy 
donor cells (N=4 mutants, 5 controls). F) Survival of animals transplanted with 2x106 BM 
or 4x106 spleen cells from moribund mutant primary recipients or healthy control primary 
recipients (N=7 mutant donors and 5 control donors). 
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 Figure II-5. VavCre+;PTPN11D61Y/+ Recipients Die of Host-Derived T-ALL. A) 
Immunohistochemistry of BM, spleen, and blood of mutant and littermate transplant 
recipients. B) Representative flow cytometry of CD45.2+ host-derived abnormal T-
lymphocytes in the BM and spleen of mutant recipients.  
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T-ALL disease could be propagated and was neoplastic (Figure II-4F). From these 
experiments we concluded that healthy donor cells could efficiently engraft mutant 
recipients and preferentially gave rise to myeloid progeny. Despite this robust engraftment, 
mutants died after transplantation due to the emergence of a recipient-derived T-ALL This 
relapsed disease could be propagated via transplantation and could not be prevented with 
a saturating dose of healthy donor cells. 
 
B. Insights from the VavCre;PTPN11E76K JMML model 
The PTPN11D61Y murine model has indolent disease progression. We reasoned 
that a different JMML-associated PTPN11 mutation that causes more rapid disease onset 
would aid our studies. The PTPN11E76K model fit this criteria. The mutation is functionally 
similar to PTPN11D61Y; both target the N-terminal SH2 domain and prevent its inhibition of 
the PTP catalytic domain (Loh et al. 2004). As such, both PTPN11E76K and PTPN11D61Y 
mutations enable constitutive phosphatase activity. However, PTPN11E76K murine models 
succumb to disease more rapidly than PTPN11D61Y models (Xu et al. 2011). Additionally, 
the PTPN11E76K mutation has been documented to occur in utero (Matsuda et al. 2010). 
We therefore hypothesized that repeating our studies with the more potent PTPN11E76K 
mouse model may permit emergence of disease manifestations that had been masked in 
our PTPN11D61Y model. 
Sorted EMPs from E10.0 VavCre;PTPN11E76K YS demonstrated GM-CSF growth 
hypersensitivity, again showing embryonic progenitors can have features of JMML (Figure 
II-6B-C). Surprisingly, when we mated VavCre mice with PTPN11E76K/+ mice we did not 
get viable VavCre;PTPN11E76K progeny (Figure II-7A). Analyses of E10.5 embryos 
showed mutants were smaller, less developed, and had a pale YS and AGM region (Figure 
II-7B). Subsequent analysis of E17.5 embryos confirmed that VavCre;PTPN11E76K 
embryos were dying in utero. These findings were surprising given that JMML patients 
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 Figure II-6. EMPs from E10.0 VavCre+;PTPN11E76K/+ Yolk Sacs Are Hypersensitive to 
GM-CSF. A) Mating strategy. B) Colony formation from sorted Ter119- cKit+ CD41dim 
E10.0 YS EMPs (n=4 embryos/group from 2 litters). C) Methylcellulose colony 
differentiation of mutant and littermate YS progenitors (N=3 litters).   
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 Figure II-7. VavCre+;PTPN11E76K/+ Mice Die In Utero with Non-Hematopoietic 
Oncogene Expression. A) Genotype ratio of animals weaned from VavCre(Croker et al) 
x PTPN11E76K/+ matings (N=45 births). B)  Representative images of E10.0 and E17.5 
embryos. F) Representative flow cytometric analysis of VavCre;ROSAYFP/+  lung, 
demonstrated highly efficient VavCre activity in both CD45+ F4/80+ macrophages and 
CD45- Ter119- CD31+ endothelial cells (gated in red) (experiment performed with Yang 
Lin). 
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can acquire their somatic PTPN11 mutations before birth (Matsuda et al. 2010; Kratz et 
al. 2005). Furthermore, other groups had previously shown VavCre;PTPN11E76K mice to 
be viable and live into adulthood (Liu et al. 2016; Dong et al. 2016). This prompted us to 
more closely characterize the identity of the model we were using.  
We discovered that there are at least 4 distinct versions of the VavCre strain, each 
with different expression patterns (de Boer et al. 2003; Stadtfeld and Graf 2005; Croker et 
al. 2004; Georgiades et al. 2002). The de Boer et al VavCre animal was used for our 
PTPN11D61Y studies because it had been bred into the mixed background of these 
animals.  The original characterization of this strain showed that in addition to 
hematopoietic expression, the de Boer VavCre also labelled the testis and ovaries. As 
such, the expression could have been transmitted through the germline and subsequently 
expressed in other lineage, including endothelium. The Croker et al VavCre was used in 
our matings with PTPN11E76K mice because both were available on a pure C57B6 
background. Its initial characterization documented expression in the endothelium as did 
the Georgiades P et al strain. We independently confirmed that this strain labels lung 
CD45- Ter119- CD31+ endothelial cells (Figure II7-C). 
The studies that produced viable VavCre;PTPN11E76K animals used the animal 
developed by Stadtfeld M & Graf T. Of the four available strains this is the only one whose 
expression appears limited to hematopoietic cells. Indeed, studies that sought to induce 
mutations after the endothelial to hematopoietic transition have relied on this strain (Chen 
et al. 2009). Even so, personal communications to our lab suggests that careful curation 
of animals is required to achieve this specificity. 
Despite the in utero lethality, EMPs from VavCre;PTPN11E76K animals at E10.0 
gave rise to a normal distribution of BFU-E, CFU-GM, and CFU-GEMM colonies (Figure 
II-6C). Since it was not possible to monitor their contribution to disease in host animals, 
we performed transplantation experiments to determine their potential to give rise to 
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disease in recipients (Figure II-8A). We transplanted 1 embryo equivalent (e.e.) FACS-
sorted EMPs from E10.5 yolk sac cells from VavCre;PTPN11E76K mice i.v. into 150cGy 
sublethally irradiated neonatal NOD.Cg-Prkdcscid  Il2rgtm1Wjl/SzJ (NSG) CD45.1+ 
recipients. We also transplanted CD45- Ter119- cKit+ VECadherin+ hemogenic 
endothelial populations from the YS and AGM of the same embryos. Prior work has 
demonstrated that this model is uniquely capable of supporting YS progenitor engraftment 
(Yoder et al. 1997; Yoder and Hiatt 1997; Johnson and Yoder 2005; Yoshimoto et al. 2010; 
Yoshimoto et al. 2012; Arora et al. 2014). Nonetheless, we did not observe peripheral 
blood engraftment or elevated leukocytes in neonatal recipients of either YS or AGM cells 
(Figure II-8B). This was consistent with recent studies that showed purified YS EMPs did 
not contribute to the circulation of neonatal recipients (McGrath et al. 2015). NSG animals 
are immune compromised and prone to infections. Our recipient animals became 
moribund due to presumed C. Bovis infection and were euthanized for humane reasons 
per the directions of the IUPUI LARC veterinary staff. 
At analysis, we were surprised to discover that donor EMPs had engrafted in 
recipient spleens as F4/80+ CD11bdim macrophages (Figure II-8C. The engraftment of 
splenic macrophages was more robust in recipients of YS EMPs than of AGM VECad+ 
cells. Notably, whereas the most prominent progeny of YS EMPs in unperturbed animals 
are microglia, we did not detect any CD45.2+ cells in the brains of YS recipients (Figure 
II-8D). These results are consistent with previous studies that showed differences in 
progenitor differentiation under native and transplant settings (Boyer et al. 2011; Beaudin 
et al. 2016; Busch et al. 2015). This highlights the pitfalls of models that rely on 
transplantation, which identify progenitor potentials under non-native conditions (Busch 
and Rodewald 2016; Hofer et al. 2016; Schlenner and Rodewald 2010; Feil et al. 2014). 
These results made it clear that evaluating the contribution of distinct hematopoietic 
phases to JMML would not be feasible using the VavCre model. 
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 Figure II-8 Neonatal Transplantation with Embryonic VavCre;PTPN11E76K 
Populations. A) Schematic of transplantations. Recipients were conditioned with 150cGy. 
B) Leukocyte counts of indicated recipients (N=2 recipients/group). C) Representative 
gating of YS EMP-derived splenic F4/80+ CD11bdim macrophages in neonatal recipients. 
D) YS EMPs do not contribute to microglial populations in engrafted animals. (Experiment 
performed with assistance from Dr. Momoko Yoshimoto). 
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C. CSF1R-MER-Cre-MER: A Hematopoietic-Restricted and Phase-Specific Model 
We set out in search of a new Cre strain that could model JMML with the 
PTPN11E76K mutation. Our criteria for this strain were as follows: i) Hematopoietic-
restricted Cre expression; ii) Well-defined expression within the hematopoietic phases; iii) 
The ability to monitor which cells express the mutation using a fluorescent marker; and iv) 
low level expression that would emulate the clonal nature of JMML We ultimately chose 
to use the CSF1R MER-Cre-MER system (Figure II-9A) (Qian et al. 2011). Therein, the 
expression of the Cre recombinase occurs in cells that actively transcribe the CSF1R (M-
CSF Receptor) gene. The N- and C-terminal ends of the Cre enzyme are linked to mutated 
estrogen receptor (MER) domains, which prevent the translocation of the enzyme to the 
nucleus. Only following the administration of tamoxifen and its hepatic conversion to the 
active 4-hydroxy tamoxifen (4-OHT) metabolite will the MER domains acquire nuclear-
localizing signals (Zhang et al. 1996). Then the MER-Cre-MER enzyme can bind to loxP 
sites, remove intervening DNA sequences through recombination, and permit the 
expression of desired genes. The recombination reaction is irreversible: once an allele is 
recombined in a progenitor then all of its progeny will also have a recombined allele. 
Nonetheless, the half-life of tamoxifen is approximately 24h (Wilson et al. 2014). 
Thereafter, the metabolite dissociates from the MER domains, whose localization once 
again becomes restricted to the cytoplasm—preventing Cre activity. Therefore, there is 
only a narrow window of time following tamoxifen administration in which recombination 
is possible in the CSF1R MER-Cre-Mer stain. As such, by timing the administration of 
tamoxifen we reasoned we would be able to specifically target each individual phase of 
hematopoiesis (Figure II-9B).  
Indeed, seminal lineage-trace studies demonstrated that E8.5 4-OHT 
administration would uniquely label YS EMPs in CSF1R-MCM;ROSAYFP embryos (Schulz 
et al. 2012; Gomez Perdiguero et al. 2015). No labelling of fetal liver HSCs, adult HSCs, 
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 Figure II-9. The CSF1R MER-Cre-MER System. A) Tamoxifen administration permits 
Cre activity as measured by expression of the YFP fluorescent protein. Tamoxifen binds 
the MER domains and permits nuclear localization of the MER-Cre-MER enzyme. Cre 
recognizes the loxP sites, removes the intervening DNA sequence containing the STOP 
cassette, and thereby permits expression of YFP. B) Timing the administration of 
tamoxifen permits targeting Cre activity to the three phases of hematopoiesis. 
MER=mutated estrogen receptor; T, TAM=tamoxifen; 4-OHT=4-hydroxy tamoxifen; 
YFP=yellow fluorescent protein. 
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or adult peripheral blood cells was observed. Additional studies that administered 
tamoxifen in adulthood suggested that tumour-associated myeloid cells were uniquely 
labelled (Qian et al. 2011). However, these studies restricted their analysis to peripheral 
tissues and to one week after injection. Personal communication with the authors (J.W.P. 
and B-Z .Q.) confirmed that weeks after adult administration of tamoxifen they saw 
labelling in circulating myeloid, B, and T cells—strongly suggesting that a multipotent 
progenitor was labelled. As such, we had strong evidence that the CSF1R-MCM model 
could be used to selectively label HSC-independent as well as both fetal and adult HSC-
dependent phases. Furthermore, by tittering the dose of tamoxifen, we would be able to 
modulate the efficiency of labelling to near-clonal levels. And by breeding the CSF1R-
MCM animals to the ROSA26YFP/YFP reporter strain, we would be able to distinguish 
mutation-expressing YFP+ cells from non-mutated YFP- cells in the same animal (Srinivas 
et al. 2001). 
A note on terminology. We outline below three cohorts of mice that were exposed 
to tamoxifen at E8.5, E14.5, or at 4 weeks of age. These cohorts had Cre activated in the 
embryonic, fetal, and adult hematopoietic phases, respectively (see Figure II-9). For 
simplicity we will name these cohort by phase. For instance, animals born following 
tamoxifen exposure at E14.5 will be the fetal cohort. As such, we will present embryonic, 
fetal, and adult cohorts of mutant and control mice. Since all CSF1R-MCM+ animals also 
possess a ROSAYFP allele, we will shorten our notation. For example: CSF1R MER-Cre-
Mer+; PTPN11E76K/+; ROSAYFP/+ mice as CSF1R-MCM;PTPN11E76K. Additionally, since 
these animals have YFP+ and YFP- cells we will refer to the sum of YFP+ and YFP- cells 
in a tissue as unfractionated cells or as net cells.  
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D. CSF1R-MCM; PTPN11E76K: Expression within the Embryonic Phase 
To generate animals that specifically express gain of function mutations in yolk sac 
erythromyeloid progenitors (YS EMPs) and their progeny, we performed timed matings 
between CSF1R-MCM+;ROSAYFP/YFP males and PTPN11E76K/+ females (Figure II-10). On 
E8.5, pregnant dams were injected i.p. with 75ug/g 4-OHT with 37.5ug/g progesterone to 
mitigate late-term abortions cause by pro-estrogenic effects of tamoxifen. We confirmed 
that at E9.5 EMPs were labelled with high efficiency and that no labelling was observed in 
fetal liver HSCs at E14.5 (Figure II-10D).  Mutant and littermate YS had comparable 
frequencies of EMPs and they were labelled with YFP at comparable efficiencies (Figure 
II-11B,C). However, we did not observe a proliferative advantage in either YFP+ or YFP- 
EMPs in mutant yolk sacs compared to controls as measured by Ki67 expression (Figure 
II-12A,C). Furthermore, we did not observe a hyperactive RAS signaling in progeny of 
mutant EMPs following GM-CSF stimulation as measured by pERK expression (Figure II-
12B,D).  
The lack of cell cycle and signaling differences was attributed to the high 
proliferative nature of all embryonic progenitors as compared with their adult counterparts. 
We reasoned that any oncogenic effects of PTPN11E76K mutation would only be manifest 
in their long-lived tissue macrophage progeny. 
 We proceeded to generate a cohort of CSF1R-MCM; PTPN11E76K animals whose 
EMPs had been activated with 4-OHT at E8.5. Despite the co-administration of 
progesterone, dams frequently experienced late-term abortions. Therefore, the majority of 
litters were delivered by C-section. Mutants were weaned at a Mendelian frequency of 
24% and were physically indistinguishable from littermates (Figure II-13A).  We monitored 
all animals in this embryonic cohort with monthly peripheral blood draws (Figure II-13B-
F). As expected, we did not observe YFP+ cells in the peripheral blood. Over a 52week 
period, we did not observe leukocytosis, anaemia, or thrombocytopenia in mutant animals. 
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 Figure II-10. CSF1R-MCM Labels YS Erythromyeloid Progenitors. A) Schematic of 
mating strategy and 4-hyroxy tamoxifen (4-OHT) administration to pregnant dams. B) 
Representative flow gating demonstrating CSF1R-MCM drives ROSAYFP expression in 
E9.5 yolk sac EMPs (Ter119- CD45+ cKit+ CD41dim). C) Representative gating of CSF1R-
MCM (E8.5 4-OHT) contribution to E12.5 fetal liver cells. D) No CSF1R-MCM activity was 
observed in HSC-dependent fetal liver populations at E14.5.  
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Figure II-11. Embryonic Phase CSF1R-MCM; PTPN11E76K: Yolk Sac EMP Frequency 
and Labeling Efficiency. A) Legend of analyzed genotypes. B) Frequency of EMPs in 
E9.5 yolk sacs. C) Proportion of EMPs that are YFP+ following E8.5 4-OHT.  
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 Figure II-12. Embryonic Phase CSF1R-MCM; PTPN11E76K: E9.5 EMP Cell Cycle and 
Signaling Analysis. A) Ki67 expression in E9.5 yolk sac EMPs (expression normalized 
to average MFI among EMPs in each litter). B) pERK expression among YS EMP-derived 
macrophages after stimulation with 20ng/ml. C) Representative cell cycle gating of YFP+ 
and YFP- YS EMPs from mutant and control yolk sacs. D) Representative gating of pERK 
expression in YFP+ and YFP- YS-derived macrophages from mutant and control embryos 
stimulated with 20ng/ml GM-CSF for indicated durations. MFI=mean fluorescence 
intensity; 4-OHT=4 hydroxy tamoxifen. 
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 Figure II-13. Embryonic Phase CSF1R-MCM; PTPN11E76K: Birth Ratio and CBC 
Analysis. A) Genotype ratios at weaning of indicated matings (Chi-squared p-
value=0.002). B) Frequency of YFP+ leukocytes in peripheral blood. C-F) CBC analysis 
of leukocyte frequency, erythrocyte frequency, hemoglobin density and platelet 
abundance. Statistical analyses were performed by two-way ANOVA.  
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 Figure II-14. Embryonic Phase CSF1R-MCM; PTPN11E76K: Survival and Blood 
Leukocyte Analysis. A) Schematic of mating and analysis (N=14 mutants and 43 
controls). B) Overall survival of CSF1R-MCM; PTPN11E76K; ROSAYFP/+  animals from the 
HSC-independent (E8.5 4-OHT) cohort (p-value=0.409 by log-rank test) C-E) Frequency 
of CD11b+ myeloid cells, B220+ B-lymphocytes, and CD3+ CD11b- T-lymphocytes in 
peripheral blood. Lineage frequency statistics performed with two-way ANOVA. 
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Furthermore, we did not see evidence of myeloproliferation or skewing of other blood 
lineages (Figure II-14). Over the course of the study, one mutant animal succumbed from 
an unclear cause. One littermate control developed sporadic T-ALL and was euthanized 
for humane reasons as per the request of IUPUI LARC veterinary staff. 
We considered that indolent MPN progression in this embryonic cohort may not 
manifest in the peripheral blood and would only be evident upon tissue examination. Upon 
analysis, mutant animals did not have enlarged spleens or livers and their thymuses were 
the same size as those of littermates (Figure II-15 B-E). There was no evidence of 
leukocyte lineage skewing in the BM and spleen of mutants, which was consistent with 
the findings obtained from our year-long analysis of peripheral blood (Figure II-15F,G). 
We proceeded to characterize the macrophage populations in the brain, heart, liver, and 
spleen, which have the greatest contribution from YS EMPs (Figure II-16) (Epelman et al. 
2014; Gomez Perdiguero et al. 2015; Bain et al. 2014). Consistent with previous reports 
we saw high proportions of YFP+ microglia and measureable proportions of YFP+ heart 
and liver macrophages. No labelled cells were detected in the BM or spleen.  PCR analysis 
confirmed the loxP-STOP-loxP cassette of the PTPN11E76K allele was recombined in the 
brain of mutant animals, demonstrating that the mutation should be expressed in microglia 
(Figure II-16F). Nonetheless, we did not observe differences in the frequency of YFP+ 
macrophages between CSF1R-MCM; PTPN11E76K and controls in any tissue. This 
suggests that the PTPN11 mutation did not confer a proliferative advantage to 
macrophages. Furthermore, whereas all CSF1R-MCM+ animals had YFP+ microglia, their 
frequency was strikingly different among analyzed litters (Figure II-16E). This suggests 
that small differences in the timing or dosing of in utero tamoxifen may result in markedly 
different labelling efficiency, irrespective of whether a mutant allele is present. As such, 
any difference in the frequency of YFP+ microglia is more likely to be attributed to litter 
than to the expression of a mutation (two-way ANOVA: p-value<0.001). Nonetheless, we 
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 Figure II-15. Embryonic Phase CSF1R-MCM; PTPN11E76K: Tissue Analysis. A) 
Animals were analyzed a 52 weeks of age. B-E) Weights of body, thymus, spleen, and 
liver. F,G) Frequency of B-cells, T-cells, and myeloid cells in the bone marrow and spleen 
of mutants and littermates as measured by flow cytometry. 
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 Figure II-16. Embryonic Phase CSF1R-MCM; PTPN11E76K: Macrophages Analysis. A-
D) Frequency of YFP+ macrophages in the brain, heart, liver, and spleen of mutant 
animals and controls at 52 weeks of age. E) Frequency of YFP+ macrophages in CSF1R-
MCM+ animals in each litter (variation due to litter: two-way ANOVA p-value<0.001). F) 
PCR analysis of genomic DNA demonstrates populations in the brain have recombination 
of LSL-PTPN11E76K locus.   
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are able to conclude that expression of PTPN11E76K in a subset of YS EMPs is not 
sufficient for the emergence of a MPN. 
 
E. CSF1R-MCM Activity within Fetal and Adult Phases 
Having analyzed the contribution of the embryonic HSC-independent phase to 
MPN development, we proceeded to compare the effects of PTPN11E76K expression in 
progenitors of the fetal and adult HSC-dependent phases. We modified the timing of 
tamoxifen administration (see Figure II-9).; the fetal cohort obtained one 75ug/g 4-OHT 
+37.5ug/g progesterone injection at E14.5, whereas the adult cohort received 3 daily 
75ug/g tamoxifen injections beginning at 4 weeks of age We had strong reason to be 
confident that the timing of our doses would activate progenitors solely from the desired 
phase. Previous studies have shown that tamoxifen exposure after E10.5 no longer labels 
EMPs in the CSF1R-MCM model (Hoeffel et al. 2015). Furthermore, between 3-4 weeks 
of age mouse HSCs undergo a pronounced functional change that defines the fetal to 
adult transition: they enter quiescence, they alter their gene expression, they have 
differential responses to cytokine signals, and they acquire biased lineage differentiation 
(Bowie et al. 2006; Benz et al. 2012; Copley et al. 2013; He et al. 2011; Yuan et al. 2012; 
Kim, Saunders, and Morrison 2007). As such, we reasoned the timing of our tamoxifen 
doses would target distinct phases of hematopoiesis and would permit evaluation of the 
specific contribution of each to MPN development. 
CSF1R is transcriptionally active in numerous hematopoietic progenitor 
populations (Wilson et al. 2015), each of which can be identified by immune phenotype 
using flow cytometry (see Figure II-17). These CSF1R-expressing progenitors include 
HSCs, multipotent progenitors (MPP), Myeloid-Dendritic cell progenitors (MDP), common 
monocyte progenitors (CMoP), early thymic progenitors (ETP), and myeloid restricted Lin- 
cKit+ Sca1- (LK) cell subsets: common myeloid progenitors (CMP), granulocyte-
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 Figure II-17. Flow Cytometric Gating Strategy of Hematopoietic Progenitors.  
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macrophage progenitors (GMP) and megakaryocyte-erythroid progenitors (MEP) (Luc et 
al. 2012; Waskow et al. 2008; Hettinger et al. 2013). Therefore, we hypothesized that 
tamoxifen injection into CSF1R MCM;ROSAYFP/+ mice would label a diverse progenitor 
population. To test this hypothesis, we analyzed 4 week-old mice 24hr after the third 
tamoxifen injection (Figure II-18). We observed 1.1 +/- 0.5(S.D.)% and 1.1 +/- 0.4% 
labelling of BM LK and LSK cells, respectively. We further observed 0.67 +/-0.28% and 
1.5 +/-0.5% labelling of spleen LK and LSK cells, respectively. This demonstrates that our 
model has reproducible, low efficiency labelling of hematopoietic progenitors. Further 
analysis demonstrated that short-lived myeloid biased progenitors, such as MDPs, 
CMoPs, and GMPs, were labelled at higher efficiencies. LK cells, LSK cells, and HSCs 
were labeled at similar efficiencies in the fetal liver following 4-OHT injection at E14.5. 
(Figure II-19). Strikingly, thymic progenitors were labelled at 6.1 +/- 3.0%, confirming that 
both myeloid and lymphoid progenitors were targeted in our model (Figure II-20). Finally, 
we determined that CSF1R-MCM was not active in non-hematopoietic mesenchymal stem 
cells or osteoblasts and had negligible activity in endothelial cells (Figure II-21). Having 
confirmed that CSF1R-MCM has hematopoietic-restricted activity and labels progenitors 
of all lineages, we proceeded to use this model to express PTPN11E76K in both adult and 
fetal progenitors. 
 
F. Comparison of PTPN11E76K/+ Expression in Fetal and Adult Phases of 
Hematopoiesis 
We hypothesized that YFP+ cells in mutant animals would have a proliferative 
advantage over YFP- cells due to the expression of PTPN11E76K. We reasoned this 
increase in mutant allele frequency could be quantified by the %YFP+ leukocytes in the 
blood. In our adult cohort, mutant and control animals had an equal %YFP+ cells 1 week 
after injection. Thereafter, the %YFP+ leukocytes were significantly expanded in mutant 
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 Figure II-18. CSF1R-MCM Labels Progenitors in the Adult Phase. Frequency of YFP+ 
cells in A,C) BM and B,D) spleen 48hrs after tamoxifen injection at 4weeks of age. 
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 Figure II-19. CSF1R-MCM Labels Progenitors in the Fetal Phase. Frequency of YFP+ 
cells in the fetal liver 48hrs after 4-OHT injection at E14.5. B) Grouped analysis. C) 
Analysis by litter shows minimal differences in LSK labeling efficiency between litters (two-
away ANOVA p-value =0.09). 
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 Figure II-20. CSF1R-MCM Labels Progenitors in the Thymus. A) Gating strategy to 
analyze thymic progenitors. B,C) Frequency of YFP+ cells in thymus 48hrs after tamoxifen 
injection at 4weeks of age.  
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 Figure II-21. CSF1R-MCM Does Not Label Endothelial Cells or BM Stromal Cells. A) 
Gating strategy to analyze BM endothelial cells and stromal cell populations. B) Frequency 
of YFP+ cells in BM 7 days after tamoxifen injection in 4 week old CSF1R-MCM;ROSAYFP/+ 
animals. MSPC=mesenchymal stem and progenitor cells. 
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animals at all analyzed time points (Figure II-22B). This difference was greatest at 24-36 
weeks after tamoxifen treatment and declined thereafter. Strikingly, mutant animals 
demonstrated overall leukocytosis compared to littermates at 5-8 weeks after treatment 
and again at 32 weeks, coinciding with the peak of %YFP+ cells. This suggested that 
oncogene expression in a minor subset of progenitors was sufficient to cause 
leukocytosis. The distribution of YFP+ cells in mutant animals was myeloid biased and 
there was a paucity of YFP+ T cells (Figure II-23A,B). Strikingly, albeit the frequency of 
YFP+ cells was never greater than 10% of leukocytes, mutant animals showed a decrease 
in net (YFP+ and YFP- combined) T-lymphocytes in older age with a concomitant increase 
in net CD11b+ neutrophils (Figure II-24A,B). Combined, these results suggest that low 
frequency expression of PTPN11E76K in adult progenitors result in a marked expansion of 
that subset with myeloid-biased differentiation and overt hematologic abnormalities in 
mutant animals.  
We performed the same analysis in our fetal cohort, in which the PTPN11E76K 
mutation was expressed in utero at E14.5. We did not observe leukocytosis or an 
increased frequency of YFP+ cells in mutant animals in the fetal cohort (Figure II-22,A,B). 
Additionally, we did not observe biased lineage distribution among YFP+ cells (Figure II-
23). Nonetheless, mutants from the fetal cohort did show increased net CD11b+ myeloid 
cells and decreases in net CD3+ T-lymphocytes (Figure II-24A,B). This suggests that 
mutant cells from the fetal phase disrupted the microenvironment and are contributing to 
MPN development in a non-cell autonomous fashion. This finding parallels the 
observations from the adult cohort. Indeed, mutant animals from both fetal and adult 
cohorts showed thrombocytopenia with increased platelet size at all analyzed time 
intervals, suggestive of a consumptive coagulopathy (Figure II-25B,C). 
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 Figure II-22. Comparison of PTPN11E76K Expression in Adult and Fetal Phases:  
Leukocytes, %YFP+, Survival. A) Leukocyte counts of cohorts over time (peripheral 
blood N=14 adult mutants, 25 adult littermates, 7 fetal mutants, 15 fetal littermates). B) 
%YFP+ leukocytes in blood as measured by flow cytometry. C) Overall survival (Survival 
analysis N= 32 adult mutants, 48 adult littermates, 7 fetal mutants, 15 fetal littermates).  
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 Figure II-23. Comparison of PTPN11E76K Expression in Adult and Fetal Phases: 
Lineage Bias of YFP+ Cells. A-C) Analysis of frequencies of CD11b+ myeloid cells, 
CD3+ CD11b- T-cells, and B220+ B-cells among YFP+ cells the peripheral blood of adult 
& fetal cohort CSF1R-MCM;PTPN11E76K/+;ROSAYFP/+ animals and their controls.  
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 Figure II-24. Comparison of PTPN11E76K Expression in Adult and Fetal Phases: 
Lineage Bias of Unfractionated Peripheral Leukocytes. A-C) Analysis of frequencies 
of CD11b+ myeloid cells, CD3+ CD11b- T-cells, and B220+ B-cells among all leukocytes 
cells the peripheral blood of adult & fetal cohort CSF1R-MCM;PTPN11E76K/+;ROSAYFP/+ 
animals and their controls.  
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 Figure II-25. Comparison of PTPN11E76K Expression in Adult and Fetal Phases: 
Erythrocyte and Platelet Analysis. A-C) Analysis of erythrocyte abundance, platelet 
abundance, and the mean platelet volume (MPV) of adult & fetal cohort CSF1R-
MCM;PTPN11E76K/+;ROSAYFP/+ animals and their controls. 
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F. Non-Cell Autonomous Effects of Hematopoietic-Restricted PTPN11E76K 
Expression 
To evaluate the effects of low mutant allele frequency on the microenvironment, 
we proceeded to analyze hematopoietic tissue compartments. We chose to look at our 
adult cohort 32 weeks after tamoxifen injection because this coincided with the most 
pronounced leukocytosis and %YFP+ cells. We observed marked hepatosplenomegaly in 
mutant animals (Figure II-26B,C). This further supports our assumption of a consumptive 
coagulopathy, as was suggested by our CBC analysis. The frequency of YFP+ cells was 
increased in mutant animals in all analyzed mature leukocyte populations in the BM, 
spleen, and thymus (Figure II-27).  This confirms that the oncogene is active in progenitors 
that are multipotent and that the oncogene confers a proliferative and/or survival 
advantage to these progenitors. Nevertheless, the mean frequency of YFP+ cells never 
exceeded 12%, suggesting that the majority of cells in the tissues of mutant animals did 
not express the mutation. We reasoned, therefore, that any observed net differences in 
population frequency would likely be the result of non-cell autonomous effects of 
oncogene-expressing cells. 
We observed a net reduction of CD8+ cells in the BM and spleen of mutant animals 
(Figure II-27D,E). In the thymus, however, we did not detect differences in the frequencies 
of CD4+, CD8+, or double positive (DP) cells (Figure II-28B). Furthermore, we did not 
observe differences in the frequency of committed T cell progenitors: the double negative 
(DN) IIa, IIb, and III populations. However, we did observe a marked expansion of early 
thymic progenitors (ETPs, Lin- CD44+ cKit+) as well as thymic dendritic cells (Lin- CD44+ 
CD11c+) (see Figure II-28C). The increase in ETPs without a concomitant increase in 
downstream progenitors is suggestive of a block in ETP commitment to the T cell lineage. 
This is supported by our finding that the expression of CD25 among committed T cell 
progenitors was decreased in mutant animals compared to controls (Figure II-28D). These 
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 Figure II-26. Adult CSF1R-MCM; PTPN11E76K: Hepatosplenomegaly. A) Mutant 
animals and controls were analyzed 12 and 32weeks after tamoxifen injection. B) Spleen, 
thymus, and liver weights among mutants and controls and indicated intervals after 
tamoxifen treatment. C) Images of mutant & control spleens 32 weeks after tamoxifen. 
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 Figure II-27. Adult CSF1R-MCM; PTPN11E76K: Leukocytes in BM and Spleen. A) 
Analysis was performed 32 weeks after tamoxifen treatment. B,C) Frequency of YFP+ 
cells among lymphoid and myeloid populations in the BM and spleen of mutants and 
controls. D,E) Overall (YFP+ and YFP-) frequency of myeloid and lymphoid cells in BM 
and spleen of mutants and controls. 
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 Figure II-28. Adult CSF1R-MCM; PTPN11E76K: Thymocytes. A) Analysis was performed 
32 weeks after tamoxifen treatment. B) Overall (YFP+ and YFP-) frequency of T and 
lymphoid cells in thymuses of mutants and controls. C) Frequency of CD11c+ dendritic 
cells and cKit+ early thymic progenitors in mutant and control thymuses. D) CD25 Mean 
florescence intensity (MFI) among DN-IIa, DN-IIb, and DN-III populations in mutant and 
control thymuses.  
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findings suggest that oncogene expression within the thymus causes defects in T cell 
production, which may be exacerbated over time.  
We proceeded to analyze myeloid cells in our mutant animals. In the spleen we 
observed an increase in net neutrophils and dendritic cells (Figure II-27D,E). This finding 
paralleled our peripheral blood analyses. However, differences in these populations were 
not detected in the BM. We proceeded to analyze the frequency of YFP expression 
amongst BM and splenic progenitors (Figure II-29). All analyzed progenitor subsets had a 
greater frequency of YFP+ cells in mutants compared to controls. However, their 
proportion never exceeded 13%. Therefore, this expansion of YFP+ cells was unlikely to 
account cell autonomously for any observed net differences.  
Indeed, we did not observe any differences in the absolute number of progenitors 
in the BM (Figure II-30B). However, we did observe an increase in the absolute number 
of splenic HSCs in mutant animals (Figure II-30C). We also observed an increase in 
mutant MEPs, which is suggestive of increased non-medullary erythropoiesis – a defining 
feature of JMML (Figure II-30E). Subsequent analysis of splenic erythroid committed 
progenitors confirmed an expansion of CD71+ Ter119- pro-erythroblasts, CD71+ Ter119+ 
early erythroblasts, and CD71- Ter119+ FSCHi late erythroblasts (Koulnis et al. 2011) (see 
Figure II-31). Similar trends were seen in the BM, albeit the differences were less 
pronounced. These findings, along with the observation of increased HSCs in the spleens 
of mutant animals, strongly suggest that non-cell autonomous effects in the context of low 
mutant allele frequency cause hematopoietic stress that promotes non-medullary 
hematopoiesis. 
We sought to further probe the functional consequences of oncogene expression 
in the tissue microenvironment of our animals. We plated unsorted (YFP+ and YFP-) BM 
cells from mutant animals in methylcellulose medium with increasing doses of GM-CSF. 
Surprisingly, we observed a marked increase in colony formation among mutant 
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 Figure II-29. Adult CSF1R-MCM; PTPN11E76K: YFP+ Progenitor Frequencies. A) 
Analysis was performed 32 weeks after tamoxifen treatment. B,C) Proportion of BM and 
splenic progenitors that express YFP.  
  
70
 Figure II-30. Adult CSF1R-MCM; PTPN11E76K: Absolute Progenitor Frequencies. A) 
Analysis was performed 32 weeks after tamoxifen treatment. B) Absolute cell number of 
YFP+ and YFP- BM progenitors in mutant and controls. C) Relative cell number of YFP+ 
and YFP- BM progenitors in mutant and controls calculated by multiplying the frequency 
of progenitors by each animal’s spleen weight. D,E) Distribution of CMP, GMP, and MEP 
populations among LK cells in the BM and spleen of mutants and controls.  
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 Figure II-31. Adult CSF1R-MCM; PTPN11E76K: Erythroid Progenitors. A) Analysis was 
performed 32 weeks after tamoxifen treatment. B) Absolute cell number of BM erythroid 
progenitors in mutant and controls. E) Relative number of splenic erythroid progenitors in 
mutant and controls calculated by multiplying the frequency of progenitors by each 
animal’s spleen weight. D) Representative flow cytometric plot of erythroid progenitors in 
mutant and control spleens. 
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progenitors at low cytokine doses (Figure II-32B). Since the frequency of YFP+ oncogene-
expressing progenitors in these samples was only 10%, it is very unlikely for them to 
account cell-autonomously for the observed hypersensitivity. We proceeded to evaluate 
RAS-ERK signaling following GM-CSF stimulation in mutant animals (Figure II-33). 
Progenitors were cultured for 7days in medium containing 10ng/ml M-CSF in order to 
differentiate them into myeloid cells. Cells were then starved of serum for 4hrs and 
stimulated with 10ng/ml GM-CSF for 0, 10, or 30min. The level of pERK expression was 
measured using flow cytometry. YFP+ and YFP- cells had equal pERK expression at all 
doses of GM-CSF. In contrast, YFP+ and YFP- mutant cells both had higher pERK 
expression at 10min of stimulation compared to cells from littermates. However this 
preliminary study was not adequately powered and will be repeated. Importantly, when 
the same experiment was performed with sorted YFP+ and YFP- cells that were assayed 
independently, only YFP+ cells demonstrated features of JMML (Figure II-34). This finding 
strongly suggests that non-cell autonomous effects of oncogene-expressing YFP+ cells 
alter the GM-CSF sensitivity healthy YFP- progenitors that cohabit the same BM niche. 
 
Discussion 
We present the first study to directly compare the expression of a JMML mutation 
within three distinct hematopoietic phases. We demonstrate that both HSC-dependent 
and HSC-independent in utero progenitors that express the PTPN11D61Y mutation bear 
defining molecular features of JMML patients: growth hypersensitivity in response to GM-
CSF and hyperactive RAS-ERK signaling. We go on to show that YS EMPs are the HSC-
independent progenitor responsible for this phenotype. Restricted expression of the 
PTPN11E76K mutation in YS EMPs was unable to produce disease manifestations after 
transplantation into neonatal recipients or under unperturbed conditions following in utero 
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 Figure II-32. Adult CSF1R-MCM; PTPN11E76K: BM Progenitors are Growth 
Hypersensitive to GM-CSF. A) Methylcellulose assays were performed using unsorted 
BM from mutants and controls 32 weeks after tamoxifen. B) Relative colony number after 
7days in culture. N=3 mutant and 3 control animals, each condition plated in triplicate. C) 
Representative images of colonies plated at indicated doses of GM-CSF (ng/ml).   
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 Figure II-33. Adult CSF1R-MCM; PTPN11E76K: Co-Cultured YFP+ and YFP- 
Progenitors Have Equally Hyperactive RAS signaling. A) Signaling assays were 
performed using unsorted BM from mutants and control that was cultured in M-CSF for 
7days (N=3/genotype). B) pERK mean fluorescence intensity (MFI) among control and 
mutant cells stimulated with 10ng/ml GM-CSF. Mutant YFP+ and YFP- cells were co-
cultured and co-stimulated. C) Representative histograms of pERK in YFP+ mutant cells, 
YFP- mutant cells, and control cells. FMO=fluorescence minus one. 
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 Figure II-34. Adult CSF1R-MCM; PTPN11E76K: Sorted YFP+ and YFP- BM Progenitors 
Have Distinct Responses to GM-CSF. A) YFP+ and YFP- progenitors were sorted from 
mutant animals (N=2). B) Colony formation of YFP+ and YFP- progenitors from the same 
animal, plated separately. C) Representative images of colonies at indicated doses of GM-
CSF, scale bar=0.5mm. D) Representative pERK expression in YFP+ and YFP- 
progenitors cultured separately in M-CSF for 7 days and stimulated separately with 
10ng/ml GM-CSF. 
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expression with tamoxifen-inducible CSF1R-MCM. In contrast, PTPN11E76K expression in 
fetal or adult HSC-dependent progenitors did produce evidence of MPN emergence.  
In the adult cohort, we saw a striking expansion of mutant YFP+ cells in myeloid, 
B cell, and T cell lineages in the blood, BM, spleen, and thymus. This was accompanied 
by a concomitant increase of YFP+ multipotent, myeloid-restricted, and lymphoid-biased 
progenitors in the BM, spleen, and thymus. We also observed non-cell autonomous effects 
of the PTPN11E76K mutation. There was a net increase in dendritic cells, neutrophils, and 
erythroid progenitors in the spleen along with a decrease of CD8+ T-lymphocytes. The 
thymus had an increase in net ETPs and dendritic cells and showed evidence of defective 
T-lymphocyte commitment 32 weeks after PTPN11E76K expression. Finally, HSCs 
numbers were increased in the spleens of mutant animals and we observed GM-CSF 
hypersensitivity and RAS-ERK hyperactivation in both YFP+ and YFP- BM progenitors. 
 Previous studies have provided tantalizing evidence for the potential contribution 
of embryonic HSC-independent hematopoiesis to JMML. First, the strikingly high relapse 
rate following HSCT suggests that HSC-independent and myeloablation-resistant 
populations contribute to disease emergence (Locatelli et al. 2013). YS EMPs admirably 
match these criteria: they contribute to tissue macrophage populations in diverse tissues 
that are long-lived and relatively resistant to myeloablation (Gomez Perdiguero et al. 2015; 
Epelman et al. 2014; Hashimoto et al. 2013; Haniffa et al. 2009). Second, JMML patients 
acquire their disease-initiating mutations in utero (Matsuda et al. 2010). Finally, several 
studies have successfully modelled JMML using patient-derived iPSCs, whose 
differentiation pathways mimic that of embryonic—and not HSC-dependent—
hematopoiesis (Gandre-Babbe et al. 2013; Mulero-Navarro et al. 2015; Vanhee et al. 
2015; Buchrieser, James, and Moore 2017). This reasoning prompted us to hypothesize 
that expression of JMML-initiating mutations in embryonic HSC-independent progenitors 
would be sufficient for disease development (Chan and Yoder 2013). 
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We demonstrated the feasibility of this hypothesis with our initial VavCre; 
PTPN11D61Y experiments. HSC-independent yolk sac EMPs from these embryos had two 
disease-defining features of JMML: growth hypersensitivity to GM-CSF and hyperactive 
RAS-ERK signaling. However, they were unable to give rise to disease manifestations 
either upon transplantation or following spatiotemporal-restricted expression using 
CSF1R-MCM. This lack of symptoms was not the result of experimental failures. 
Amazingly, and in contrast to previous reports (McGrath et al. 2015), we were able to 
show that mutation-bearing VavCre;PTPN11E76K YS EMPs engrafted neonatal recipients 
and contributed to a self-replenishing macrophage population for at least 18 weeks after 
transplantation. Furthermore, in our CSF1R-MCM lineage trace studies, we demonstrated 
that all 1 year old mutant animals had YFP+ myeloid cells that had recombined their 
mutant PTPN11 locus. As such, we have strong evidence that in both of these studies 
HSC-independent progenitors persisted in adult tissues, expressed the JMML-initiating 
mutation, but were unable to give rise to a MPN. 
There are several possible explanations for the lack of disease in our embryonic 
cohorts. First, YS EMPs may not possess the differentiation potential required for 
fulminant MPN emergence. Indeed, the long lived progeny of EMPs are tissue resident 
macrophages, which are functionally, transcriptionally, and epigenetically distinct from the 
monocytes/neutrophil lineage that is expanded in JMML patients (Lavin et al. 2014; 
Gosselin et al. 2014). Indeed, healthy EMPs are already so proliferative that oncogene 
expression had no effect on their expression of the cell-cycle marker Ki67. Furthermore, 
only 35% of E9.5 EMPs were targeted in our model. This is a much lower frequency than 
the >90% efficiency obtained from most published conditional mouse models, such as 
Mx1Cre or VavCre. Finally, whereas the CSF1R-MCM can only label EMPs between E8.5 
and E9.5 (Gomez Perdiguero et al. 2015; Hoeffel et al. 2015), the transcriptional program 
that drives the emergence of EMPs begins between E6.5 and E7.5. The first EMPs 
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emerge at E8.25, continue to arise until as late as E11.5, and EMPs will proliferate until 
birth (Tanaka et al. 2012; Tober et al. 2013; Chen et al. 2011). As such, our system labels 
only a minority of one subset of EMPs and it is possible that other HSC-
independent progenitors, including distinct EMP subpopulations and neonatal 
repopulating cells, may respond differently when expressing PTPN11 mutations (Frame 
et al. 2016; Sheng, Ruedl, and Karjalainen 2015; Yoder et al. 1997). Nonetheless, our 
results permit the conclusion that PTPN11E76K expression in a subset of E9.5 YS EMPs 
does not result in an expansion of mutant macrophages and is not sufficient for MPN 
emergence in a mouse model of JMML. 
HSC-dependent hematopoiesis is markedly different from that of yolk sac EMPs. 
HSC-dependent progenitors from the fetal and adult phases are more numerous, self-
renew indefinitely, and produce cells from all lineages. Nonetheless, fetal progenitors differ 
from adult ones: the former are more proliferative, have greater repopulating potential, 
give rise to more myeloid colonies in semi-solid culture, have unique gene expression 
signatures, and have more lymphoid-biased long-term differentiation potential (Lansdorp, 
Dragowska, and Mayani 1993; Bowie et al. 2006; Bowie et al. 2007; Copley, Beer, and 
Eaves 2012; Copley et al. 2013). Additionally, strong evidence suggests that it is a fetal 
progenitor that is responsible for the emergence of JMML. Disease-initiating mutations are 
known to occur in utero and JMML is the only malignancy characterized by persistently 
elevated levels of fetal hemoglobin (Matsuda et al. 2010; Kratz et al. 2005; Weinberg et 
al. 1990).The fetal to adult transition has been inferred to occur at 2 years of age, which 
coincides with the mean JMML age of onset (Rufer et al. 1999; Sidorov et al. 2009). The 
majority of JMML patients have BM cells with a fetal-like gene expression signature, which 
further correlates with inferior prognosis. This same signature is present in only 10% of 
pediatric AML, 2% of pediatric ALL, and is absent from other pediatric MDS (Helsmoortel, 
De Moerloose, et al. 2016; Helsmoortel, Bresolin, et al. 2016) For this reason, we 
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hypothesized that PTPN11E76K expression within a fetal progenitors would produce a more 
faithful JMML model than expression within adult progenitors. 
 Our study used fluorescent lineage trace methods to define the expression pattern 
of CSF1R-MCM following tamoxifen administration at E14.5 and at 4weeks of age. We 
show durable year-long contributions to peripheral lymphocytes from all lineages. This 
was the result of low efficiency labelling of HSCs either in the fetal liver or in the BM and 
spleen. In addition, we simultaneous labeled more committed progenitors including MPPs, 
and myeloid- and lymphoid-committed progenitors in the BM, spleen, and thymus. 
Importantly, we showed that there was negligible activity of CSF1R-MCM in 
mesenchymal, osteoblast, and endothelial lineages. As such, we confirmed that this model 
would meet our a priori criteria for evaluating the contribution of distinct hematopoietic 
phases to MPN. Namely: i) hematopoietic restricted expression; ii) spatiotemporally 
regulated; iii) low level efficiency to mimic the disease clonality; and iv), the ability to trace 
mutation-expressing cells using fluorescent molecules.  
Both fetal and adult cohorts of CSF1R-MCM; PTPN11E76K mice had evidence of 
MPN. The fetal cohort had an increase in net CD11b+ peripheral leukocytes compared to 
controls. It was surprising, however, that these animals did not show a net increase in 
%YFP+ cells and that there was no myeloid-biased differentiation among YFP+ cells. In 
contrast, the adult cohort showed a pronounced increase in %YFP+ cells. YFP+ cells in 
the adult cohort preferentially contributed to CD11b+ myeloid cells and showed diminished 
contributions to T-lymphocyte populations. This suggested that the oncogene caused a 
cell autonomous block in T-lymphocyte commitment in the adult cohort, which was not 
observed in the fetal cohort. Similar reductions in T-lymphocyte frequencies have been 
reported in the BM, spleen, and peripheral blood of patients (Oliveira et al. 2016; 
Krombholz et al. 2016). Furthermore, whereas patient’s multipotent progenitors do 
express JMML-initiating mutations, the majority of peripheral T-lymphocytes do not 
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(Sakaguchi et al. 2013; Stieglitz, Troup, et al. 2015). This provides clinical validation of the 
decreased T cell frequencies in our adult cohort and suggests that a more focused clinical 
evaluation of T-lymphocyte subsets in patients is warranted.  
We sought to evaluate the cellular mechanism for this T cell paucity in our adult 
cohort. The thymus of mutant animals was of normal size and there was a normal 
distribution of T-cell committed progenitors beyond the DN IIa stage. However, we 
did observe a striking increase in overall ETPs and dendritic cells in mutant animals. 
This suggests that the multipotent ETP may preferentially give rise to CD11c+ 
histiocytes, rather than commit to a T cell lineage (Luc et al. 2012). Indeed, we 
equally observed a decrease IL2Ra (CD25) expression among thymic progenitors 
committing to the T cell lineage. This suggests these progenitors may have a dampened 
response to IL2-mediated proliferative signals. It will be important to determine whether 
CD25 expression is equally reduced on peripheral T-lymphocyte populations, since 
such a deficiency is known to contribute to immunodeficiency and could explain the 
heightened susceptibility of JMML patients to infections (Caudy et al. 2007). 
The ability to distinguish PTPN11E76K/+ YFP+ cells from PTPN11Δ/+ YFP- cells 
permitted us to measure cell-autonomous and non-cell autonomous effects of the 
oncogene. The striking expansion of YFP+ progenitors and YFP+ mature progeny in the 
BM, spleen, thymus, and blood of mutant animals was indicative of the cell-autonomous 
effects of PTPN11E76K. However, the frequency of YFP+ cells in each subset was only 
~10%. We hypothesized, therefore, that any net differences in population size above a 
10% change must be the result of non-cell autonomous effects. Indeed, we observed 
striking increases in the overall frequency of myeloid and dendritic cells in the spleens of 
mutant animals along with a concomitant decrease in CD8 T-lymphocytes. This was 
accompanied by an expansion of splenic HSCs. These net changes were characteristic 
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of other JMML mouse models where disease-initiating mutations had been knocked-in to 
the majority of hematopoietic cells (Chan, Kalaitzidis, et al. 2009; Xu et al. 2011) 
This mobilization of HSCs may have been the result of an unfavourable niche in 
the BM, potentially due to the increased cycling and differentiation of downstream 
progenitors. Indeed, we observed a net decrease of LSK CD135+ CD34+ cells in mutants’ 
bone marrow. Furthermore, when unsorted BM cells were plated in colony forming assays 
with increasing doses of GM-CSF, we observed a striking GM-CSF hypersensitivity with 
up to a 10-fold greater number of colonies. This difference could not have been accounted 
by the mere 10% of BM progenitors that are YFP+. This suggests that mutant YFP+ cells 
secrete factors that cause PTPN11Δ/+ YFP- cells to show features of JMML. An abnormal 
microenvironment has already been implicated in JMML. Increased reactive oxygen 
species, metabolic activity, and inflammatory cytokines have been described (Dong et al. 
2016; Liu et al. 2016; Zheng et al. 2013). Our signaling experiments further implicate the 
microenvironment in JMML. Following GM-CSF stimulation YFP+ and YFP- cells had 
equal pERK expression; suggesting that they are equally sensitive to this cytokine. On the 
other hand, myeloid cells from control animals had markedly lower pERK expression than 
either YFP+ or YFP- cells from mutants. Furthermore, when YFP+ and YFP- cells were 
sorted from mutants and assayed separately, only the YFP+ fraction demonstrated 
features of JMML (Figure II-34). This suggests that it is the mutant niche – and not the 
mutation itself – that is the primary determinant of aberrant GM-CSF signaling. Below we 
outline future experiments that will more formally evaluate this hypothesis. 
JMML patients present with both peripheral manifestations (leukocytosis, 
monocytosis, anaemia, thrombocytopenia) as well as tissue abnormalities 
(hepatosplenomegaly, hypercellular BM, cutaneous lesions). One intriguing feature of the 
three models presented herein is the divergence between the observations in tissues and 
observations in the peripheral blood. The HSC-independent cohort had YFP+ mutant cells 
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in the CNS, liver, and heart. Nonetheless, it showed no evidence of peripheral blood 
manifestations. Similarly, the adult cohort had pronounced hepatosplenomegaly and 
alterations in progenitor subsets; nonetheless it had a relatively indolent myeloproliferation 
in the peripheral blood. This suggests that the pathophysiology of the disease may include 
a latent period. Consider, the disease may initially alter tissue homeostasis, disrupt the 
BM microenvironment, and initiate extramedullary hematopoiesis. During this time, 
peripheral blood manifestations may remain undetectable. Given the in utero origin of 
JMML, such a latency period may occur before birth. Only after a sufficient disruption of 
normal hematopoiesis—potentially from exposure to ex utero pathogens—would the MPN 
become fulminant. Given the decreased T-lymphocyte frequencies, such pathogens may 
be particularly virulent for JMML patients and for our mutant animals. Indeed, despite the 
pathogen-free conditions of our animal facility, the few moribund mutant animals we 
observed had clear evidence of infection, including fulminant monocytosis and peritoneal 
abscesses. The decreased T-lymphocytes may, in part, explain such a susceptibility. 
While this notion of a latency period is speculative, it is inherently testable in our model 
and we outline our proposed future experiments below. 
Our findings of non-cell autonomous effects of PTPN11 mutations further suggest 
why healthy donor HSCT failed to cure VavCre;PTPN11D61Y mice. Any residual host cells 
that remained following myeloablation would have continued to exert paracrine effects on 
the healthy donor cells. As such, the environment of the host niche would never have 
recovered and would have continued to bear features of hyperactive RAS-ERK signaling. 
Nonetheless, the dominance of cell autonomous effects of mutations cannot be 
overlooked. Both in our animal model and in JMML patients, disease relapse after 
HSCT occurs from host cells. To our knowledge, there are no reports of JMML patients 
relapsing with donor-derived disease. Indeed, the importance of representative mouse 
models of rare hematologic disease such as JMML cannot be overstated. 
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In this light, consider that a significant proportion of hematopoietic studies rely 
on transplantations. They generate mutation-expressing progenitors and adoptively 
transfer them into myeloablated recipients. Post-transplantation hematopoiesis, however, 
is markedly different from unperturbed hematopoiesis (Busch and Rodewald 2016). 
Following transplantation, the vast majority of progenitors exhaust within the first few 
weeks; only a tiny fraction of cells will have durable multi-lineage contribution 4 months 
after transfer (Yamamoto et al. 2013). In contrast, progenitors in the context of 
unperturbed hematopoiesis have much greater lifespans (Busch et al. 2015; Sun et al. 
2014; Henninger et al. 2017). Our CSF1R-MCM system can induce and monitor mutations 
in the context of unperturbed hematopoiesis and thereby avoids additional pitfalls of 
transplantation. For instance, whereas 90% of myeloid cells are labelled by FLT3Cre in 
unperturbed animals, this drops to nearly 50% following transplantation with a limiting 
dose of HSCs (Boyer et al. 2011). Additionally, transplantation will permit progenitors to 
undergo atypical differentiation patterns following exposure to non-physiologic signaling 
cues (Beaudin et al. 2016; Schlenner and Rodewald 2010). Finally, transplantation 
disrupts normal embryonic development by removing cells from their in utero conditions 
and transferring them into the foreign host environment. This can equally alter the 
differentiation potential of donor cells, as we observed in our YS EMP transplants. These 
readily contributed to splenic macrophage populations but did not contribute to microglia, 
which is the dominant progeny of YS EMPs in unperturbed hematopoiesis. Therefore, by 
forgoing transplantation, our studies rely on a more patient-relevant model that is 
compatible with unperturbed hematopoiesis. 
Previous studies modeling myeloid disease with conditional PTPN11 mutant mice 
have relied on numerous Cre strains: VavCre, Mx1Cre, and LysMCre. Each one has 
purported benefits: VavCre as being active in all hematopoietic cells in utero, Mx1Cre as 
being inducible by pI:pC administration, and LysMCre as being restricted to the myeloid 
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lineage. In actuality, none of these claims are accurate. All three demonstrate Cre activity 
in non-hematopoietic cells, including endothelial cells, osteoblasts, mesenchymal stem 
cells, alveolar cells, and/or septal cells (Stadtfeld, Ye, and Graf 2007; Desai, Brownfield, 
and Krasnow 2014; Dong et al. 2016). LysMCre does show activity in up to 10% of B and 
T-lymphocytes (Ye et al. 2003), and Mx1Cre will become spontaneously active in up to 
10% of HSCs by 5weeks of age due to endogenous interferon release (Sabnis et al. 2009). 
In contrast, we demonstrated that CSF1R-MCM shows no activity in the absence of 
tamoxifen and negligible activity in non-hematopoietic stromal and endothelial cells. As 
such, this is the first study to have evaluated the hematopoietic-restricted expression of 
PTPN11E76K in unperturbed hematopoiesis. Given that expression of other JMML-initiating 
mutations using VavCre, Mx1Cre, or LysMCre leads to lethality from non-hematopoietic 
causes (Staffas et al. 2015; Tang et al. 2013; Desai, Brownfield, and Krasnow 2014), it is 
challenging to directly compare our hematopoietic-restricted model with those published 
previously. Indeed, the rapid lethality observed in Mx1Cre; PTPN11E76K mice may have 
been the result of synergistically deleterious effects of the mutation on hematopoietic, 
endothelial, and stromal cells. This hypothesis is supported by a recent study that showed 
PTPN11E76K expression restricted to the stromal compartment is sufficient for MPN 
development (Dong et al. 2016). Therefore, we highlight the pitfalls of using Cre strains 
that are not cell type specific. We strongly advocate that future studies of neoplasms take 
advantage of lineage trace methods to monitor oncogene-expressing cells and to track 
the mutant allele frequency. 
In summary, we have characterized the effect of PTPN11E76K expression restricted 
to three distinct hematopoietic phases. We have shown that the YS HSC-independent 
phase bears functional features of JMML but that it cannot initiate an MPN either upon 
transplantation or following unperturbed in utero expression. Expression within the fetal 
HSC-dependent phase causes a mild monocytosis but does not cause an overall 
85
expansion or lineage skewing of YFP+ PTPN11E76K cells. In contrast, expression within 
the adult HSC-dependent phase showed a drastic increase in YFP+ PTPN11E76K cells and 
their biased differentiation into myeloid cells. Furthermore, we obtained strong evidence 
that expression of PTPN11E76K alters the BM niche causing an egress of HSCs to the 
spleen and causing YFP- PTPN11Δ/+ cells to acquire functional features of JMML 
progenitors including growth hypersensitivity to GM-CSF due to hyperactive RAS-ERK 
signaling. As such, we have observed non-cell autonomous effects of low frequency 
hematopoietic restricted expression of PTPN11E76K.  
Ongoing Studies and Future Directions 
The fetal and adult CSF1R-MCM;PTPN11E76K cohorts described above are part of 
an ongoing study. We will continue to monitor them until 90 weeks of age. This 
prolongation of the current 40-60 week study will address key unanswered questions. Will 
the frequency of YFP+ leukocyte in mutants and controls remain stable? Will the number 
of T cells continue to decline with a concomitant increase in neutrophils? Will the 
hepatosplenomegaly continue to progress and will this be accompanied by further 
exacerbation of extramedullary hematopoiesis? These questions will be addressed by 
tissue analysis. Progenitors in the fetal cohort will prove particularly interesting given that 
these animals had an increase in net peripheral neutrophils, but that YFP+ cells did not 
show a myeloid-bias. This analysis will therefore permit us to further evaluate pathologic 
features that are distinct between the fetal and adult cohorts.  
We will also be better able to correlate MPN features in the peripheral blood with 
the concomitant progenitor abnormalities in tissues. This will permit us to draw conclusions 
as to the potential latency period of hematopoietic-restricted PTPN11E76K expression. For 
instance, it is possible that 90 weeks after tamoxifen administration, in addition to 
progenitor hypersensitivity to GM-CSF, we may also observe a fulminant MPN in the 
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peripheral blood. This would support our hypothesis of a latency period between tissue 
abnormalities and peripheral blood manifestations following clonal JMML-initiating 
mutations. The prolongation of the study will also make our survival analyses more robust. 
It will be imperative to determine the sensitivity and specificity of YFP as a readout 
for PTPN11E76K expression. Do only YFP+ cells express PTPN11E76K? To answer this 
question we will use published quantitative PCR protocols that measure the amount of 
the non-recombined allele (Dong et al. 2016). We will isolate YFP+ and YFP- cells from 
the blood, spleen, and BM of mutant animals, isolate genomic DNA, and compare the 
abundance of the non-recombined allele to a reference allele. We anticipate that all sorted 
YFP+ cells would express the mutation and have little non-recombined allele. In contrast, 
we anticipate YFP- cells will have complete retention of their non-recombined allele. This 
would confirm that only YFP+ cells can express the mutation and would validate our 
conclusions regarding the non-cell autonomous effects of the PTPN11E76K mutation. 
Interestingly, we have already obtained some functional data that supports our 
hypothesis that only YFP+ cells express the mutation (Figure II-34). We sorted YFP+ and 
YFP- myeloid progenitors from mutant animals and plated them in methylcellulose assays 
with increasing doses of GM-CSF. YFP+ progenitors demonstrated a marked GM-CSF 
hypersensitivity compared to the YFP- progenitors that had developed in the same BM 
niche. Furthermore, when RAS-ERK signaling was measured in these sorted progenitors 
we observed a pronounced hyperactivity in YFP+ cells that was not observed in YFP- 
cells. This suggests that when cultured in isolation, YFP+ cells behave as JMML-initiating 
cells whereas YFP- progenitors from the same animal and niche have normal function.  
This would suggest that the oncogene is indeed only expressed in YFP+ cells. This 
preliminary experiment will need to be repeated to provide robustness to our conclusions. 
These findings also suggest that YFP+ mutant cells do not exert an irreversible effect 
on the healthy YFP- progenitors. Instead, it suggests that short acting paracrine signals 
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from mutant cells act directly on healthy progenitors—without first affecting a stromal cell 
intermediate. Going forward, we will repeat our GM-CSF hypersensitivity and pERK 
experiments with unfractionated BM cells. Next, we will repeat pERK signaling 
experiments with three co-cultured cell types: i) YFP+ cells from a mutant animal; ii) YFP- 
cells from a mutant animal; and iii) CD45.1+ cells from a healthy animal. If CD45.1+ cells 
have hyperactive signaling, this would confirm the paracrine signal is secreted by the 
mutant YFP+ cells and would be present in the medium. In contrast, if YFP+ and YFP- 
cells are hyperactive but CD45.1+ cells are not, this would suggest that the paracrine 
signal is restricted the BM niche. We will then proceed to measure cytokine levels in the 
mutant BM and compare it to that of healthy controls. In so doing, we will identify several 
candidate molecules that may mediate the observed non-cell autonomous effects. Likely 
candidates are IL1β, CCL3, CXCL12, and TNFα, all of which have been shown to mediate 
leukemogenic and/or inflammatory effects in tissue niches (Dong et al. 2016; Randhawa 
et al. 2016; Schiwon et al. 2014). However, novel targets may equally be identified. We 
would validate them through pharmacological inhibition to see if the MPN features of YFP- 
cells can be reversed.  
Finally, we have demonstrated that the monocytosis in our adult cohort is 
accompanied by a concomitant decrease in CD8+ T-lymphocytes with additional evidence 
of abnormal T-lineage commitment in the thymus. We speculate that this may render our 
animals immune compromised. Whereas we did observe moribund animals with overt 
evidence of infection, this was not common due to the pathogen-free conditions in which 
our animals were housed. Therefore, to directly test whether our animals have a 
compromised immune response, we propose to directly challenge them with an 
exogenous pathogen (Castro, Dee, and Malek 2012). Mice will be inoculated with L. 
monocytogenes and survival will be monitored. We hypothesize that mutant animals will 
be more susceptible to infection and death due to a diminished number of CD8 effector T-
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lymphocytes. In follow up experiments, we would immunize mutant and littermate animals 
with the ovalbumin (OVA) peptide and then challenge them 4 weeks later with an L. 
monocytogenes strain that expresses the OVA. This would help determine whether CD4 
memory T cells have acquired memory to OVA and are able to help clear infections. Given 
that JMML patients may have decreased and/or abnormal T-lymphocyte functions and are 
prone to infections, these studies would help determine the degree to which JMML 
patients should be protected from pathogen exposure.  
In summary, we have described the first mouse model that has hematopoietic 
restricted expression of PTPN11E76K that is spatiotemporally restricted to distinct 
developmental phases. We show that whereas YS EMPs do not contribute to disease 
development, HSC-dependent progenitors from fetal and adult phases provoke a MPN. 
The adult cohort in particular has pronounced expansion of mutation-expressing cells in 
all lineages. Using our model we have defined non-cell autonomous effects of 
hematopoietic-restricted PTPN11E76K expression. We observe extramedullary 
hematopoiesis, and both YFP+ and YFP- progenitors are hypersensitive to GM-CSF due 
to hyperactive RAS signaling. These findings provide insight into the hematopoietic niche 
of JMML patients and suggest that future therapies will need to mitigate the deleterious 
effects that mutant cells exert on healthy clones.  
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CHAPTER III 
MODELING JMML WITH KRASG12D MUTATIONS IN MICE 
Abstract 
Juvenile Myelomonocytic Leukemia is a pediatric myeloproliferative disorder that 
bears distinct characteristics of a fetal origin. This disease has been extensively modeled 
with mice bearing conditional JMML-initiating mutations. However, these studies have 
failed to recapitulate defining features of the disease due to in utero lethality, non-
hematopoietic expression, and the pervasive emergence of T-ALL. We present a novel 
model of JMML using FLT3Cre;KrasG12D mice that express KrasG12D in utero, are born at 
normal Mendelian ratio, develop hepatosplenomegaly, anaemia, thrombocytopenia, and 
succumb to a rapidly progressing and fully penetrant neonatal myeloid disease. 
FLT3Cre;KrasG12D mice have altered HSC and progenitor populations that are 
hypersensitive to GM-CSF due to hyperactive RAS-ERK signaling. These progenitors 
have biased differentiation that results in an expansion of neutrophils and dendritic cells 
with a concomitant decrease in T-lymphocytes. These features can be evoked upon fetal 
liver transplantation but not upon transplantation of BM progenitors from moribund 
animals. FLT3Cre;PTPN11E76K mice have an indolent MPN progression and show 
diminished T-lymphocyte populations. In contrast, CSF1R-MCM; KrasG12D mice develop 
T-ALL with complete penetrance, irrespective of whether the mutation was expressed in
fetal or adult progenitors. In summary, we describe FLT3Cre; KrasG12D as the first mouse 
model that reproducibly develops a faithful JMML-like disease with this oncogene. This 
model will prove useful for pre-clinical drug studies and for elucidating the developmental 
origins of pediatric neoplasms. 
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Introduction 
A. Ras Mutations in JMML
Ras proteins are inner plasma membrane-bound GTPases that bind guanosine 
triphosphate (GTP) and hydrolyze it to guanosine diphosphate (GDP). This hydrolysis 
reaction is spontaneous, but is catalyzed by mediators including neurofibronin, which is 
encoded by NF1. Ras-GDP is inactive; Ras-GTP is active and can promote signaling via 
downstream mediators such as the MEK-ERK cascade or Phosphoinositide 3-kinase. 
These signaling events are vital for numerous biological processes including proliferation, 
differentiation, apoptosis, and migration (Lodish et al. 2000).  
Given the growth-promoting properties of Ras, it may be expected that aberrant 
Ras signaling would be involved in tumorigenesis. Indeed, Ras genes were the first 
identified oncogenes and they are the most frequently mutated alleles in human cancers 
(Hunter et al. 2015; Parada et al. 1982). Strikingly, most Ras mutations are SNPs, a single 
amino acid substitution will inhibit the hydrolysis of GTP and lock Ras in an active state. 
Despite the frequency of Ras mutations in cancer, initial studies suggested that in isolation 
they were not sufficient to initiate tumorigenesis; secondary mutations that target 
complementary cancer hallmarks—such as immune evasion and DNA repair—were 
deemed necessary for Ras-induced malignancy (Seeburg et al. 1984; Hanahan and 
Weinberg 2011).  
It was surprising, therefore, to discover that 20-25% of JMML patients harbor 
mutations in Nras or Kras (Flotho et al. 1999) and that these polymorphisms are frequently 
the only genetic abnormality identified in these children (Stieglitz, Taylor-Weiner, et al. 
2015; Sakaguchi et al. 2013). This demonstrates that Ras mutations are sufficient for the 
development of pediatric MPN. However, the prognosis of children with somatic Ras 
mutations in hematopoietic cells is unpredictable. Whereas gain of function PTPN11 
mutations confer a uniformly poor prognosis without transplantation, there are a subset of 
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patients with Ras mutations who show no signs of disease even into adulthood (Calvo et 
al. 2015). It has been proposed that these patients have a distinct disorder termed Ras-
associated autoimmune leukoproliferative disorder (RALD). However, apart from their 
clinical course, no features that distinguish RALD and JMML have been identified. 
Clinicians continue to debate whether these are distinct disorders (Anastas and Calvo 
2016). 
Interestingly, aberrant Ras function in JMML may occur independently of mutation 
via DNA methylation. One group has reported that RASA4 hypermethylation is frequently 
observed in JMML patients irrespective of the causative genetic mutation and that this 
modification is associated with an inferior prognosis (Poetsch et al. 2014). This finding 
further supports the prevailing hypothesis that multiple complementary lesions targeting 
the RAS-ERK pathway confer worse prognosis to JMML patients (Caye et al. 2015). 
Importantly, aberrant DNA methylation is widespread in JMML and not restricted to Ras 
genes. Cell cycle mediators that are known to be tumor suppressor genes, such as 
p15/INK4b encoded by CDKN2B and p16 encoded by CDKN2A, are hypermethylated in 
JMML patients (Hasegawa et al. 2005). Indeed, DNA methyltransferase inhibitors have 
shown some in vitro efficacy in reversing the abnormal methylation patterns observed in 
JMML patients (Wilhelm et al. 2016). Such therapeutic strategies hold promise for Ras 
associated malignancies given that direct pharmacological inhibition of Ras has not been 
possible (McCormick 2015). Indeed, one clinical trial using DNA methyltransferase 
inhibitors in JMML is already recruiting patients (NCT02447666). It is therefore important 
to find animal models that can recapitulate Ras-induced JMML and determine if they have 
evidence of aberrant DNA methylation. Such a representative model would permit testing 
of new therapeutic strategies for a disease with a very poor prognosis. 
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B. FLT3Cre: a Tool in the Study of Fetal Hematopoiesis
We have described in Chapter I the rationale and mechanism of the Cre-loxP 
system. This is a powerful tool to introduce mutations in animals within specific cell 
populations and at specific developmental stages. The specificity of the system relies on 
the cis-regulatory elements that control the expression of the Cre recombinase. We 
described in detail that the most common Cre strains used to study hematopoiesis and 
myeloid development–VavCre, Mx1Cre, LysMCre–are all expressed in non-hematopoietic 
tissues and have poorly characterized temporal expression. Researchers have therefore 
sought to develop new Cre strains whose expression would be more predictable and 
restricted to hematopoietic lineages. 
The fms-like tyrosine kinase 3 (FLT3; also called Flk2, CD135) is a receptor 
tyrosine kinase that binds the growth-promoting cytokine FLT3L. FLT3 is highly expressed 
in hematopoietic progenitor cells and in other unfractionated tissue samples including 
brain, placenta, kidney, heart, lung and germ tissues (Matthews et al. 1991). Subsequent 
studies revealed that within the LSK progenitor population, further depletion of cells 
expressing FLT3 would enrich for long-term serial repopulating potential (Christensen and 
Weissman 2001). This suggested that expression of FLT3 was among the first genes 
upregulated following asymmetric HSC division and differentiation. This hypothesis was 
confirmed in subsequent studies that identified the LSK FLT3+ cells as the multipotent 
progenitor (MPP), capable of contributing to all blood lineages but without indefinite self-
renewal (Yamamoto et al. 2013). These studies suggested that all hematopoietic cells 
derived from a FLT3-expressing intermediate progenitor. 
This hypothesis was formally tested using FLT3Cre;ROSA26mTmG/mTmG mice and a 
clever lineage trace strategy (Boyer et al. 2011). In this model, cells that express FLT3 will 
undergo a fluorescent switch from Tomato to GFP (Figure III-1A). This is achieved through 
the irreversible excision of a loxP-flanked DNA sequence that encodes both the Tomato 
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Figure III-1. Analysis of FLT3Cre Activity in HSC-Dependent and HSC-Independent 
Hematopoiesis. A) Cells that have active Cre recombinase can be monitored by flow 
cytometry by the irreversible switch from Tomato+ to GFP+ expression. B) FLT3Cre 
activity was shown to begin in MPPs; it is not active in HSCs in adult BM. C) FLT3Cre 
activity in E9.5 yolk sacs. No GFP+ cells were observed, including among EMPs, gated in 
red. 
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allele and a STOP cassette. The removal of both permits the expression of GFP, which 
will continue to be expressed in all progeny. This group showed that >90% of myeloid, B 
cell, T cell, erythroid, and platelet populations were GFP+. Furthermore, they identified 
that phenotypic HSCs were Tomato+ and that the switch to GFP expression occurred in 
the MPP compartment. Subsequent functional studies confirmed that only Tomato+ LSK 
cells from adult BM could be serially transplanted; GFP+ LSK cells had only transient 
contributions in recipients (Boyer, Beaudin, and Forsberg 2012). These experiments 
confirmed that FLT3Cre was active downstream of HSCs and that it would label the 
majority of mature hematopoietic cells in adults (Figure III-1B). 
 Subsequent studies sought to further characterize the precise embryonic 
populations labelled by FLT3Cre. Interestingly, it was shown that E8.5 activated CSF1R-
MCM and FLT3Cre were active in mutually exclusive populations in the fetal liver (Gomez 
Perdiguero et al. 2015; Epelman et al. 2014). Additional studies showed that FLT3Cre was 
not active in HSC-independent hematopoietic cells (Hoeffel et al. 2015), and we 
independently confirmed that E10.0 Ter119- cKit+ CD45+ yolk sac EMPs were not 
labelled in all 5 analyzed embryos (Figure III-1C). This feature would prove useful in further 
discerning the contributions of HSC-independent and HSC-dependent embryonic 
hematopoiesis to adult tissues. Elegant studies that directly compared (E8.5) CSF1R-
MCM and FLT3Cre contributions to myeloid tissues showed that all brain microglia were 
derived from the yolk sac, all adult intestinal macrophages were HSC-derived, and heart, 
liver, lung and spleen macrophages had contributions from both phases (Epelman et al. 
2014; Bain et al. 2014). Thus, FLT3Cre is a useful tool to distinguish HSC-independent 
from HSC-dependent hematopoiesis. 
 Early studies also suggested that FLT3 expression may be able to distinguish fetal 
vs. adult HSC-dependent hematopoiesis. Whereas FLT3+ LSK cells from adult BM could 
not self-renew upon transplantation, FLT3+ LSK cells from E14.5 fetal liver cells did 
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engraft and produce multilineage progeny (Christensen and Weissman 2001). More 
recent studies using FLT3Cre;ROSA26mTmG/mTmG mice also suggested that a small 
proportion of fetal HSCs were FLT3+. Given that FLT3 signaling strongly promotes 
proliferation and that fetal HSCs are actively cycling, the expression of this receptor on 
fetal HSCs may be an adaptation to promote their rapid growth. Furthermore, these 
studies suggested a functional difference: that FLT3+ HSCs preferentially gave rise to 
innate-like lymphoid cells, such as peritoneal B1a and B1b populations.  
These studies, however, had numerous shortcomings. First, they transplanted bulk 
populations of FLT3+ cells. As such, they were unable to evaluate the clonal contribution 
to progeny—a defining feature of HSCs. Additionally, these studies relied on adoptive 
transfer experiments; they did not consider if FLT3+ fetal cells functioned as HSCs under 
unperturbed hematopoiesis. Indeed, evidence suggests that they do not. Since GFP+ cells 
in adult FLT3Cre;ROSA26mTmG/mTmG mice cannot be transplanted, this indicates that fetal 
FLT3+ HSCs do not self-renew under homeostatic conditions. Additionally, if FLT3+ fetal 
progenitors contribute to long-lived innate lymphoid populations, one would expect these 
populations to have a high frequency of GFP expression. There is no supporting evidence 
for this in the manuscript. Indeed, our preliminary experiments using unperturbed 
FLT3Cre;ROSA26mTmG/mTmG mice showed that peritoneal B1a and B1b populations had a 
lower frequency of GFP expression that BM-derived B2 populations (Figure III-2). As such 
it is possible that the insights drawn from FLT3+ fetal HSCs are the result of non-
physiologic potentials evoked by transplantation. The physiological and developmental 
relevance of FLT3+ fetal HSCs in unperturbed conditions remains unclear. 
Following the differentiation of FLT3+ MPPs, FLT3 is re-expressed on certain 
hematopoietic cells. Committed lymphoid progenitors (CLPs) and both B-cell restricted 
and T-cell restricted progenitors express FLT3. This is contrast to common myeloid 
progenitors (CMPs), which do not express FLT3 (Karsunky et al. 2008). As such, lymphoid 
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Figure III-2. FLT3Cre Activity in Peritoneal B-Lymphocytes. A) Gating strategy to 
identify adaptive B2 cells and innate-like B1a and B1b cells. B) Assessment of GFP+ cells 
in the above gated populations. This study was not adequately powered to detect a 
difference. This experiment was performed with assistance from Momoko Yoshimoto. 
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cells  in FLT3Cre;ROSA26mTmG/mTmG  mice have additional opportunities to transition 
through a FLT3+ intermediate and thus a greater proportion of them are GFP+ compared 
with myeloid cells. However, dendritic cells (DCs) are the only mature hematopoietic 
population to express FLT3 (Waskow et al. 2008). Since DCs are ubiquitous in all tissues, 
the original reports showing FLT3 expression in non-hematopoietic organs need to be re-
evaluated. It remains unclear whether FLT3 expression is restricted to hematopoietic cells. 
Further complicating this analysis is the finding of multiple transcript lengths encoded by 
FLT3. This suggests context-specific or tissue-specific FLT3 expression.  
Of relevance to our study is the spatiotemporal activity of FLT3Cre, which may be 
different from the expression pattern of the protein itself. For instance, CSF1R-Cre activity 
has been shown to only partially overlap with the receptor’s expression (Hoeffel et al. 
2015). Unfortunately, the original characterization of the FLT3Cre animal did not provide 
sufficient detail to know the sequence of the cis-regulatory elements that drive Cre 
expression (Benz et al. 2008). As such, FLT3Cre activity must be measured functionally 
using a lineage trace strategy such as ROSAmTmG. To date, no reports have suggested 
non-hematopoietic activity of FLT3Cre mice and we determined it is not expressed in lung 
and BM endothelial cells. In so doing, we have shown FLT3Cre overcomes the major 
specificity hurdle of Mx1Cre, VavCre, and LysMCre. As such, we deemed it the best model 
with which to evaluate hematopoietic-restricted expression of JMML-initiating mutations. 
 
C. Rationale for the FLT3Cre+;KrasG12D Model of JMML 
Juvenile Myelomonocytic Leukemia is a pediatric myeloproliferative disorder 
caused by somatic mutations in RAS-ERK signaling genes, including KRAS, NRAS, 
PTPN11, NF1, and c-CBL (Chan, Cooper, et al. 2009).  These mutations result in a 
hypersensitivity of hematopoietic progenitors to GM-CSF and lead to monocytosis, 
anaemia, thrombocytopenia, hepatosplenomegaly, and infiltration of peripheral tissues 
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with histiocytes (Loh 2011; Ng et al. 1988). Compared to other pediatric hematologic 
malignancies, the prognosis of JMML patients is very poor. Allogeneic hematopoietic stem 
cell (HSC) transplantation is the only curative therapy, which nonetheless has a 5 year 
overall survival of only 52% (Locatelli et al. 2013). 
The majority of JMML cases result from a mutation in a single gene (Stieglitz, 
Taylor-Weiner, et al. 2015; Sakaguchi et al. 2013; Caye et al. 2015). As such, disease 
models using the most common JMML-initiating mutations have been readily generated 
(Xu et al. 2011; Chan, Kalaitzidis, et al. 2009; Le et al. 2004). The Mx1Cre;KrasG12D mouse 
was the first conditional animal model of JMML and continues to be studied extensively 
(Braun et al. 2004). However, these mice ultimately die from non-hematopoietic KrasG12D 
expression or from T cell acute lymphoblastic leukemia/lymphoma (T-ALL) (Kindler et al. 
2008; Kong et al. 2013; Staffas et al. 2015; Sabnis et al. 2009). In utero KrasG12D 
expression using LysMCre or VavCre have led to lung adenocarcinoma or to prenatal 
lethality, respectively, both from non-hematopoietic expression of the oncogene (Desai, 
Brownfield, and Krasnow 2014; Tang et al. 2013). Thus, existing KrasG12D models have 
failed to address the fetal origin of JMML and have failed to recapitulate the myeloid nature 
of the disease. 
Converging clinical evidence suggests that the origin of JMML is closely 
associated with fetal development. Patients present very young with a median age of 
<2years and retrospective analyses of tissue samples collected at birth suggest that the 
majority of patients acquire the somatic disease-initiating mutation in utero (Kratz et al. 
2005; Matsuda et al. 2010; Locatelli and Niemeyer 2015). Furthermore, bone marrow 
progenitors of most patients exhibit a fetal-like gene expression signature, which 
correlates with an inferior prognosis (Helsmoortel, Bresolin, et al. 2016). These findings 
strongly implicate a developmental origin of JMML and imply that a genetic alteration must 
occur within an appropriate spatial and temporal context to initiate this disease. 
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Fetal hematopoietic progenitors are functionally distinct from adult progenitors. 
Murine fetal progenitors have greater engraftment efficiency, biased lineage 
differentiation, and altered susceptibility to transformation compared with adult 
counterparts (Bowie et al. 2006; Bowie et al. 2007; Benz et al. 2012; Copley et al. 2013; 
Yuan et al. 2012; Porter et al. 2016). Analogous studies in humans showed fetal and cord 
blood CD34+ cells are more proliferative and have a greater propensity to form myeloid 
colonies in methylcellulose culture than adult BM cells (Lansdorp, Dragowska, and Mayani 
1993; Broxmeyer et al. 1992). These characteristics of fetal progenitors suggest a 
mechanism through which they may evoke clinical features of JMML when challenged 
with a somatic oncogenic mutation.    
 We hypothesized that temporal expression of KrasG12D during fetal hematopoiesis 
and limited functionally to the hematopoietic progenitor population would produce a JMML-
like disease. Recently, the expression pattern of FLT3Cre has been extensively studied 
using lineage-tracing methods (Boyer et al. 2011; Epelman et al. 2014). FLT3Cre activity 
begins in multipotent progenitors (MPPs) at embryonic day E10.5 and it is subsequently 
observed in >90% of mature leukocytes. We now demonstrate that KrasG12D is sufficient 
to produce a perinatal myeloproliferative disease when expressed in fetal hematopoietic 
progenitors using FLT3Cre. We have thereby defined the crucial cellular and 
developmental environment needed to produce authentic features of KrasG12D-induced 
JMML.  
 
Results 
A. FLT3Cre+;KrasG12D Mice Develop A Transplantable JMML-Like Myeloid Disease 
We mated FLT3Cre+;ROSAmTmG/mTmG studs with KrasG12D/+ dams to generate 
FLT3Cre+;ROSAmTmG/+;KrasG12D/+ mice (hereafter FLT3Cre;KrasG12D) in which oncogene 
expression can be monitored by a switch from Tomato to Green Fluorescent Protein (GFP) 
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expression. FLT3Cre;KrasG12D mutants were born at expected Mendelian ratio and had 
weight gain comparable to littermates until 2 weeks of age (Figure III-3A,B). Mutants and 
littermates had equivalent activity of FLT3Cre as measured by %GFP+ cells and KrasG12D 
expression in mutant mice was confirmed by PCR (Figure III-1C,D). After 2 weeks, 
FLT3Cre;KrasG12D mice showed progressive weight loss, leukocytosis, anaemia, 
thrombocytopenia, hepatosplenomegaly, and died at a median age of 26 days (Figure III-
4). Histological organ examination revealed a monocytic infiltrate in the liver and spleen 
and a marked expansion of CD11b+ Gr1+ cells in the blood, spleen, liver, and bone 
marrow (BM) was confirmed by flow cytometry (Figure III-5). Notably, the frequency of 
CD3+ T-lymphocytes and B220+ B-lymphocytes was decreased and FLT3Cre;KrasG12D 
mice had an atrophied thymus compared to littermates (Figure III-4C).  Consistent with a 
faithful model of hyperactive Ras-induced JMML, BM progenitors from FLT3Cre; KrasG12D 
animals demonstrated hypersensitivity to GM-CSF in colony forming assays which was 
corrected by MEK inhibition (Figure III-6). This was strong evidence of hyperactive Ras-
ERK signaling. However, as previous studies have shown (Braun et al. 2004), myeloid 
cells derived from BM progenitors of moribund mutant animals did not demonstrate 
elevated phosphorylation of ERK (Figure III-7). 
To confirm the disease in FLT3Cre;KrasG12D animals was initiated in utero and 
could be propagated autonomously in vivo, we transplanted E14.5 fetal liver cells into 
adult BoyJ animals (Figure III-8). Progenitors from mutant donors showed robust 
engraftment, and rapidly contributed to monocytosis, anaemia, and thrombocytopenia 
(Figure III-8B,C). Recipients of mutant cells succumbed to a JMML-like myeloid disease 
with a median survival of 9 weeks (Figure III-8D). At analysis, mutant recipients had 
hepatosplenomegaly with expanded donor-derived myeloid populations in the BM and 
spleen (Figure III-8E-I). In stark contrast to other KrasG12D models, primary recipients of 
FLT3Cre;KrasG12D progenitors did not develop enlarged thymuses or show signs of T-ALL. 
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 Figure III-3. FLT3Cre;KrasG12D: Birth Ratio, Weight Gain, and Cre Activity. A) 
Genotypes at birth of Flt3Cre+ ROSA26mTmG/mTmG x KrasG12D/+ progeny (N=95, Chi squared 
p=0.05). B) Weight gain (N=12 mutants, 19 controls). C) Proportion of peripheral blood 
cell lineages that express Tomato or GFP in mutant animals (N=10) and littermates (N=8). 
Statistical analysis by two-way ANOVA followed by Tukey's multiple comparisons test. D) 
PCR gel electrophoresis demonstrating successful recombination of the Lox-STOP-Lox 
KrasG12D allele in the bone marrow, spleen, and thymus of 5 analyzed Flt3Cre;KrasG12D 
animals.   
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 Figure III-4. FLT3Cre;KrasG12D: CBC, Tissue Weights, and Survival. A) Peripheral 
blood analysis or moribund animals and littermates. B) Spleen, liver, and thymus weights 
normalized to body weight. C) Representative image of mutant and littermate spleen and 
thymus. D) Overall survival (analysis by Mantel-Cox test).  
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Figure III-5. FLT3Cre;KrasG12D Mice Develop a Myeloproliferative Disease. A) 
Pathohistological analysis (scale bars = 100µm, representative of N=2). B) Flow 
cytometric quantification of tissue leukocytes. 
  
105
 Figure III-6. FLT3Cre;KrasG12D: GM-CSF Growth Hypersensitivity. A) 7 day 
methylcellulose colony formation of BM cells (N=2 mutant and 3 littermate biological 
replicates, each plated in triplicate). B) 7 day BM colony formation with 100nM PD0325901 
or 0.1% DMSO (N=3 biological replicates/group, each plated in triplicate). C) 
Representative images of colonies quantified in B; scale bar=0.5mm. All analyses 
performed on moribund 3-4 week-old Flt3Cre+ KrasG12D/+ and age-matched littermates.  
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 Figure III-7. FLT3Cre;KrasG12D: Signaling Analysis. BM cells from moribund mutants 
and littermate controls were cultured in M-CSF for 7 days. Cultured cells were starved of 
serum overnight and then stimulated with 1ng/ml GM-CSF for indicated durations. Cell 
lysates were probed with the indicated antibodies. Representative image of 3 independent 
experiments. 
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 Figure III-8. FLT3Cre;KrasG12D: Fetal Liver Transplantation Propagates a JMML-Like 
Disease. A) Schematic of fetal liver transplantations (N=12 mutant and 8 control 
recipients). Analysis of donor cell B) engraftment and C) myeloid contributions in 
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peripheral blood. D) Overall survival following transplantation (analysis by Mantel-Cox 
test). E-G) Normalized thymus, spleen, and liver weights of analyzed animals. Flow 
cytometric quantification of donor leukocytes in H) BM and I) spleen of recipients. 
Statistical analyses by unpaired t-test unless indicated. p<0.05; ** p<0.01; ***p<0.001. 
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These findings indicate that temporal expression of KrasG12D in utero transforms fetal 
hematopoietic progenitors into transplantable JMML-initiating cells. 
We proceeded to analyze the effect of fetal KrasG12D expression on the frequency 
and distribution of HSCs and progenitors. In contrast to Mx1Cre;KrasG12D animals (Sabnis 
et al. 2009) we observed a reduction of HSCs and MPPs in both the BM and spleen of 
moribund FLT3Cre;KrasG12D mice (Figure III-9A,B). We reasoned this decrease was due 
to progenitor exhaustion incurred by increased myeloid differentiation in FLT3Cre;KrasG12D 
animals. In characterizing the progeny of FLT3Cre;KrasG12D progenitors, we found that BM 
cells cultured in cytokine-free medium gave rise to histiocytes that expressed CD11c+ and 
CD135+ (Figure III-10A). This finding is reminiscent of reports describing dendritic cell 
(DC)-like tumor cells in JMML patients (Longoni et al. 2002; Ng et al. 1988; Estrov et al. 
1986) and prompted us to analyze DC populations in the tissues of FLT3Cre;KrasG12D 
animals. We observed a marked increase in the frequency of CD11c+ cells in the BM and 
spleen (Figure III-10B). Strikingly, the CD11c+ cell expansion was particularly prominent 
in the atrophied thymus (Figure III-10C), where we saw a concomitant deficit of CD4- CD8- 
CD25+ committed T-cell progenitors and CD4+ CD8+ double positive cells (Figure III-11). 
This propensity for preferential DC differentiation was also observed in recipients of 
FLT3Cre;KrasG12D fetal liver progenitors (Figure III-10D,E), in which we confirmed that 
splenic CD11c+ MHCII+ DCs were distinct from the equally expanded CD11b+ Gr1+ 
neutrophil population. 
We present the first KrasG12D model to unify JMML disease-defining features: an in 
utero origin, viability at birth followed by a failure to thrive, anaemia, thrombocytopenia, 
monocytosis, hepatosplenomegaly, and infiltration of tissues with histiocytes. All 
FLT3Cre;KrasG12D mice succumbed to a myeloid disease that could be recapitulated 
following fetal liver transplantation. This is in stark contrast to existing KrasG12D models, 
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 Figure III-9. FLT3Cre;KrasG12D: Depletion of BM and Splenic HSCs. A) Representative 
gating of LSK CD150+ CD48- HSCs in the BM of mutants and littermates. B) 
Quantification of HSCs and progenitor subsets in the BM and spleen of moribund mutants 
and littermates 
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 Figure III-10. FLT3Cre;KrasG12D: Enhanced Dendritic Cell Differentiation. A) 
Histiocytes obtained from cytokine-free culture of BM cells. B) Quantification of CD11c+ 
dendritic cells in BM, spleen, and thymus. C) Representative gating of thymic dendritic 
cells D) Quantification of dendritic cell frequency following fetal liver transplants E) 
Representative gating demonstrating CD11c+ MHCII+ dendritic cells (red) are distinct 
from CD11b+ Gr1+ neutrophils (blue). 
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 Figure III-11. FLT3Cre;KrasG12D: Defective T-cell Differentiation. A) Representative 
gating of T-cell generation in thymuses of moribund mutants and littermates. B,C) Flow 
cytometric quantification of thymic progenitors.) 
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which die from T-ALL or non-hematopoietic expression (Staffas et al. 2015; Desai, 
Brownfield, and Krasnow 2014; Tang et al. 2013). 
 
B. In-depth Analysis of FLT3Cre;KrasG12D Transplantations 
 Hematopoietic transplantations bypass normal developmental processes by 
removing hematopoietic progenitors from their native niche and requiring them to engraft 
a foreign host. It is possible, however, to use age-matched donors and recipients to 
minimize the differences between native and host environments. Experiments that have 
used such donor-recipient matching have identified novel progenitor types with novel 
differentiation potentials (Yoder et al. 1997). However, this approach has not been applied 
to the study of disease-initiating cells. Given that fetal liver progenitors from 
FLT3Cre;KrasG12D mice could serially propagate a JMML-like disease when transplanted 
into adult recipients, we sought to determine if the same disease would be observed when 
neonatal recipients and/or adult BM progenitors from moribund mice were used (see 
schematic in Figure III-12). 
 We observed that recipients of FL cells had a diminished survival compared to 
recipients of 4week old BM cells (Figure III-13A). No difference in survival was observed 
when neonatal and adult primary recipients were compared. However, adult recipients of 
secondary transplants succumbed more rapidly than neonatal recipients of adult 
transplants (Figure III-14). This suggests that the duration a progenitor resides in a 
particular niche may influence the rate of disease progression. All recipients of mutant 
progenitors had hepatosplenomegaly compared to control recipients. However, we did not 
observe differences in spleen or liver weights based on the age of the recipient or the 
phase of the donor cells (Figure III-13B). 
 Adult recipients of FL progenitors had leukocytosis 5 weeks after transplant (Figure 
III-15A). However, this leukocytosis was not evident in subsequent blood draws from these 
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 Figure III-12. Developmentally Coordinate Transplants. Schematic of transplantations 
used to assess the contribution i) fetal vs. adult progenitors and ii) neonatal vs. adult 
hematopoietic niche to the development of disease following transplantation of KrasG12D-
expressing progenitors. 
115
 Figure III-13. FLT3Cre;KrasG12D: Primary Transplants. A) Overall survival of recipients. 
P-value denotes FL vs. adult donor cohorts. Survival differences between adult vs. 
neonatal recipients are not significant (N= 12 FL>Adult; 6 FL>Neonate; 5 BM>Neonate; 
10 BM>Adult). B) Normalized spleen, thymus, and liver weights of moribund recipients. 
Donor cell numbers: FL>Adult=2x106 iv; FL>Neonate=1x106 iv; BM>Adult=2x106 iv; 
BM>Neonate=5x106 ip. 
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 Figure III-14. FLT3Cre;KrasG12D: Secondary Transplants. A) Schematic of 
transplantations. B) Overall survival of secondary transplant recipients with >0.5% donor 
engraftment (N=6 Adult; 22 Neonates). C) Normalized spleen, thymus, and liver weights 
of moribund recipients, p-values are relative to primary recipients of littermates, shown in 
black and in Figure III-13B. Donor cell numbers: FL>Adult>Adult=4x106 iv; 
FL>Neonate>Neonate=8x106 ip.  
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 Figure III-15. FLT3Cre;KrasG12D Transplants: Engraftment, Leukocytosis, 
Monocytosis. A) Leukocyte counts of transplant cohorts. B) Peripheral blood engraftment 
of transplant cohorts. C) Contribution of donor cells to CD11b+ neutrophils in peripheral 
blood. Statistical analysis compares BM>Neo with BM>Adult & FL>Neo with FL>Adult; p-
values obtained by unpaired t-tests. Neonatal secondary recipients that had <0.5% 
engraftment were excluded from this analysis.   
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animals. Furthermore, no other transplant cohort had signs of leukocytosis. However, 
there were pronounced differences in engraftment efficiency (Figure III-15B). FL>Adult 
had better donor engraftment than BM>Adult. Neonatal recipients had a significantly 
inferior engraftment that their adult counterparts. However, FL>Neonate engraftment 
markedly increased over time whereas BM>Neonate did not. Importantly, fetal progenitors 
had significantly greater contribution to CD11b+ myeloid cells compared to BM donors 
when transplanted into either neonates or adults (Figure III-15C). 
We set out to determine the relationship between engraftment efficiency and the 
propensity for myeloid-biased differentiation. In all recipients of mutant donors there was 
a direct correlation between CD45.2 engraftment and donor differentiation into CD11b+ 
cells (Figure III-16A-D). This correlation was not seen in recipients of healthy littermate 
progenitors (Figure III-16E). This suggests that myeloid-biased differentiation of mutant 
progenitors is not entirely a cell autonomous decision. Rather, the presence of mutant 
cells in the niche may influence the lineage output of progenitors. This suggests that the 
development of MPN is determined, in part, by the proportion of total cells that express 
the mutation. Importantly, residual and competitive CD45.1 host cells did not show this 
myeloid biased differentiation (Figure II-16F). This suggests that the non-cell autonomous 
effect of transplanted KrasG12D cells are restricted to the mutant progenitors themselves. 
 Whereas fetal donors gave rise to a JMML-like disease in both adult and neonatal 
recipients, FLT3Cre;KrasG12D BM cells from 4 week old moribund animals preferentially 
gave rise to T-ALL upon transplantation (Table III-1). This propensity for lymphoid disease 
was observed following BM transplantation into both adult and neonatal recipients. This 
shows that the microenvironment does not have a decisive role in determining the lineage 
of KrasG12D-induced disease. Rather, it suggests that innate properties of fetal and adult 
progenitors cause myeloid and lymphoid diseases, respectively. The FLT3Cre;KrasG12D 
model provides a tool to seek the nature of those innate differences. 
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 Figure III-16. FLT3Cre;KrasG12D Transplants: Correlation Between Engraftment and 
Monocytosis. Relationship between %CD45.2 engraftment and donor cell biased 
differentiation into CD11b+ neutrophils. A-D) FLT3Cre;KrasG12D donor transplants. E) 
Littermate transplants. F) Competitive and residual CD45.1+ cells in recipients of 
FLT3Cre;KrasG12D. Each dot represents one peripheral blood draw. Analysis of the same 
animal at multiple timepoints are included in this analysis. P-values calculated using 
Pearson’s correlation. 
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Donor Recipient 
Donor 
Cells 
Cohort 
Size 
Median 
survival 
(weeks) 
JMML-like 
(# deaths) 
T-ALL 
(# deaths) 
N/A 
FLT3Cre 
KrasG12D 
(No Transplant) 
N/A 18 (NA) 3.7 100% (18) 0% 
  
2x106 
(iv) 
12 (12) 9.1 100% (12) 0% 
  
1x106 
(iv) 
6 (6) 10.4 100% (6) 0% 
  
2x106 
(iv) 
10 (10) 12.9 17% (1) 83% (5) 
  
5x106 
(ip) 
5 (5) 13.9 20% (1) 40% (2) 
 Secondary 
4x106 
(iv) 
6 (6) 6.0 83% (5) 17% (1) 
 Secondary 
8x106 
(iv) 
22 (12) 14.0 25% (3) 50% (6) 
Table III-1. Summary of FLT3Cre;KrasG12D Cohorts and Survival. Death totals may not 
add up to 100% due to deaths from uncertain causes. Donors were unfractionated cells 
from E14.5 fetal livers or BM from 4 week-old moribund animals. 
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C. FLT3Cre;PTPN11E76K Develop An Indolent Myeloproliferative Disease. 
 Given the successful modeling of JMML using FLT3Cre;KrasG12D mice, we 
proceeded to evaluate whether the same Cre strain would produce a faithful disease 
model using the PTPN11E76K oncogene. FLT3Cre+;PTPN11E76K;ROSAmTmG/+ (hereafter 
FLT3Cre;PTPN11E76K) mice were born at expected Mendelian ratio (Figure III-17A). 
However, unlike the KrasG12D cohort, FLT3Cre;PTPN11E76K mice developed an indolent 
disease with transient leukocytosis, minor anaemia, and thrombocytopenia (Figure III-18). 
Nonetheless, peripheral blood analysis revealed markedly elevated CD11b+ cells with a 
concomitant reduction of CD3+ or CD4/CD8 single positive T-lymphocytes in PTPN11E76K 
mutants compared to controls (Figure III-17B-D). The overall survival of mutants was lower 
than that of controls, but a mean survival could not be calculated due to an 80% survival 
rate at 60 weeks of age (Figure III-18E). 
 An interesting observation in FLT3Cre;PTPN11E76K mice was the progressive 
decline in the %GFP+ cells (Figure III-19A,B). Since GFP+ cells are the progeny of 
progenitors with active Cre, these GFP+ cells should also be the only cells that 
recombined the PTPN11E76K allele and express the oncogene. We considered two 
hypotheses to explain diminishing GFP+ frequency. First, healthy clones may be 
preferentially contributing to hematopoiesis in mutant animals. Alternatively, the finding 
may be an ancillary consequence of monocytosis. Recall, myeloid cells have a lower 
frequency of GFP expression than either B- or T-lymphocytes because only CLPs and not 
CMPs express FLT3. Therefore, a relative monocytosis would cause the total frequency 
of GFP+ leukocytes to diminish. To address these hypotheses we analyzed the %GFP+ 
cells in each lineage over time (Figure III-19C). Using two-way ANOVA analysis, we 
confirmed that %GFP+ by lineage was T-cells > B-cells > myeloid cells in mutants (P-
value<0.0001; accounting for 17% of the variance). In contrast, the age of the animal had 
a minor contribution to %GFP+ among CD11b+ cells (5.4% of the variance; P-value 0.03). 
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 Figure III-17. FLT3Cre;PTPN11E76K: Birth Ratio and Peripheral Leukocyte Analysis. 
Birth ratios at weaning of FLT3Cre;ROSAmTmG/mTmG x PTPN11E76K/+ matings. B-D) Analysis 
of peripheral blood lineages in mutant (N=13) and control (N=18) animals. P-values in C 
and D are significant at all time points. 
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 Figure III-18. FLT3Cre;PTPN11E76K: CBC and Survival Analyses. A-D) FLT3Cre; 
PTPN11E76K develop a leukocytosis, thrombocytopenia, and late-onset anaemia. E) 
Overall survival; p-values calculated by Mantel-Cox test. F) Representative image of 
FLT3Cre; PTPN11E76K peripheral blood. Scale bar=20um. 
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 Figure III-19. FLT3Cre;PTPN11E76K: Analysis of GFP+ Leukocytes. A,B) Frequencies 
of GFP+ and Tomato+ leukocytes in peripheral blood at indicates ages C) Analysis of 
GFP+ and Tomato+ expression among CD11b+ cells in mutants and littermates. Two-way 
ANOVA indicates that genotype accounts for 17% of variance in GFP+ myeloid cells (p-
value<0.001) whereas age accounts for 5.4% of variance (p-value=0.03). 
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These results strongly suggest that the dominant contribution to decreasing %GFP+ cells 
in the peripheral blood is the result of the relative monocytosis and not due to preferential 
expansion of non-mutated Tomato+ clones. 
 Three FLT3Cre;PTPN11E76K animals died in the course of our study. Two died at 
33 weeks of age, from the same cage, had normal sized spleens and thymuses, and 
showed no evidence of disease. One mutant died at 45 weeks of age with limb weakness 
(Figure III-20). On examination, this animal had an atrophied thymus, pronounced 
hepatosplenomegaly and BM hypercellularity. The spleen was infiltrated with CD11c+ 
MHCII+ DCs and both BM and spleen had expanded CD11b+ Gr1+ neutrophil 
populations. Interestingly, the spleen had an increased CD71+ Ter119- erythroblast 
population, suggesting marked extramedullary erythropoiesis. Consistently, the frequency 
of LSK CD34- CD135- HSCs was also greater in the spleen than BM (Figure III-20B,C), 
suggesting that hematopoietic progenitors had shifted out of the BM. Inexplicably, the 
%GFP+ among both BM and spleen HSCs was increased (74% and 58%, respectively), 
which is much greater than historic, non-littermate controls (Boyer et al. 2011). This 
suggests that the HSC compartment has inappropriately begun to express the Cre 
recombinase and the PTPN11E76K oncogene. 
 
D. Comparing the Contributions of Fetal vs. Adult Hematopoietic Phases to 
KrasG12D-Induced Disease 
 In Chapter II we described the CSF1R-MCM model as a tool to monitor the 
temporal expression of oncogenes in hematopoietic progenitors. In this chapter, we have 
described that fetal KrasG12D expression in unperturbed animals leads to a JMML-like 
myeloid disease and that transplantation of fetal liver progenitors can propagate this MPN. 
In contrast, transplantation of adult progenitors from moribund FLT3Cre;KrasG12D 
frequently resulted in T-ALL. These results suggest that the fetal hematopoietic phase can 
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 Figure III-20. FLT3Cre;PTPN11E76K: Moribund Animal Analysis. FE-51 succumbed at 
45 weeks of age with splenomegaly (982mg), hepatomegaly (1890mg), and thymic 
atrophy (11mg). Flow cytometric analysis revealed A) an expanded CD4- CD8- population 
in the thymus with a marked decrease of CD44+ CD25+ DNIIa and DNIIb cells. B-C) There 
was a marked decrease in BM HSCs and a minor expansion of splenic HSCs. LSK cells 
in both tissues were actively cycling and differentiating, as measured by the visualization 
of Tomato to GFP switch. 
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uniquely provide the appropriate spatial and temporal milieu for KrasG12D-induced myeloid 
disease. We sought to formally test this hypothesis using the CSF1R-
MCM+;ROSA26YFP/YFP system, which we showed in Chapter II to permit restricted 
expression of conditional mutations to specific phases of hematopoiesis. 
 We mated CSF1R-MCM+;ROSA26YFP/YFP studs with loxP-STOP-loxP-KrasG12D 
dams to generate CSF1R-MCM+;ROSA26YFP/+;loxP-STOP-loxP-KrasG12D (hereafter 
CSF1R-MCM+;KrasG12D), CSF1R-MCM;Kras+/+, and Cre- littermate controls. In these 
animals, Cre-mediated recombination may be detected by the expression of the 
fluorescent protein YFP. As such, YFP+ cells in CSF1R-MCM+;KrasG12D mice express the 
oncogene and YFP- do not or have silenced their ROSA26 locus, as has been reported 
by other groups (Sabnis et al. 2009). We proceeded to inject these animals 3x with 75ug/g 
tamoxifen at 4 weeks of age to induce Cre activity in hematopoietic stem and progenitors 
cells of the adult phase (Figure III-21A). 
 Peripheral blood examination showed no evidence of leukocytosis in CSF1R-
MCM;KrasG12D mutants compared to CSF1R-MCM;Kras+/+ controls (Figure III-21B). 
Mutants developed anaemia and thrombocytopenia 12 weeks after tamoxifen injection. 
Flow cytometric analysis revealed YFP labelling in mutant and controls was equivalent 1 
week after tamoxifen. Thereafter, %YFP+ leukocytes expanded in mutants, peaking at 12 
weeks (Figure III-22B). Concomitantly, mutant animals had an expansion of CD11b+ 
myeloid cells and a paucity of CD3+ T-lymphocytes up to 12weeks after tamoxifen (Figure 
III-22C-E). Importantly, in mutant animals, YFP+ cells showed a much greater contribution 
to CD11b+ myeloid cells than to CD3+ T-cells, suggesting biased, cell autonomous 
differentiation (Figure III-22F-G). Nonetheless, mutant animals showed a rapid demise 
with a median survival of 18 weeks (Figure III-23A). Upon autopsy, these animals 
uniformly had massively enlarged spleens and thymuses, suggestive of a T cell 
leukemia/lymphoma (T-ALL) (Figure III-23B). 
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 Figure III-21. Adult CSF1R-MCM;KrasG12D: CBC Analysis. A) Schematic of 
experimental design. 8 mutants and 12 controls were serially analyzed over time. B-E) 
Mutant animals show anaemia and thrombocytopenia without leukocytosis.  
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 Figure III-22. Adult CSF1R-MCM;KrasG12D: Peripheral Blood Leukocytes Analysis. B-
E) Flow cytometric analysis of overall (YFP+ and YFP-) leukocytes in peripheral blood 
reveals monocytosis and a paucity of T-cells. F-G) YFP+ cells preferentially contribute to 
CD11b+ neutrophils rather than CD3+ CD11b- T-cells in mutants.  
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 Figure III-23. Adult CSF1R-MCM;KrasG12D: Survival and Tissue Weights. A) Adult 
cohort mutants succumb with a median survival of 18 weeks (N=22 mutants and 12 
controls). B) Moribund mutants die with large spleens and strikingly enlarged thymuses. 
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We proceeded to analyze the lineages present in the organs of moribund animals. 
We observed a striking increase in the frequency of CD11b+ neutrophils in the spleens of 
mutants (Figure III-24B,C). There was a concomitant decrease in the frequency of CD4 
and CD8 single positive T-lymphocytes. However, there was an appreciable infiltration of 
CD4+ CD8+ double positive (DP) T-lymphocytes. This phenotypic population is usually 
restricted to the thymus; we therefore proceeded to characterize thymus progenitor 
frequencies. Within the enlarged thymuses of mutant animals, we observed a striking 
increase of CD8 single positive or CD4 CD8 double positive cells (Figure III-25,26). 
Interestingly, these cells were YFP-, which suggests that this abnormal population was 
able to silence its ROSA26 locus. Concomitantly, we saw a decrease in the number of 
CD4+ or CD4-CD8- (DN) cells and a profound reduction of CD25+ DN II and DN III 
populations in mutants (Figure II-26C). This strongly suggests the occurrence of a 
differentiation block in T-lymphocyte commitment. 
We hypothesized that CSF1R-MCM;KrasG12D mutants would have abnormal 
hematopoietic progenitors. Indeed, we observed a striking reduction in the frequency of 
LSK progenitors in the BM and their concurrent expansion in the spleen (Figure III-27D,E). 
Interestingly, we also observed an increase in the frequency of LK cells in both the BM 
and spleen. However, whereas BM progenitors saw an expansion of granulocyte-
macrophage progenitors (GMP), the spleen had a pronounced increase in 
megakaryocytic-erythroid progenitors (MEPs, see Figure III-27F,G). This suggests that 
whereas the BM has become committed to myeloid cell production, the spleen of mutant 
animals has become the dominant site of erythropoiesis. The decrease in common 
myeloid progenitors (CMPs) in both in BM and spleen, together with the very rapid disease 
onset, suggests a tremendously high rate of myeloid and erythroid differentiation in mutant 
animals. Importantly, whereas the frequency of YFP+ cells was increased in progenitors 
compared to CSF1R-MCM;Kras+/+ controls, this frequency was only ~7.5% (Figure III-
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 Figure III-24. Adult CSF1R-MCM;KrasG12D: Tissue Leukocyte Analysis. B-C) Analysis 
of net leukocytes in BM and spleen reveals a paucity of splenic CD4+ cells, a concomitant 
expansion of CD11b+ splenic neutrophils and the presence of abnormal CD4 CD8 double 
positive thymocytes in both spleen and BM. D-E) Mutant YFP+ preferentially contribute to 
CD11b+ neutrophils at the expense of contributions to CD4+ and CD8+ mature T-
lymphocytes as well as abnormal CD4 CD8 double positive malignant cells. 
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 Figure III-25. Adult CSF1R-MCM;KrasG12D: T-ALL Immunophenotype. Representative 
thymus flow cytometric gating of A) healthy littermate and B) 9 mutant animals.  
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 Figure III-26. Adult CSF1R-MCM;KrasG12D: Thymocyte Analysis. B) Mutant thymuses 
have relative decrease of CD4+ and DN populations due to abnormal CD8+ cells. C) There 
is a lack of CD25+ DN II and DN III committed T cell progenitors in mutant thymuses. D) 
YFP+ cells in mutants contribute to myeloid and B cell populations but do not label CD8+ 
malignant cells; see also Figure III-31. 
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 Figure III-27. Adult CSF1R-MCM;KrasG12D: Hematopoietic Progenitor Analysis. B-C) 
Compared to littermates, mutants have BM and splenic progenitors that are more 
frequently YFP+. D-E) Net BM LSK cells are depleted whereas net LK cells are expanded 
in both the BM and spleen of mutants. F) GMPs are enriched in mutant BM whereas MEPs 
are enriched in spleens.  
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27B,C). This suggests that either i) a large proportion of oncogene-expressing cells are 
silencing their ROSA26 locus or ii) moribund mice have a low mutant allele frequency but 
that mutated progenitors are having non-cell autonomous effects of on healthy clones.
 These results in CSF1R-MCM;KrasG12D activated with tamoxifen at 4 weeks of age 
closely parallel previous studies in Mx1Cre;KrasG12D mice. This is not surprising since both 
Cre systems were used to target the adult HSC-dependent hematopoietic phase. We 
proceeded to repeat these studies with a cohort that had their mutation activated in the 
fetal HSC-dependent phase via E14.5 injection of 4-hydroxy tamoxifen (Figure III-28A). 
We hypothesized that restricted expression of KrasG12D in fetal hematopoietic progenitors 
with CSF1R-MCM would produce a faithful JMML-like disease similar to that of the 
FLT3Cre;KrasG12D animals. 
 Due to a high frequency of late-term abortions, we obtained 7 mutants and 7 
littermate controls. All were delivered by C-section. We saw that a considerably smaller 
frequency of YFP+ cells in the blood of this fetal cohort compared with previous CSF1R-
MCM cohorts (Figure III-28B). Nonetheless, whereas there was no difference in the 
%CD11b+ cells, there was a striking decrease in CD4+ T-lymphocytes in our fetal cohort 
mutants compared to littermates (Figure III-28E). We did not observe leukocytosis or 
anaemia in these mice (Figure III-29B-D). Nonetheless, all fetal-cohort CSF1R-
MCM;KrasG12D mice succumbed to a T-ALL disease by 18 weeks of age (Figure III-29F,G) 
The decrease in CD4+ T-lymphocytes prompted us to analyze the lymphoid 
progenitors in these mutants. We observed a striking decrease in the frequency of 
common lymphoid progenitors (CLPs) in the bone marrow of our mutants compared to 
controls (Figure III-30B,D). The frequency of MDP and CMoP myeloid progenitors were 
not changed. Consistently, we observed a decrease in the frequency of CD4- CD8- cells 
in the thymus with a concomitant lack of CD25+ committed T-lymphocyte progenitors. As 
was observed in adult-cohort CSF1R-MCM;KrasG12D animals, our fetal-cohort mutants had 
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 Figure III-28. Fetal CSF1R-MCM;KrasG12D: Peripheral Blood Leukocytes Analysis. B) 
This cohort has low YFP expression in peripheral blood. C-F) mutants have a paucity of 
CD4 T-lymphocytes from an early age. G) Representative gating demonstrates expanded 
neutrophils and abnormal CD4 CD8 double positive cells in peripheral blood.  
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 Figure III-29. Fetal CSF1R-MCM;KrasG12D: CBC and Survival Analysis. B-E) Mutants 
show late-onset leukopenia and thrombocytopenia. F) Overall survival (N=7 mutants and 
7 littermates). G) Tissue weights or moribund animals and littermates.  
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a striking expansion of CD4+ CD8+ or CD8+ single positive T-lymphocytes in the spleen. 
These mutant cells were uniformly YFP-, again suggesting that abnormal regulatory 
elements were silencing the ROSA26 locus. In contrast with our FLT3Cre;KrasG12D mice, 
we did not see an expansion of CD11c+ dendritic cells in the BM, spleen, or thymuses of 
our CSF1R-MCM;KrasG12D mice.  
We have observed a very similar phenotype in both fetal-cohort and adult-cohort 
CSF1R-MCM;KrasG12D animals. Both succumb 12-20 weeks after tamoxifen treatment 
from a T-ALL that does not express the YFP+ reporter. Preceding the animals’ demise, 
they show myeloproliferation and a decrease of circulating T-lymphocytes. The 
overlapping features of myeloproliferation and T cell disease were strongly indicative of a 
particular T-ALL subset: early thymic progenitor (ETP) T-ALL. The hallmarks of ETP T-
ALL is that it bears distinct features of dual lineage expansion (Zhang et al. 2012). BM 
progenitors from these patients have gene expression profiles that are enriched for 
myeloid progenitors in addition to T-cell progenitors. Additionally, only 17% of ETP-ALL 
had mutations in Notch1, compared with over 50% in other T-ALL cases, suggesting an 
alternate disease mechanism. Hyperactive RAS signaling is common in ETP-ALL and K-
ras mutations have been observed in these patients (Zhang et al. 2012). Finally, abnormal 
methylation has been recently characterized in ETP-ALL and has been associated 
with silencing of specific genes including GATA3, a well-characterized regulator of T-cell 
development in the thymus (Naito et al. 2011; Fransecky et al. 2016). Importantly, with the 
exception of the ETP-ALL subgroup, GATA3 is typically overexpressed in T-ALL. We 
therefore proceeded to analyze the expression of GATA3 and other genes whose 
expression is known to regulate T cell development. We found that that mutants from both 
the fetal and adult cohorts had lower expression of GATA3 and Bcl11b in their thymuses 
compared to littermate controls (Figure III-30E). This strongly suggests that the disease 
emerging in CSF1R-MCM;KrasG12D mice is a model of human ETP-ALL. 
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 Figure III-30. Fetal CSF1R-MCM;KrasG12D: Progenitor Analysis. B,C) Representative 
flow cytometry plots of myeloid and lymphoid progenitors in BM of fetal cohort mutants 
and littermates. D) Quantification of progenitors shown in B,C. E) Gene expression in 
unfractionated thymocyte samples; CT values normalized to GAPDH expression.   
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Discussion 
A. The FLT3Cre+ KrasG12D Model of JMML 
We present the first murine KrasG12D model to unify JMML disease-defining 
features: an in utero origin, viability at birth followed by a failure to thrive, anaemia, 
thrombocytopenia, monocytosis, hepatosplenomegaly, and infiltration of tissues with 
histiocytes. All FLT3Cre;KrasG12D mice succumbed to a myeloid disease that could be 
recapitulated following fetal liver transplantation. This is in stark contrast to existing 
KrasG12D models, which die from T-ALL or non-hematopoietic expression (Staffas et al. 
2015; Desai, Brownfield, and Krasnow 2014; Tang et al. 2013; Braun et al. 2004). 
FLT3Cre has a markedly different expression pattern from Mx1Cre, which may 
explain the observed respective myeloid vs lymphoid disease outcomes. Mx1Cre is used 
to target adult progenitors whereas FLT3Cre becomes active in fetal MPPs (Beaudin et 
al. 2016). As such, FLT3Cre initiates KrasG12D expression within an in utero progenitor that 
is more proliferative, has greater repopulating ability, and has enhanced myeloid cell 
production compared to adult progenitors targeted by Mx1Cre (Benz et al. 2012; Copley 
et al. 2013; Dykstra et al. 2007). This context emulates JMML patient studies that 
highlighted the fetal origins of this disease: the causative somatic mutations occur before 
birth and BM cells have a gene expression signature that is characteristic of fetal – and 
not adult – progenitors (Matsuda et al. 2010; Helsmoortel, Bresolin, et al. 2016). Therefore, 
in contrast to Mx1Cre, FLT3Cre targets KrasG12D expression to the appropriate progenitor 
at the appropriate developmental stage to recapitulate the origin of JMML. 
Previous studies have suggested that the HSC is the cell of origin for KrasG12D-
evoked T-ALL (Zhang et al. 2009; Sabnis et al. 2009). In contrast, FLT3Cre is not 
expressed in adult HSCs; its activity is restricted to MPPs and their progeny (Boyer, 
Beaudin, and Forsberg 2012). As such, HSCs in FLT3Cre;KrasG12D animals do not 
express the mutation and therefore would not be able to initiate T-ALL. In the setting of 
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transplantation, however, the circumstances change. We show that the majority of 
recipients of BM from moribund FLT3Cre;KrasG12D mice do develop T-ALL. This finding 
further highlights the differences between unperturbed and post-transplant hematopoiesis. 
Additionally, since FLT3Cre is not active in BM HSCs, our study challenges the hypothesis 
that T-ALL is initiated from an HSC. Instead it suggests that oncogene expression within 
MPPs is sufficient for T-ALL development in a transplantation setting.  
The lack of recombinase activity in HSCs also permits analysis of HSC-intrinsic vs 
extrinsic effects of oncogene expression. For instance, we were surprised to observe that 
FLT3Cre;KrasG12D mice have decreased frequencies of HSCs in both the BM and spleen. 
This suggests that non-mutated HSCs may exhaust from the increased cycling of 
oncogene-expressing downstream progenitors. Our results suggest that studies that rely 
on Mx1Cre-induced genetic alterations to draw conclusions about HSC functions should 
distinguish: i) intrinsic effects of genetic alterations on HSCs and ii) extrinsic effects in 
downstream progeny that affect HSC function via feedback mechanisms. 
The cellular origin of JMML has been controversial. On the one hand, case reports 
have shown CD34+ CD38- patient cells express disease-initiating mutations (Busque et 
al. 1995; Stieglitz, Taylor-Weiner, et al. 2015) and xenotransplantation of patient 
progenitors will produce mutated myeloid, B, and T cells with a common clonal origin 
(Nakamura et al. 2005). On the other hand, circulating T-lymphocytes from most patients 
do not express the disease-initiating mutation (Flotho et al. 1999; Sakaguchi et al. 2013). 
These findings suggest that JMML is initiated within a multipotent progenitor that 
subsequently undergoes a differentiation block during T-lymphocyte commitment.  
Consistent with this hypothesis, case reports have noted decreased T cell frequencies in 
the blood, bone marrow, and spleen of JMML patients (Weinberg et al. 1990; Krombholz 
et al. 2016; Oliveira et al. 2016). These findings parallel our FLT3Cre;KrasG12D model, 
which has an atrophied thymus and decreased peripheral T-lymphocytes. It will be 
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important to understand the significance of abnormal T-cell development in JMML and its 
contribution to patient morbidity; we discuss this is more detail below. 
Another group found similarly skewed T-lymphocyte development when KrasG12D 
expression was restricted to dendritic cells in p53-/- mice via Clec9a-Cre (Bottcher et al. 
2015). Importantly, this group demonstrated that KrasG12D-expressing DCs are capable of 
antigen presentation to T-lymphocytes and that these DCs permit proliferation and normal 
T-Cell Receptor gene rearrangements. These mice had diminished overall survival but the 
cause of their lethality was not explicitly stated. Our results build on these findings and 
suggest that KrasG12D expression in a fetal multipotent progenitor is sufficient for 
preferential DC differentiation in the thymus. 
Dendritic cell biased differentiation was observed in tissues apart from the thymus. 
BM progenitors from FLT3Cre;KrasG12D mice could spontaneously differentiate into DC-
like cells in vitro, as has been observed in patient samples (Longoni et al. 2002; Estrov et 
al. 1986). DCs were also markedly expanded in the BM and spleen of our model and were 
distinct from neutrophils, which were also increased in number. Importantly, case reports 
have equally noted JMML patient tissues are infiltrated by atypical histiocytes (Ozono et 
al. 2011; Ng et al. 1988). Future clinical studies will need to evaluate whether these cells 
are functional antigen presenting DCs and whether they contribute to JMML patient 
morbidity. 
In summary, we describe the first KrasG12D mouse model that recapitulates defining 
features of JMML. FLT3Cre;KrasG12D mice are viable, develop monocytosis, anaemia, 
thrombocytopenia, hepatosplenomegaly, and they die from a fully penetrant and 
transplantable myeloid disease. This model further emulates underappreciated features 
of JMML such as the paucity of mature T-lymphocytes and an expansion of dendritic cells 
and thereby hints at potential new therapeutic strategies. FLT3Cre;KrasG12D mice will 
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prove useful for preclinical drug studies targeting the RAS-MEK-ERK signaling pathway 
and will help elucidate the developmental origins of JMML and pediatric leukemias.  
 
B. FLT3Cre;KrasG12D Age-Matched Transplantations 
We performed age-matched transplantations of E14.5 fetal liver (FL) and 4 week-
old BM from FLT3Cre;KrasG12D mice into both neonatal and adult congenic recipients. 
These studies permitted us to gauge the relative importance of the fetal progenitor and of 
the fetal niche in contributing to our JMML-like disease. We show that—compared to BM 
donors—FL progenitors lead to more rapid mortality when transplanted into either adult or 
neonatal recipients. Equally, we determined that whereas all recipients of fetal progenitors 
developed a JMML-like disease, the majority of BM recipients developed T-ALL. These 
results suggest, that the primary determinant of myeloid vs. lymphoid disease and the rate 
of onset is the progenitor itself; not its microenvironment. 
We did not find differences in survival when comparing adult and neonatal 
recipients of FL progenitors. Upon secondary transplantation, however, we saw that adult 
secondary recipients succumbed more rapidly than neonatal recipients. This is likely due 
to the competitive nature of neonatal transplantations. Since sublethal conditioning 
regimens must be used, the donor cells compete with the newborn’s native progenitors. 
Therefore, whereas adult recipients of fetal progenitors had >90% engraftment 5 weeks 
after transplantation, neonatal recipients showed 35% engraftment. Secondary neonatal 
recipients showed less than 10% engraftment even 13 weeks after transplantation. 
Another striking difference between fetal and BM donors was that the proportion 
of fetal progenitors that contributed to CD11b+ myeloid cells was much greater than that 
of adult donors. Whereas 90% of donor cells in FL>Adult and 75% of FL>Neonate were 
CD11b+, less than 50% were CD11b+ when BM donors were used. These findings agree 
with previous studies that show fetal progenitors are more proliferative and produce more 
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and larger myeloid colonies than BM progenitors (Broxmeyer et al. 1992; Lansdorp, 
Dragowska, and Mayani 1993). Notably, this does not contradict single cell studies that 
showed fetal HSCs preferentially contribute to lymphoid cells whereas adult HSCs 
preferentially contribute to myeloid cells (Benz et al. 2012). This is because our study 
considered the short-term (<13weeks) contribution of MPPs to disease manifestation, 
whereas the Benz et al. study considered the durable (>16week) contribution of single cell 
HSCs. 
We made a remarkable finding when we correlated engraftment with the frequency 
of donor-derived CD11b+ myeloid cells. The greater the engraftment of CD45.2 cells, the 
more their differentiation is biased towards CD11b+ myeloid cells (Figure III-16). This trend 
was observed in all 4 of our transplant cohorts. Importantly, it was not observed among 
FLT3Cre;Kras+/+ control transplant cohorts. This finding suggests that greater engraftment 
of mutant cells will cause changes in the hematopoietic niche that further exacerbate the 
MPN phenotype. This change could be a cytokine that causes mutant progenitors to 
become more proliferative and myeloid biased. If such a cytokine is secreted by mutant 
cells, then greater engraftment = more secretion = more myeloid proliferation. Such a 
scenario is consistent with the non-cell autonomous findings in our the CSF1R-
MCM;PTPN11E76K model where both YFP+ mutated cells and YFP- WT cells in the same 
niche are equally hypersensitivity to GM-CSF, presumably due to cytokine secretions. 
This parallel prompted us to determine if the residual host CD45.1+ cells that 
resisted myeloablation were also myeloid-skewed following FLT3Cre;KrasG12D 
transplantation. Given the results from our CSF1R-MCM;PTPN11E76K cohort, it was 
surprising that CD45.1+ cells were not myeloid-biased. There are two potential 
explanations. First, post-transplant hematopoiesis may not recapitulate the unperturbed 
findings of the CSF1R-MCM cohort. Indeed, residual cells in a lethally-irradiated host are 
typically long-lived B-cells and T-cells. Alternatively, the effect of the KrasG12D mutation on 
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the niche may be different from that of the PTPN11E76K mutation. Whereas we did observe 
non-cell autonomous effects following PTPN11E76K expression, the effects of KrasG12D in 
the niche may be restricted to cells that express the mutation. 
We acknowledge that the findings from these transplants must be considered in 
context. The donor populations were not sorted and the number of progenitors per 
recipient varied among the 4 cohorts. For instance, the frequency of MPPs and HSCs in 
the fetal liver of mutants is 0.4% and 0.03% respectively, whereas the frequencies in the 
BM are much lower: 0.08% and 0.001%, respectively. Furthermore, engraftment in 
neonates is much lower than in adult recipients, albeit this difference is less pronounced 
for fetal progenitors (Arora et al. 2014). As such, the definitive conclusion from these 
transplants is limited: fetal progenitors propagate a JMML-like disease whereas BM 
progenitors do not. Additional studies that control for the number of transplanted 
progenitors and account for engraftment differences would need to be performed to 
directly compare effects of neonatal vs. adult recipients. 
C. Comparison of KrasG12D and PTPN11E76K Models of JMML
Among JMML patients, mutations in PTPN11 are particularly deleterious and are 
associated with an inferior prognosis compared to other mutations, including KRAS. 
(Yoshida et al. 2009). Indeed, the presence of RAS mutations in JMML patients has been 
suggested to be correlated with superior overall survival, even the potential 
of spontaneous remission (Matsuda et al. 2007). However, in murine studies 
KrasG12D mutants have notably inferior survival to PTPN11E76K mutants. Median survival 
following pI:pC for Mx1Cre;KrasG12D is 11 weeks, whereas for Mx1Cre;PTPN11E76K it is 
28 weeks. This suggests there are differences between murine and human signaling 
pathways downstream of these nodes. 
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We also observed differences in signaling between our PTPN11 and KRAS 
models. Progeny of VavCre;PTPN11D61Y yolk sac EMPs had hyperactive RAS as 
measured by increased phosphorylation of ERK following GM-CSF stimulation. In 
contrast, we did not observe increased phosphorylation of ERK, STAT5, or AKT in our 
FLT3Cre;KrasG12D model. These findings are consistent with previous murine studies 
(Braun et al. 2004) that also failed to see elevated MEK or AKT activation in cells cultured 
from Mx1Cre;KrasG12D BM. On the other hand, freshly harvested LK cells from these mice 
do show elevated ERK activation following GM-CSF stimulation (Lyubynska et al. 2011). 
These findings highlight that signaling downstream of KrasG12D is inadequately understood 
and that species-specific differences may account for the incongruent survival of human 
patients and mouse models expressing oncogenic KRAS. 
As such, our observation that FLT3Cre;PTPN11E76K mice have prolonged survival 
compared to FLT3Cre;KrasG12D mice is consistent with previous murine models. What may 
be surprising is the large difference in survival we observed. Whereas FLT3Cre;KrasG12D 
mice succumb with a median age of 26 days, more than 75% of FLT3Cre;PTPN11E76K
mice remained alive 1 year after birth. This finding suggests that previous PTPN11E76K
models—which used Mx1Cre, VavCre, or LysMCre—had significant morbidity from non-
hematopoietic expression. Unfortunately, these other models did not assess the 
contribution of endothelial and stromal cell oncogene-expression to disease. 
The differential responses of the two oncogenes to expression by CSF1R-MCM 
vs. FLT3Cre are equally striking. Both FLT3Cre;PTPN11E76K and CSF1R-MCM; 
PTPN11E76K mice acquire MPN. In contrast, FLT3Cre;KrasG12D uniformly die of MPN 
whereas all CSF1R-MCM;KrasG12D acquire T-ALL. Notably, the age at which CSF1R-MCM 
was activated did not alter the dominant disease manifestations in either model. This 
argues that the fetal vs. adult phase of the progenitor is not per se the dominant 
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determinant of disease manifestation. Rather, it suggests that the mutant allele frequency 
may determine disease outcome for KrasG12D but not for PTPN11E76K. 
 Cre efficiency is a direct surrogate for measuring the mutant allele frequency. 
FLT3Cre results in the activation of >80% of hematopoietic progenitors. In contrast, we 
activated no more than 2% of progenitors using CSF1R-MCM. As such, the initial mutant 
allele frequency in FLT3Cre cohorts is much greater than that in CSF1R-MCM cohorts. 
The greater allele frequency in FLT3Cre;KrasG12D may permit myeloid populations to 
expand sufficiently early and quickly to cause lethality. In contrast, the myeloid expansion 
in CSF1R-MCM;KrasG12D is pronounced but simply cannot produce monocytosis to the 
same extent as the FLT3Cre cohort. Instead, the paucity of circulating T-lymphocytes may 
provoke greater cycling among thymic progenitors and lead to lymphoma. 
 In contrast, we observed extensive non-cell autonomous effects in the setting of 
PTPN11E76K. Non-mutated YFP- progenitors that cohabit the niche in CSF1R-MCM; 
PTPN11E76K animals demonstrate the same degree of GM-CSF hypersensitivity as do 
YFP+ mutant-expressing progenitors. This suggests that even in the setting of a low 
mutant allele frequency, PTPN11E76K will provoke MPN development due to alterations in 
the BM niche.  
In this light, the comparison between FLT3Cre; PTPN11E76K and CSF1R-MCM; 
PTPN11E76K mice is remarkable. These cohorts have high and low mutant allele 
frequencies, respectively. However, the MPN manifestations in these animals are 
equivalent. Both have nearly 50% net CD11b+ cells and fewer than 20% net T-cells in 
peripheral blood at 1 year of age. The overall survival is equal (p=0.45) and the leukocyte 
counts are equal. This suggests that the same MPN will emerge in the setting of both high 
and low hematopoietic-restricted PTPN11E76K allele frequencies. 
This finding highlights the importance of murine studies that assess low mutant 
allele frequency contributions to disease—particularly in the setting of unperturbed 
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hematopoiesis. Human studies have demonstrated the pervasiveness of clonal 
hematopoiesis and its direct correlation with all-cause mortality (Jaiswal et al. 2014; 
Genovese et al. 2014). Therefore, models that permit monitoring of hematopoietic 
subpopulations within an animal would be very beneficial to this field. However, it will not 
be possible to use Mx1Cre and VavCre because of their broad and indiscriminate 
activation patterns. We present CSF1R-MCM has the most readily available tool that is 
compatible with existing conditional mouse models and can emulate the clonal nature of 
hematologic malignancies.  Given the striking findings of our studies we strongly urge 
other researchers to adopt similar strategies. 
D. T-Lymphocyte Development in JMML
We observed a common feature in all of our models of JMML. Prior to overt 
disease, all mutant animals demonstrated myeloproliferation with a concomitant decrease 
in peripheral T-lymphocytes. The frequency of B-lymphocytes was not changed until 
fulminant disease manifestations. These findings strongly suggest that a convergent 
pathway is driving this lineage bias. Evidence from both PTPN11 and Kras cohorts 
suggests that there is a marked defect in the maturation of DN I progenitors to the DN II 
and DN III stages. Functionally, this transition is normally characterized by expression of 
CD25, and the downregulation of cKit. As the progenitor loses cKit expression, the DNIIa 
to DNIIb checkpoint is reached. This transition marks the irreversible commitment to T-
lymphocytes. Prior to this point, thymic progenitors are capable of multilineage 
differentiation including into myeloid cells and dendritic cells (Kueh et al. 2016; Luc et al. 
2012). Coordinate cues are required for this commitment including Notch signaling as well 
as sequential transcription factors: GATA3, TCF7, and BCL11b (Naito et al. 2011). 
These findings prompted us to search whether parallel findings have been reported 
among JMML patients. Indeed, we found several reports that describe reduced T-
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lymphocyte numbers in these children (Weinberg et al. 1990; Oliveira et al. 2016; 
Krombholz et al. 2016). Additionally, reports suggest that T-cells may not express 
the disease-initiating mutation (Flotho et al. 1999; Sakaguchi et al. 2013). These results 
are consistent with our finding that oncogene expression causes defective T cell 
maturation and a concomitant decrease in mature progeny. Interestingly, our findings 
of decreased CLPs in the BM of CSF1R-MCM;KrasG12D mice suggest that the causes of 
this block may not be solely restricted to the thymus. 
It will be important to understand the significance of this observation in patients. 
Lack of functional T-lymphocytes would likely exacerbate the morbidity of MPN but may 
equally suggest alternative treatment strategies. JMML patients’ elevated susceptibility to 
infection further provides evidence that they may lack a normal adaptive immune system. 
Additionally, several case reports have identified JMML patients who subsequently 
developed T-ALL with the same mutant clone (Raikar et al. 2016; Cooper et al. 2000). 
This suggests that under certain conditions, the defect in T cell development may be 
overcome and cause a leukemia. As such, further evaluate T-cell maturation in JMML 
patients and probing the mechanisms of a potential differentiation block may identify 
strategies prevent lineage switching and improve outcomes following infection. 
Ongoing Studies and Future Directions 
A. Further characterization of FLT3Cre;KrasG12D
We will continue to analyze our JMML model with the intention of understanding 
the pathophysiology of disease in patients. We have noted a marked expansion of 
dendritic cells in our model. Whereas case reports present similar patient findings, it is 
unclear how common DC expansion is in JMML and whether it contributes to morbidity. 
We will isolate CD11c+ DCs from the spleens of our mice and assess their ability to 
stimulate T-cells via antigen presentation. DCs from mutants and controls will be 
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separately co-cultured with naïve CD4+ cells from OT-II mice, which uniquely express a 
T-cell receptor specific for ovalbumin. Ovalbumin will then be added to the culture medium. 
If the CD11c+ DCs are bona fide antigen presenting cells then they should be able to 
process the ovalbumin, present it on their MHCII, and thereby stimulate the CD4+ cells to 
proliferate. This proliferation will be measured through the dilution of a dye, such as CFSE. 
We would then proceed to more thoroughly characterize the abundance of DCs in 
patients. We have been fortunate to acquire tissue blocks of JMML patient spleens. We 
would section them onto cover slips and stain them with human DC markers, including 
CD11c, MHCII, CD1c, and CD141. If we saw an expansion, we could then follow up with 
stains of activated DCs, such as CD80 and CD86, to determine if they were more likely to 
be presenting antigen than DCs from controls. Finally, if we were able to obtain live cells 
from human spleens, we could determine whether patient DCs share the same 
functional antigen presentation characteristics as DCs from our model. 
Apart from dendritic cells, we will further characterize the progenitor compartment. 
We assume that only cells with active Cre recombinase express the mutation and that 
only GFP+ cells express Cre. Nonetheless, we will directly confirm this using genomic 
quantitative PCR. We have designed primers that can distinguish recombined vs non-
recombined alleles of the LSL-KrasG12D locus. We will therefore sort GFP+ and Tomato+ 
subsets and quantify the frequency of recombined oncogene to ensure that only GFP+ 
cells express the oncogene and that Tomato+ cells do not. 
If Tomato+ cells truly are WT we will proceed to characterize why we see a 
depletion of Tomato+ HSCs in our model. Our hypothesis is that increased differentiation 
of downstream progenitors causes HSCs to enter the cell cycle. We will test this using 
Ki67 and DAPI staining in Tomato+ Lin- cKit+ Sca1+ CD150+ CD48- HSCs. Alternatively, 
it is possible that HSCs fail to appropriately seed the BM and spleen. HSCs in mutant 
animals may remain confined to the liver, potentially due to a lack of chemokine receptors 
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such as CXCR4, PSGL-1, and CD44 (Magnon and Frenette 2008). If we do not detect a 
difference in HSC cell cycle, we will proceed to characterize the expression of these 
markers on peri-natal HSCs. 
 
B. Transplantations with sorted FLT3Cre;KrasG12D subsets 
 We will further study our progenitors with transplantations using sorted 
populations. This will enable head-to-head comparison of distinct progenitors from both 
the fetal and adult (4 week old BM) phases. By enabling transplantations with defined 
numbers of progenitors, we will build on findings from our CSF1R-MCM;KrasG12D studies, 
which suggested that the mutant allele frequency was more important than the 
hematopoietic phase in determining a myeloid vs. lymphoid disease with this oncogene. 
 There are four variables to consider in these transplant studies: i) fetal vs. adult 
phases; ii) GFP+ vs. Tomato+, corresponding to the presence and absence of active 
mutation, respectively; iii) progenitor immunophenotype, be it HSC, MPP, or lineage 
committed progenitors; and iv) the number of donor cells. In each scenario FLT3Cre; 
KrasG12D donors will be transplanted alongside CD45.1 supportive cells. Concurrent 
transplants with FLT3Cre:Kras+/+ littermates will be performed as controls. Recipients will 
be adult BoyJ animals; we will describe novel strategies for neonatal transplants below. 
 Initially, we will transplant 100 Tomato+ HSCs from fetal and adult phases. 
Following their engraftment, the progeny of these HSCs will transition through a FLT3+ 
intermediate whereby they will begin to express GFP and the oncogene. This transplant 
will determine whether progenitors from the fetal phase cause a JMML-like disease 
whereas those from the adult phase cause T-ALL. If the fetal transplant results in T-ALL, 
we will repeat the experiment using 500 fetal Tomato+ donors to gauge if increased mutant 
allele frequency alters disease outcome. Finally, we will transplant the fetal GFP+ HSCs 
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(Beaudin et al. 2016), which would assess whether this transient population may 
contribute to disease manifestations in our model. 
 Next, we will transplant 500 GFP+ MPPs from fetal and adult phases. These are 
the populations that actively express the oncogene in our model. As such they are the 
presumptive candidate for the JMML-initiating cell. We expect that adult MPPs will 
transiently contribute to peripheral leukocytes but will not durably engraft and will not 
contribute to disease. This would support similar progenitor transplantations reported 
using the Mx1Cre;KrasG12D model (Zhang et al. 2009). Fetal MPPs, on the other hand, 
may be sufficiently proliferative to evoke a fulminant MPN. If fetal MPPs do not cause 
disease, this would suggest that the MPN in our model was the result of persistent 
contributions from Tomato+ HSCs to GFP+ MPPs. Each such differentiation would 
produce a new MPP clone that expresses KrasG12D. This would indicate that the MPN 
observed in our model was not clonal, but rather the result of incessant mutagenesis 
following each asymmetric HSC division. 
 Finally, we will transplant lineage-committed cells to determine if they have been 
transformed and can propagate the disease. We will begin by transplanting dendritic cells 
from the spleens of moribund mice. Previous work suggested that transfer of KrasG12D-
expressing DCs is sufficient to kill recipient mice (Bottcher et al. 2015). However, they did 
not characterize the nature of the resulting disease. Our study could address whether DCs 
are sufficient to alter the T-cell differentiation observed in the thymus of our animals and 
whether this contributes to myeloid-biased progenitor differentiation. 
 
C. Neonatal Transplants. 
 We described the first study that sought to assess disease outcomes following 
age-matched transplantations. Our goal was to determine if the fetal vs. adult 
hematopoietic niche contributes to the myeloid vs. lymphoid disease following KrasG12D 
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expression. We noted, however, that it is challenging to interpret these experiments due 
to differences in the conditioning regimens of neonatal and adult mice. The former can 
only be sublethally irradiated. As a result, neonatal transplants are inherently competitive. 
Previous attempts by the Yoder lab to standardize the conditioning regimens and permit 
head-to-head comparison of neonatal vs. adult recipients have not identified a viable 
strategy. Below we propose another approach that may prove fruitful. 
 The transcription factor Myb is required for the emergence and maintenance of 
HSCs (Mucenski et al. 1991). Previous studies have deleted Myb using Mx1Cre as a 
conditioning regimen and performed transplants in the absence of irradiation (Schulz et 
al. 2012). Our proposal is to generate FLT3Cre;Mybfl/fl mice. These animals would have 
normal development of HSCs (since they do not express FLT3), but the progeny of HSCs 
would subsequently lose Myb expression and undergo defective differentiation. FLT3Cre 
is active in >90% of hematopoietic cells, suggesting that the extent of deletion should be 
pronounced but that an adequate number of leukocytes and erythrocytes should be 
present to permit viability. We would then compare engraftment into non-irradiated 
neonatal and adult FLT3Cre;Mybfl/fl mice. In such a setting, both neonatal and adult 
transplants would be equally competitive, yet the donors would be competing against a 
highly defective hematopoietic program. 
  
D. Completion of the FLT3Cre;PTPN11E76K Study 
 Our analysis of FLT3Cre;PTPN11E76K suggests that previous models using this 
oncogene had extensive morbidity due to non-hematopoietic effects. Our model shows 
indolent progression of MPN despite a mutant allele frequency that is almost the same as 
that in Mx1Cre and VavCre models. It will therefore be important to assess the long-term 
effects of hematopoietic-restricted PTPN11E76K expression. We have already confirmed 
FLT3Cre is not active in endothelial cells. We will test its activity in stromal populations, 
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including osteoblasts (Lin- CD140a+ Sca1-) and MSPCs (Lin- CD140a+ Sca1+). 
Thereafter we will continue our study to address the following questions. 
FLT3Cre;PTPN11E76K mice show progressive myeloid bias with development of 
pronounced anaemia, thrombocytopenia but with rather unremarkable leukocytosis. It will 
be important to determine whether the total leukocyte counts further increase. 
Leukocytosis is, after all, a defined feature of JMML. Since FLT3Cre is not active in all 
hematopoietic progenitors, it is possible that healthy clones will outcompete the mutant 
clones. As such, we will continue to monitor %GFP+ cells in all lineages as a surrogate 
for mutant allele frequency. If we continue to see a decline in the frequency of mutant 
cells, this will suggest that healthy clones are indeed preferentially expanding. 
We will be able to confirm this through the analysis of tissue populations. At the 
end of our study, we will be able to assess the frequency of Tomato+ progenitor subsets. 
If we see that a greater proportion of MPPs in mutants are Tomato+ than in littermates, 
we will conclude one of the following: i) healthy clones preferentially expanded in mutants 
or ii) increased rate of progenitor cycling in mutants resulted in stress hematopoiesis. 
Others have shown that stress hematopoiesis in the FLT3Cre model results in expansion 
of Tomato+ cells because each clone spends less time as a FLT3+ intermediate. As a 
result, the cis-regulatory elements that enable Cre activation are less active and fewer 
clones have active recombinase. By assessing the number of HSCs in our animals, we 
would be able to differentiate between scenario i) and ii). In i), we would expect to see an 
equal number of HSCs in mutants and controls. However, in ii) we would expect mutant 
HSCs to be depleted due to exhaustion following the increased cycling of downstream 
progenitors. 
As we continue monitoring these animals, we will closely compare their disease 
manifestations with those of the CSF1R-MCM; PTPN11E76K. Thus far we have seen very 
similar morbidities in these two cohorts. This is despite FLT3Cre continuously driving 
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PTPN11E76K expression in ~90% of LSK cells whereas CSF1R-MCM was activated only 
once at 4 weeks of age and targeted only 1.1% of LSK cells. If we continue to see no 
differences in survival, leukocytosis, myeloid differentiation, or T-cell differentiation we will 
seek to further validate non-cell autonomous effects of PTPN11E76K. We will do so by 
assessing growth hypersensitivity and RAS-ERK activation following GM-CSF stimulation 
among GFP+ and Tomato+ progenitors from FLT3Cre;PTPN11E76K mice. Next, we will 
assess the clinical relevance of our findings. We hypothesize that the overall survival of 
patients should be inversely related to their mutant allele frequency at the time of 
transplant. Furthermore, we will perform pERK signaling studies with patient samples co-
cultured with progenitors from healthy children. This will determine if mutant cells secrete 
a cytokine that evokes GM-CSF hypersensitivity in healthy cells. 
E. Methylation in KrasG12D models
We noted in our introduction that methylation is frequently observed in JMML, 
particularly among those patients that have mutated RAS. It has been shown 
that modulating DNA methylation has therapeutic efficacy in JMML models ex vivo. 
Indeed, an ongoing clinical trial (NCT02447666) is actively recruiting pediatric MDS 
and JMML patients to test 5-azacytidine—a DNA methyltransferase inhibitor. 
Therefore, we propose to assess CpG methylation in FLT3Cre;KrasG12D and CSF1R-
MCM;KrasG12D mice to determine if they may be suitable pre-clinical models to 
test future therapeutics. 
We have data that suggests aberrant methylation occurs in these animals. 
ROSAmTmG should be active in all cells that transcribe this locus, which includes all 
nucleated hematopoietic cells. Since this is a dual fluorescent system, all cells should 
be either GFP+ or Tomato+. Cells that have silenced their ROSA26 locus would express 
neither. We observed there was a clear subset of cells that do not express GFP or 
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Tomato in mutant tissues. We identified that these cells were CD11c+ MHCII+ dendritic 
cells (Figure III-31). No other lineage demonstrated silencing of the ROSA26 locus in 
these mice. This finding is consistent with aberrant methylation of the ROSA26 promoter. 
To formally test this, we will isolate DNA from Tomato- GFP- dendritic cells and bisulfide 
convert it, such that all non-methylated CpG become UpG. Subsequent sequencing will 
identify the number of CpG sites that were methylated. We would expect to see increased 
CpG methylation of the ROSA26 promoter in these mutant DCs. 
Fluorescent marking in the ROSAYFP system, on the other hand, is less clear. 
Whereas YFP+ cells should express the mutation, YFP- cells may either have inactive Cre 
or they may have silenced their ROSA26 locus. Fortunately, mutant cells in our CSF1R-
MCM;KrasG12D have a definitive phenotype: CD4 CD8 double positive cells in non-thymic 
tissues. It is interesting to see that in nearly all of our mice, these cells were uniformly 
YFP- (Figure III-31). This also suggests that aberrant DNA methylation is involved in this 
T-ALL disease. Importantly, aberrant DNA methylation is a hallmark of ETP-ALL, a 
disease which has similar characteristics as our model, including myeloproliferation, and 
decreased expression of GATA3. We will therefore perform bisulfide sequencing from 
mutant cells from our CSF1R-MCM;KrasG12D mice. In particular we will assess the 
ROSA26 and GATA3 loci, the latter of which is also hypermethylated in ETP-ALL patients. 
If these preliminary studies are informative we will proceed to seek the cause of the 
aberrant methylation. We will measure the mRNA expression of DNA 
methyltransferases and demethylases, including DNMT3A, TET1/2, and IDH1/2 as well 
as the cell cycle regulators known to be methylated in JMML: CDKN2A and CDKN2B. 
Finally, we will proceed to pre-clinical studies to test whether inhibition of 
methyltransferases would alter morbidity and disease outcomes in our models. 
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Figure III-31. Neoplastic KrasG12D Cells Silence the ROSA26 Locus. A) CD4+ CD8+ 
cells in the spleen of moribund CSF1R-MCM;KrasG12D;ROSAYFP animal are uniformly 
YFP-. B) CD11c+ MHCII+ dendritic cells in thymuses of FLT3Cre;KrasG12D animals do not 
express GFP or Tomato. 
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APPDENDIX 
Reaction Primers Interpretation 
LSL-
KrasG12D 
GTCTTTCCCCAGCACAGTGC 
CTCTTGCCTACGCCACCAGCTC 
AGCTAGCCACCATGGCTTGAGTAAGTCTGC
A 
WT Kras 
Allele=622bp 
LSL-
KrasG12D=500bp 
loxP-
KrasG12D=650bp 
Sly / Xlr 
(gender) 
   
GATGATTTGAGTGGAAATGTGAGGTA 
CTTATGTTTATAGGCATGCACCATGTA 
Male=280bp; 
Female= 
480bp+660bp+685b
p 
LSL-PTPN11 
D61Y 
CCTGAATGAACTGCAGGACG  
GTTTCGCTTGGTGGTCGAAT 
NeoR+=248bp 
CSF1R-MCM 
CTAGGCCACAGAATTGAAAGATCT 
GTAGGTGGAAATTCTAGCATCATCC 
AGATGCCAGGACATCAGGAACCTG 
ATCAGCCACACCAGACACAGAGATC 
Cre+ 236bp 
Control 324bp 
E76K 
genotype 
GGGAATTGAACTCAGGACCT 
CCCACTCACCTTGTCATGTA E76K=350bp 
E76K 
recombinatio
n 
TGGGAAGACAATAGCAGGCA 
CCCACTCACCTTGTCATGTA 
 
WT = 247bp 
E76K.rec = 336bp 
ROSA26-
YFP 
AAG ACC GCG AAG AGT TTG TC 
AAA GTC GCT CTG AGT TGT TAT 
GGA GCG GGA GAA ATG GAT ATG 
YFP=320bp 
WT=600bp 
ROSA26-
mTmG 
CTC TGC CTC CTG GCT TCT 
CGA GGC GGA TCA CAA GCA ATA 
TCA ATG GGC GGG GGT CGT T 
WT=330bp 
mTmG=250bp 
Primer Sequences Used For Genotyping PCR Analyses.  
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Primer Pair Sequence Efficiency 
mGAPDH Fwd TGGTGAAGCAGGCATCTGAG 
92.8% // 96.1% 
mGAPDH Rev TGTTGAAGTCGCAGGAGACAAC 
Lin28b-Fwd GAGTCCAGGATGATTCCAAGA 
87.4% 
Lin28b-Rev TGCTCTGACAGTAATGGCACTT 
HMGA2-Fwd GGTGCCACAGAAGCGAGGAC 
91.7% 
HMGA2-Rev GGGCTCACAGGTTGGCTCTT 
Igf2bp1-Fwd GGCTCAGTACGGTACAGTGGA 
83.7% 
Igf2bp1-Rev ACCACAGCTGTCTCACTTTCAG 
Igf2bp2-Fwd GGGAAAATCATGGAAGTTGACTA 
103.0% 
Igf2bp2-Rev CGGGATGTTCCGAATCTG 
Igf2bp3-Fwd AAACAGCTTTCTCGCTTTGC 
99.1% 
Igf2bp3-Rev TCCGCACTTTAGCATCTGGT 
TCF7-Fwd CGCAGAGACTTTTCCCGGAC 
93.9% 
TCF7-Rev TTGTTATGCAGCGGGGGTTG 
GATA3-Fwd GCTCCTTGCTACTCAGGTGAT 
92.7% 
GATA3-Rev GGAGGGAGAGAGGAATCCGA 
BCL11b-Fwd GGAGAACATTGCAGGGCCG 
97.1% 
BCL11b-Rev TGGGAAGAGGAGGCAGCTAT 
Clec4b2-Fwd GAAGTGCTCTCTCAGGGGTG 
105% 
Clec4b2-Rev GTGCCAGAATGTGGCTCTATC 
Primer Sequences Used For Quantitative RT-PCR. 
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